Oseltamivir is a neuraminidase inhibitor used to treat and prevent influenza A and B infections. Its synthesis involves a multi-step process starting from shikimic acid, a natural compound extracted from the Chinese star anise. Oseltamivir inhibits the neuraminidase enzyme, which is crucial for the release of new virus particles from infected cells, thereby reducing the spread of the virus. Its importance lies in its ability to shorten the duration of influenza symptoms and reduce the risk of complications. Oseltamivir is studied extensively to understand its mechanism of action, develop resistance-resistant variants, and explore its potential in combination therapies. Studies also focus on evaluating its efficacy and safety in different patient populations and for various influenza strains.'
Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 65028 |
| CHEMBL ID | 1229 |
| CHEBI ID | 7798 |
| SCHEMBL ID | 32035 |
| MeSH ID | M0282076 |
| Synonym |
|---|
| BIDD:GT0426 |
| ethyl (3r,4r,5s)-5-amino-4-acetamido-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate |
| bdbm5025 |
| gop-a-flu |
| HY-13317 |
| AB00173476-02 |
| BRD-K76011241-045-01-5 |
| AKOS015843442 |
| gs-4104 , |
| tamvir |
| 1-cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3r,4r,5s)- |
| hsdb 7433 |
| oseltamivir [inn:ban] |
| NCGC00178698-01 |
| oseltamivir |
| C08092 |
| 196618-13-0 |
| gs 4104 |
| ro-64-0796 |
| gs4104 |
| ethyl (3r,4r,5s)-4-acetamido-5-amino-3-(1-ethylpropoxy)cyclohexene-1-carboxylate |
| ethyl (5s,3r,4r)-4-(acetylamino)-5-amino-3-(ethylpropoxy)cyclohex-1-enecarboxylate |
| tamiflu (*phosphate salt 1:1*) |
| 1-cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3r-(3alpha,4beta,5alpha))- |
| ethyl (3r,4r,5s)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate |
| (-)-oseltamivir |
| DB00198 |
| ethyl (3r,4r,5s)-4-acetamido-5-amino-3-pentan-3-yloxy-cyclohexene-1-carboxylate |
| oseltamivirum |
| ethyl (3r,4r,5s)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate |
| CHEBI:7798 , |
| agucort |
| HMS2090C11 |
| ro64-0796 |
| CHEMBL1229 |
| gs-4071 ethyl ester |
| ro-640796 |
| ro 640796 |
| ethyl (3r,4r,5s)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate |
| oseltamivir (inn) |
| D08306 |
| agucort (tn) |
| NCGC00178698-02 |
| tamiflu-free |
| unii-20o93l6f9h |
| 20o93l6f9h , |
| ebilfumin |
| AKOS015960501 |
| NCGC00178698-04 |
| oseltamivir [inn] |
| oseltamivir [vandf] |
| oseltamivir [mi] |
| oseltamivir [who-dd] |
| oseltamivir [hsdb] |
| oseltamivir [ema epar] |
| CS-0552 |
| SCHEMBL32035 |
| (3r,4r,5s)-4-acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid ethyl ester |
| ethyl (3r, 4r, 5s)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate |
| (3r,4r,5s)-ethyl 4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylate |
| (3r,4r,5s)-4-acetylamino-5-amino-3-(1-ethyl-propoxy)cyclohex-1-enecarboxylic acid ethyl ester |
| VSZGPKBBMSAYNT-RRFJBIMHSA-N |
| DTXSID9044291 , |
| AB00173476_04 |
| sr-05000001499 |
| (3r,4r,5s)-4-acetylamino-5-amino-3(1-ethylpropoxy) -1-cyclohexene-1-carboxylic acid ethyl ester |
| SR-05000001499-1 |
| DT-0013 |
| oseltamivir 100 microg/ml in acetonitrile |
| Q211509 |
| EX-A3415 |
| oseltamivir-phosphate |
| gs 4104;gop-a-flu;gs-4104;tamiflu-free;tamvir |
| NCGC00095191-12 |
| NCGC00095191-16 |
| NCGC00095191-06 |
| gtpl11427 |
| ro640796 |
| O0591 |
| E84533 |
| rel-ethyl (3r,4r,5s)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate |
| 182367-47-1 |
| dtxcid7024291 |
| j05ah02 |
| ethyl (3r,4r,5s)-4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate |
Oseltamivir is an orally administered antiviral medication. It selectively inhibits the influenza neuraminidase enzymes that are essential for viral replication and it is active against both influenza A and B viruses.
Oseltamivir for PEP has an efficacy of 58.5% (15.6% to 79.6) for households and of 68% (34.9 to 84.2%) to 89% in contacts of index cases. The drug has a good tolerability profile in infants and children aged ≤24 months.
Oseltamivir has been used for treatment of influenza A and B infections, but recent reports documented that it was less active against the latter. By April 30, 2010, a total of 285 resistant cases were reported worldwide, including 45 in the United Kingdom.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Oseltamivir has a good tolerability profile in infants and children aged ≤24 months. " | ( A prospective observational study of oseltamivir safety and tolerability in infants and young children ≤24 months. Blumentals, WA; Miller, MK; Rath, BA; Starzyk, K; Tetiurka, B; Wollenhaupt, M, 2015) | 2.13 |
| "Oseltamivir for PEP has an efficacy of 58.5% (15.6% to 79.6) for households and of 68% (34.9 to 84.2%) to 89% in contacts of index cases." | ( Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Demicheli, V; Di Pietrantonj, C; Jefferson, TO; Jones, M; Rivetti, D, 2006) | 1.06 |
| "Oseltamivir has the most abundant evidence, including in the hospital and long-term care (LTC) facilities, and the strongest evidence for reducing mortality and complications." | ( Treatment and prevention of influenza in geriatric patients. Bulloch, MN, ) | 0.85 |
| "Oseltamivir has the most versatility in preventing and treating influenza in geriatric patients. " | ( Treatment and prevention of influenza in geriatric patients. Bulloch, MN, ) | 1.57 |
| "Oseltamivir has not been shown to have efficacy, and corticosteroids are currently not recommended." | ( Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. Cutrell, JB; Jodlowski, TZ; Monogue, ML; Sanders, JM, 2020) | 1.28 |
| "Oseltamivir has been used to treat children with influenza for nearly 2 decades, with treatment currently approved for infants aged ≥2 weeks. " | ( Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials. Brooks, WA; Heikkinen, T; Malosh, RE; Martin, ET; Monto, AS; Whitley, RJ, 2018) | 2.23 |
| "Oseltamivir has been found less binding affinity with MT." | ( The inhibitory performance of flavonoid cyanidin-3-sambubiocide against H274Y mutation in H1N1 influenza virus. Kannan, S; Kolandaivel, P, 2018) | 1.2 |
| "Oseltamivir has complex PK which requires modelling to properly understand the relationship between dose and concentration with time, and there is a lack of clarity on appropriate pharmacodynamic endpoints." | ( Pharmacokinetics and pharmacodynamics of oseltamivir in neonates, infants and children. Lutsar, I; Standing, JF; Tsolia, M, 2013) | 1.38 |
| "Oseltamivir has been demonstrated to prevent disease among exposed individuals, as well as to shorten the duration of illness and lessen the likelihood of complications among those infected." | ( Oseltamivir for influenza in pregnancy. Beigi, RH; Caritis, SN; Venkataramanan, R, 2014) | 2.57 |
| "Oseltamivir has a good tolerability profile in infants and children aged ≤24 months. " | ( A prospective observational study of oseltamivir safety and tolerability in infants and young children ≤24 months. Blumentals, WA; Miller, MK; Rath, BA; Starzyk, K; Tetiurka, B; Wollenhaupt, M, 2015) | 2.13 |
| "Oseltamivir has been demonstrated to prevent disease after exposure, treat infected individuals, as well as lessen the likelihood of complications." | ( Oseltamivir for the treatment of H1N1 influenza during pregnancy. Beigi, RH; Caritis, SN; Pillai, VC; Venkataramanan, R, 2015) | 2.58 |
| "Oseltamivir has been widely used to treat patients with influenza; however, its effects have been debated. " | ( Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials. Pan, H; Qiu, S; Shen, Y; Wang, J; Zhang, Q, 2015) | 2.15 |
| "Oseltamivir has no protective effect on mortality among patients with 2009A/H1N1 influenza." | ( Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Del Mar, CB; Doshi, P; Hama, R; Heneghan, CJ; Howick, J; Jefferson, T; Jones, MA; Mahtani, KR; Nunan, D; Onakpoya, I; Spencer, EA; Thompson, MJ, 2016) | 1.16 |
| "Oseltamivir has been predicted to reach high concentrations in surface waters and sewage works." | ( An environmental risk assessment for oseltamivir (Tamiflu) for sewage works and surface waters under seasonal-influenza- and pandemic-use conditions. Straub, JO, 2009) | 1.35 |
| "Oseltamivir carboxylate has high bioavailability and penetrates sites of infection at concentrations that are sufficient to inhibit viral replication." | ( Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. Davies, BE, 2010) | 1.41 |
| "Oseltamivir (has known by its brand name 'Tamiflu') is a prodrug, requiring ester hydrolysis for conversion to the active form, Oseltamivir carboxylate. " | ( Oseltamivir: a first line defense against swine flu. Agrawal, R; Kalra, A; Kokil, GR; Rewatkar, PV; Verma, A, 2010) | 3.25 |
| "Oseltamivir has been used widely for prophylaxis or treatment during outbreaks of the pandemic influenza virus (H1N1) in several countries. " | ( Detection of oseltamivir sensitive/resistant strains of pandemic influenza A virus (H1N1) from patients admitted to hospitals in Thailand. Makkoch, J; Payungporn, S; Poomipak, W; Poovorawan, Y; Rianthavorn, P; Theamboonlers, A, 2011) | 2.18 |
| "Oseltamivir has been widely used for pandemic (H1N1) 2009 virus infection, and by April 30, 2010, a total of 285 resistant cases were reported worldwide, including 45 in the United Kingdom. " | ( Oseltamivir-resistant pandemic (H1N1) 2009 virus infection in England and Scotland, 2009-2010. Calatayud, L; Lackenby, A; McMenamin, J; Pebody, R; Phin, NF; Reynolds, A; Zambon, M, 2011) | 3.25 |
| "Oseltamivir has dominated the U.S. " | ( U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic. Borders-Hemphill, V; Mosholder, A, 2012) | 1.82 |
| "Oseltamivir (Tamiflu) has been shown to be effective as a treatment and chemoprophylaxis for influenza virus infections. " | ( Oseltamivir inhibits both viral entry and release but enhances apoptosis of cells infected with influenza A H1N1. Du, N; Gao, R; Li, Z; Liu, D; Shu, Y; Zhu, Y, 2013) | 3.28 |
| "Oseltamivir has been shown to prevent influenza when given for long-term prophylaxis or for post-exposure prophylaxis." | ( Early therapy with the neuraminidase inhibitor oseltamivir maximizes its efficacy in influenza treatment. Gillissen, A; Höffken, G, 2002) | 1.29 |
| "Oseltamivir has been studied over the course of a 5-year development programme in >11000 subjects from North America, Europe and the Southern Hemisphere, including otherwise healthy adults, approximately 500 elderly/high-risk subjects, and children (>1000) aged 1-12 years." | ( Safety and pharmacology of oseltamivir in clinical use. Dutkowski, R; Froehlich, E; Oo, C; Suter, P; Thakrar, B; Ward, P, 2003) | 1.34 |
| "Oseltamivir (Tamiflu) has been shown to be effective in the treatment and prevention of epidemic influenza infection in adults, adolescents and children (> or = 1 year)." | ( Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. Dutkowski, R; Small, I; Smith, J; Suter, P; Ward, P, 2005) | 2.49 |
| "Oseltamivir has proven to be safe and effective for the prevention or treatment of all known influenza subtypes, reducing the severity and duration of symptoms, the complications arising from influenza infection (pneumonia, hospitalisation, antibiotic use) and mortality." | ( Oseltamivir in the management of influenza. Oxford, J, 2005) | 2.49 |
| "Oseltamivir for PEP has an efficacy of 58.5% (15.6% to 79.6) for households and of 68% (34.9 to 84.2%) to 89% in contacts of index cases." | ( Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Demicheli, V; Di Pietrantonj, C; Jefferson, TO; Jones, M; Rivetti, D, 2006) | 1.06 |
| "Oseltamivir has been shown to decrease antibiotic use, the number of hospitalizations, and, probably, the risk of death after influenza." | ( Antiviral management of seasonal and pandemic influenza. Hayden, FG; Pavia, AT, 2006) | 1.06 |
| "Oseltamivir resistance has been reported in up to 2% of patients in clinical trials of oseltamivir and in up to 18% of treated children." | ( Neuraminidase inhibitor resistance in influenza viruses. Reece, PA, 2007) | 1.06 |
| "Oseltamivir has shown excellent tolerability and a low potential for viral resistance in pediatric studies." | ( The role of oseltamivir in the treatment and prevention of influenza in children. Whitley, RJ, 2007) | 1.44 |
| "Oseltamivir has been used for treatment of influenza A and B infections, but recent reports documented that it was less active against the latter. " | ( Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, Japan. Gejyo, F; Li, D; Oguma, T; Saito, R; Sakai, T; Sasaki, A; Sato, I; Sato, M; Shobugawa, Y; Suzuki, H; Suzuki, Y; Tanabe, N; Tsukada, H, 2008) | 2.13 |
Oseltamivir may increase survival when used within five days of symptom onset in influenza H1N1-infected patients who require ICU admission. A lower virological response was associated with female gender (OR, 0.45; 0.21-0.96) and baseline viral load ≥5 log cgeq/μL. OseltAmivir did not produce clinically relevant changes on nocturnal polysomnographic variables in young men.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Oseltamivir may increase survival when used within five days of symptom onset in influenza H1N1-infected patients who require ICU admission. " | ( Influenza treatment with oseltamivir outside of labeled recommendations. Blair, M; McQuade, B, 2015) | 2.16 |
| "Oseltamivir and zanamivir cause small reductions in the time to first alleviation of influenza symptoms in adults. " | ( Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Del Mar, CB; Doshi, P; Hama, R; Heneghan, CJ; Howick, J; Jefferson, T; Jones, MA; Mahtani, KR; Nunan, D; Onakpoya, I; Spencer, EA; Thompson, MJ, 2016) | 1.88 |
| "Oseltamivir did not produce clinically relevant changes on nocturnal polysomnographic variables in young Japanese men." | ( Absence of adverse effects of oseltamivir on sleep: a double-blind, randomized study in healthy volunteers in Japan. Abe, M; Davies, BE; Hosaka, Y; Inoue, Y; Kumagai, Y; Kuwahara, H; Mishima, K; Prinssen, EP; Rayner, CR; Toovey, S; Uchimura, N, 2011) | 1.38 |
| "For oseltamivir, a lower clinical response was associated with female gender (HR, 0.53; 95% CI, 0.36-0.79), baseline symptoms score >14 (HR, 0.47; 0.32-0.70), viral load ≥5 log cgeq/μL (HR, 0.63; 0.43-0.93), and initiation of antibiotics (HR, 0.30; 0.12-0.76); a lower virological response was associated with female gender (OR, 0.45; 0.21-0.96), baseline viral load ≥5 log cgeq/μL (OR, 0.40; 0.20-0.84) and days 0-2 incomplete compliance (OR, 0.31; 0.10-0.98)." | ( Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008-2009 winter. Blanchon, T; Bouscambert, M; Carrat, F; Charlois-Ou, C; Dornic, Q; Duval, X; Enouf, V; Leport, C; Mentré, F; Mosnier, A, 2013) | 1.1 |
Oseltamivir treatment of intranasally infected mice with the mouse hepatitis coronavirus 3 (MHV-3) decreased lung neutrophil infiltration, viral load, and tissue damage. Odds of death were reduced by two thirds (odds ratio (OR): 0.32; 95% confidence interval (CI):”0.11-0.93), in inpatients treated with a standard course of oseltimivir 75 mg two times daily for 5 days.
There were no statistically significant differences in the occurrence of adverse neurologic events during therapy among subjects treated with oseltamivir versus those treated with the adamantanes (P = 0.02). Importantly, osel tamsivir phosphate administration had adverse effects on the liver of mice and significantly increased messenger R.
The prodrug oseltamivir has been shown to be efficacious and safe for the treatment of influenza. However, pharmacokinetic information was lacking for children below 5 years of age. Two studies were conducted to assess the potential for pharmacokinetics of peramvir when coadministered with oselmivir or rimantadine. Pregnancy had only a modest effect upon the pharmacokinetically parameters of osel tamivirs.
This study aims to explore the efficacy and safety of Lianhua Qingwen preparations combined with Oseltamivir in the treatment of influenza patients.
| Excerpt | Reference | Relevance |
|---|---|---|
| " In vivo and in vitro studies were conducted to evaluate the renal drug-drug interaction potential of oseltamivir." | ( The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Barrett, J; Cihlar, T; Hill, G; Ho, ES; Liu, B; Oo, C; Prior, K; Ward, P; Wiltshire, H, 2002) | 0.84 |
| " Probenecid plus oseltamivir 45 mg achieved all the pharmacokinetic parameters expected of oseltamivir alone, but combination with oseltamivir 30 mg and dose interval extension approaches did not." | ( Population pharmacokinetics of oseltamivir when coadministered with probenecid. Boak, LM; Chanu, P; Gieschke, R; Jonsson, EN; Rayner, CR, 2008) | 0.97 |
| " Healthy volunteers were randomized to a three-arm, open-label study and given 75 mg oral oseltamivir every 24 h (group 1), 75 mg oseltamivir every 48 h (q48h) combined with 500 mg probenecid four times a day (group 2), or 75 mg oseltamivir q48h combined with 500 mg probenecid twice a day (group 3) for 15 days." | ( Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Cunningham, F; Davey, RT; Deyton, LR; Goetz, MB; Holodniy, M; Lee, KK; Lin, ET; Olivo, N; Penzak, SR; Raisch, DW; Straight, TM, 2008) | 0.84 |
| " These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases." | ( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009) | 0.35 |
| " Along with the case studies, several hurdles for drug development such as dose selection, frequency of dosing, and duration of the clinical studies, picking the right surrogate(s) for efficacy, evaluation of drug-drug interaction potential with other co-substrates have been discussed in line with the current day requirements for a sound clinical and regulatory strategy." | ( Is there a place for drug combination strategies using clinical pharmacology attributes?--review of current trends in research. Srinivas, NR, 2009) | 0.35 |
| " The adverse events related to ribavirin and drug-drug interactions during therapy for hepatitis C are discussed." | ( Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction? Buti, M; Esteban, R; Simón-Talero, M, 2012) | 0.68 |
| " Three dimensional analysis of drug-drug interactions revealed that IFN-λ1 interacted with IFN-β and oseltamivir carboxylate in an additive or synergistic manner, respectively, to inhibit influenza A virus replication in human airway epithelial cells." | ( In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate. Donnelly, RP; Ilyushina, NA, 2014) | 0.84 |
| " Here, we investigated the antiviral efficacy of the peptidomimetic furin inhibitor MI-701 in combination with oseltamivir carboxylate and ribavirin against the infection of highly pathogenic avian influenza viruses (HPAIV) that are activated by the host protease furin." | ( Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells. Böttcher-Friebertshäuser, E; Dahms, SO; Garten, W; Hardes, K; Klenk, HD; Lu, Y; Steinmetzer, T; Than, ME, 2015) | 0.87 |
| " This mechanistic static approach was further applied to quantitatively predict renal drug-drug interactions (AFE ∼1." | ( Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach. Feng, B; Litchfield, J; Mathialagan, S; Piotrowski, MA; Tess, DA; Varma, MV, 2017) | 0.46 |
| " This study evaluated the therapeutic antiviral effects of PUL-042 against established influenza A pneumonia, when given alone or in combination with oseltamivir." | ( Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir. Dickey, BF; Evans, SE; Gilbert, BE; Kirkpatrick, CT; Leiva-Juarez, MM; Markesich, D; Scott, B; Tuvim, MJ, 2018) | 0.88 |
| "To assess correlation of cytokines levels and therapy regimes a relationship of the time course of changes in the cytokines IFN-γ, IFN-α, IL-18, and TNF-α to the treatment option for influenza A (H1N1) pdm09 with umifenovir (Arbidol) 800 mg/day for 5 days (n=50); oseltamivir (Tamiflu) 150 mg/day for 5 days (n=50); umifenovir (Arbidol) 800 mg/day for 5 days in combination with Kagocel 72 mg/day for 2 days." | ( [Time course of changes in cytokines (IFN-γ, IFN-α, IL-18, TNF-α) in the treatment of moderate influenza A (H1N1) pdm09 (2013-2016) with oseltamivir (Tamiflu) and umifenovir (Arbidol) alone and in combination with Kagocel]. Dmitrenko, KA; Popov, AF; Shchelkanov, MY; Simakova, AI, ) | 0.51 |
| " The aim of this study was to assess the drug-drug interaction between baloxavir marboxil and oseltamivir." | ( Evaluation of Drug-Drug Interaction Potential between Baloxavir Marboxil and Oseltamivir in Healthy Subjects. Ishibashi, T; Kawaguchi, N; Koshimichi, H; Wajima, T, 2018) | 0.93 |
| "Eighteen healthy adult subjects received three treatments in a crossover fashion: single administration of baloxavir marboxil 40 mg alone, repeated twice-daily administration of oseltamivir at 75 mg for 5 days, or single administration of baloxavir marboxil at 40 mg in combination with repeated twice-daily administration of oseltamivir at 75 mg for 5 days." | ( Evaluation of Drug-Drug Interaction Potential between Baloxavir Marboxil and Oseltamivir in Healthy Subjects. Ishibashi, T; Kawaguchi, N; Koshimichi, H; Wajima, T, 2018) | 0.9 |
| "The lack of a clinically meaningful drug-drug interaction between baloxavir marboxil and oseltamivir has been established." | ( Evaluation of Drug-Drug Interaction Potential between Baloxavir Marboxil and Oseltamivir in Healthy Subjects. Ishibashi, T; Kawaguchi, N; Koshimichi, H; Wajima, T, 2018) | 0.93 |
| " Here we examined the use of TIZ in combination with oseltamivir, both in vitro and using the ferret model for influenza infection and found that the combination of the two drugs did not provide significant benefit in reducing the emergence or selection of oseltamivir-resistant virus." | ( Host-targeted nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir. Barr, IG; Hurt, AC; Koszalka, P; Mifsud, E; Rossignol, JF; Tilmanis, D, 2020) | 1.02 |
| " The aim of this study was to interpret the clinical efficacy and safety of CPM combined with oseltamivir in the treatment of adult influenza by reviewing all relevant randomized controlled trials, and to provide new ideas and methods for the treatment of influenza." | ( Clinical Efficacy and Safety of Chinese Patent Medicine Combined with Oseltamivir for the Treatment of Adult Influenza: A Systematic Review and Meta-Analysis. Duan, N; Li, L; Li, X; Liu, B; Lu, C; Xiong, Y; Zhang, C; Zhang, Y, 2022) | 1.17 |
| "This study aims to explore the efficacy and safety of Lianhua Qingwen preparations combined with Oseltamivir in the treatment of influenza patients." | ( [Systematic review and Meta-analysis of Lianhua Qingwen preparations combined with Oseltamivir in treatment of influenza]. Guo, YH; Li, B; Li, ZY; Liu, QQ; Yan, YM; Yang, XJ; Zhao, CX; Zhao, GZ, 2022) | 1.16 |
| " Combined with LFD, the limit of detection of RPA-CRISPR/Cas12a-LFD is about 20 copies of target sequence per reaction." | ( An ultrasensitive, rapid and portable method for screening oseltamivir-resistant virus based on CRISPR/Cas12a combined with immunochromatographic strips. Fei, C; Gu, F; Liu, J; Liu, Y; Wang, M; Xue, F; Yang, F; Yang, M; Zhang, H; Zhang, L; Zhu, C, 2022) | 0.96 |
The goal of this study was to improve the intestinal mucosal cell membrane permeability of the poorly absorbed guanidino analogue of a neuraminidase inhibitor, oseltamivir carboxylate. The results support the feasibility of modified-release formulation development.
| Excerpt | Reference | Relevance |
|---|---|---|
| "GS4071 is a novel potent inhibitor of influenza neuraminidase (Ki < 1 nM) with low (< 5%) oral bioavailability in animals." | ( Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Bidgood, A; Cundy, KC; Eisenberg, EJ, 1997) | 0.3 |
| " Both parent compounds and the prodrug of the guanidino analog exhibited poor oral bioavailability (2 to 4%) and low peak concentrations in plasma (Cmaxs; Cmax <0." | ( Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Bischofberger, N; Chen, MS; Cundy, KC; Eisenberg, EJ; Escarpe, PA; Jakeman, KJ; Kim, CU; Lew, W; Li, W; Mendel, DB; Merson, J; Sweet, C; Williams, M; Zhang, L, 1998) | 0.3 |
| " The absolute bioavailability of the active metabolite from orally administered oseltamivir is 80%." | ( Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. He, G; Massarella, J; Ward, P, 1999) | 0.8 |
| " Zanamivir is delivered by inhalation because of its low oral bioavailability whereas oseltamivir is administered by mouth." | ( Influenza virus neuraminidase inhibitors. Gubareva, LV; Hayden, FG; Kaiser, L, 2000) | 0.53 |
| "We have investigated the long-term prophylactic efficacy and safety of oseltamivir phosphate (Ro64-0796), an orally bioavailable prodrug of novel, potent and selective type A and type B influenzavirus neuraminidase inhibitor, when Ro64-0796 was administered orally to the healthy volunteers." | ( [Efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir for prophylaxis against influenza--placebo-controlled double-blind multicenter phase III trial]. Kashiwagi, S; Kudoh, S; Watanabe, A; Yoshimura, I, 2000) | 0.78 |
| " It is highly bioavailable in capsule and suspension formulations and, after conversion to the active metabolite in the liver, distributes throughout the body, including the upper and lower respiratory tract." | ( Oseltamivir: a clinical and pharmacological perspective. Aoki, FY; Doucette, KE, 2001) | 1.75 |
| " The bioavailability (90% confidence intervals) of Ro 64-0802 following administration of oseltamivir together with Maalox suspension vs administration of oseltamivir alone, was 90% (83." | ( Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids. Barrett, J; Dorr, A; Oo, C; Snell, P, 2002) | 0.75 |
| " The results support the feasibility of modified-release formulation development whilst confirming the high and consistent oral bioavailability of oseltamivir." | ( Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules. Barrett, J; Dorr, A; Liu, B; Oo, C; Snell, P; Wilding, I, 2003) | 0.76 |
| " The C-1 ethyl ester prodrugs of the substituted C-4 vinyl analogues gave compounds with excellent oral bioavailability (F > 60%) when dosed in rat." | ( Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors. Carrick, RJ; Gu, YG; Kati, WM; Kempf, DJ; Kempf-Grote, A; Kohlbrenner, WE; Krueger, AC; Laver, WG; Madigan, DL; Maring, CJ; Marsh, KC; Molla, A; Montgomery, DA; Sham, HL; Steffy, KR; Stewart, KD; Stoll, VS; Sun, M; Xu, Y; Zhao, C, 2005) | 0.33 |
| " This review describes the surprising breakthrough findings leading to the development of Tamiflu, a clinically efficacious orally bioavailable drug targeting the active site of influenza neuraminidase (NA)." | ( Optimization of small molecule drugs binding to highly polar target sites: lessons from the discovery and development of neuraminidase inhibitors. Graves, BJ; Klumpp, K, 2006) | 0.33 |
| "The bioavailability of oseltamivir phosphate and oseltamivir carboxylate were assessed in healthy volunteers when delivered as a solution of the active pharmaceutical ingredient (API) compared with the commercial capsule formulation." | ( Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study. Brewster, M; Dutkowski, R; Robson, R; Smith, JR, 2006) | 0.64 |
| " Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects." | ( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007) | 0.34 |
| " 150 mg bid of oseltamivir was well absorbed and converted extensively to OC." | ( Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. Anh, GT; Bien, NM; Binh, NG; Chau, NQ; Crusat, M; Day, N; de Jong, MD; Farrar, JJ; Fox, A; Ha, NH; Hanh, TT; Hien, ND; Horby, P; Lien, TT; Lindegardh, N; Ngoc, NM; Stepniewska, K; Taylor, WR; Thinh, BN; Trung, NV; Wertheim, H; White, NJ, 2008) | 2.14 |
| " The purpose of this study was to compare the bioavailability of two 75 mg oral formulations of oseltamivir: a generic drug, GOP-A-Flu (test, Government Pharmaceutical Organization, Thailand) and Tamiflu (reference, Hoffmann-La Roche Ltd." | ( A randomized, open-label, 2-period, crossover bioequivalence study of two oral formulations of 75 mg oseltamivir in healthy Thai volunteers. Chatsiricharoenkul, S; Kongpatanakul, S; Panich, U; Pongnarin, P; Sangvanich, P; Sathirakul, K, 2008) | 0.78 |
| " The low affinity of OC to sediments suggests that presence of sediments would not reduce its bioavailability to microbial degradation." | ( Environmental fate of the antiviral drug Tamiflu in two aquatic ecosystems. Accinelli, C; Fick, J; Lindberg, R; Olsen, B; Saccà, ML, 2009) | 0.35 |
| " Case studies discussed in this review include: a) the use of probenecid to block the organic anion renal transport of oseltamivir carboxylate (a key active metabolite of oseltamivir phosphate) to reduce the oral dose of oseltamivir phosphate; b) the use of rifampicin to induce the CYP2C19 enzyme and thereby, promote the formation of a potent active metabolite M8 (nelfinavir hydroxyl-t-butylamide) and achieve sustained blood levels to combat HIV infection along with ritonavir; c) the use of CYP3A4 inhibitors such as ketoconazole, cyclosporin A, ritonavir etc to overcome the extensive presystemic metabolism of docetaxel and enhance the oral bioavailability of docetaxel." | ( Is there a place for drug combination strategies using clinical pharmacology attributes?--review of current trends in research. Srinivas, NR, 2009) | 0.56 |
| "The objective of this study was to assess the relative bioavailability of oseltamivir carboxylate (active metabolite) following oral administration of the market suspension, the clinical trial suspension and the market capsule formulations of oseltamivir (prodrug) in healthy subjects." | ( Oseltamivir oral suspension and capsules are bioequivalent for the active metabolite in healthy adult volunteers. Barrett, J; Kirkpatrick, C; Lennon, S; Rayner, C, 2009) | 2.03 |
| "Oseltamivir was well absorbed enterically in critically ill patients admitted to the ICU with suspected or confirmed pandemic (H1N1) influenza." | ( Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. Ahern, S; Ariano, RE; Kanji, S; Kumar, A; Pisipati, A; Rello, J; Sitar, DS; Zarychanski, R; Zelenitsky, SA, 2010) | 2.07 |
| " Oseltamivir carboxylate has high bioavailability and penetrates sites of infection at concentrations that are sufficient to inhibit viral replication." | ( Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. Davies, BE, 2010) | 1.59 |
| " According to the currently available literature, the pharmacokinetics of oseltamivir carboxylate after oral administration of oseltamivir are characterized by mean ± SD bioavailability of 79 ± 12%, apparent clearance of 25." | ( Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. Aouri, M; Buclin, T; Decosterd, LA; Ivanyuk, A; Meylan, P; Widmer, N, 2010) | 2.03 |
| " This drug is available in oral solid and liquid formulations, has excellent peroral bioavailability in adults, and generally has a very favorable safety profile." | ( Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant. Abdel-Rahman, SM; Kearns, GL; Newland, JG, 2011) | 0.65 |
| " The absolute oral bioavailability of these compounds was lower than 12%." | ( Development of oseltamivir phosphonate congeners as anti-influenza agents. Chen, CA; Chen, CL; Cheng, TJ; Cheng, YS; Fang, JM; Hsieh, WC; Hu, OY; Huang, PW; Jan, JT; Lin, WH; Shie, JJ; Tarbet, EB; Wang, SY; Weinheimer, S; Wong, CH, 2012) | 0.73 |
| " Guanidine oseltamivir carboxylate (GOCarb) is a highly active polar antiviral agent with insufficient oral bioavailability (4%) to be an effective therapeutic agent." | ( Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue. Amidon, GL; Dahan, A; Gupta, D; Hilfinger, J; Lee, KD; Tsume, Y; Varghese Gupta, S, 2013) | 0.99 |
| " Among different prodrug strategies pursued, a simple amidoxime ethyl ester (9) exhibited a superior PK profile with an oral bioavailability of 31% (rats), which is comparable to oseltamivir (36%)." | ( Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A. Clement, B; Koch, O; Kotthaus, J; Müller-Fielitz, H; Raasch, W; Riebling, L; Schade, D; Schmidtke, M; Seidel, N, 2014) | 0.85 |
| " The lower bioavailability may explain the lower toxicity of zanamivir compared to oseltamivir." | ( Neuraminidase inhibitors for preventing and treating influenza in adults and children. Del Mar, CB; Doshi, P; Hama, R; Heneghan, CJ; Howick, J; Jefferson, T; Jones, MA; Mahtani, KR; Nunan, D; Onakpoya, I; Spencer, EA; Thompson, MJ, 2014) | 0.63 |
| " Unfortunately, low oral bioavailability precludes their development as second generation neuraminidase inhibitors for treating influenza as this leaves them unsuitable for use in an oral formulation." | ( Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay. Arns, S; Bourque, E; Dercho, S; Galey, A; Gusti, V; Liggins, R; Paquette, J; Ross, F; Sun, S; Tan, J; Udechukwu, J; Webb, M; Withers, SG; Zisman, N, 2015) | 0.42 |
| "The goal of this study was to improve the intestinal mucosal cell membrane permeability of the poorly absorbed guanidino analogue of a neuraminidase inhibitor, oseltamivir carboxylate (GOC) using a carrier-mediated strategy." | ( Carrier-Mediated Prodrug Uptake to Improve the Oral Bioavailability of Polar Drugs: An Application to an Oseltamivir Analogue. Amidon, GL; Gose, T; Hilfinger, J; Incecayir, T; Lipka, E; Nakanishi, T; Sun, J; Tamai, I; Tsume, Y; Xu, H, 2016) | 0.84 |
| " Transport experiments using Caco-2 cell monolayers often lead to misestimation of the intestinal absorption of prodrugs because of this difference, as prodrugs designed to increase the bioavailability of parent drugs are made to be resistant to hCE2 in the intestine, so that they can be hydrolyzed by hCE1 in the liver." | ( Establishment and Characterization of a Novel Caco-2 Subclone with a Similar Low Expression Level of Human Carboxylesterase 1 to Human Small Intestine. Imai, T; Kurokawa, K; Nishiyama, H; Ohura, K; Saco, S, 2016) | 0.43 |
| " The lipophilic acyl substituents were verified to improve cell permeability, and may also improve the bioavailability of acylguanidine compounds." | ( Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses. Cheng, TJ; Cheng, YE; Chiu, DC; Fang, JM; Hsu, PH; Jan, JT; Lee, PS; Tsai, KC; Wu, KL, 2018) | 0.74 |
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| " This comprehensive review covers a range of OS analogs shown to be effective against influenza virus, comparing different types of substituent group that contribute to the activity and bioavailability of these compounds." | ( Oseltamivir analogs with potent anti-influenza virus activity. Durvasula, R; Goicoechea, S; Kempaiah, P; Kumar, S; Pearce, CM; Rathi, B, 2020) | 2 |
Oseltamivir had no physiologically relevant effect on body temperature, but induced a short-lived and small dose-independent decrease in temperature in all active treatment groups at 1 hr after dosing only. The pharmacokinetic profile of the active metabolite is linear and dose-proportional, with less th th.
| Role | Description |
|---|---|
| prodrug | A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. |
| EC 3.2.1.18 (exo-alpha-sialidase) inhibitor | An antiviral drug targeted at influenza viruses. Its mode of action consists of blocking the function of the viral neuraminidase protein (EC 3.2.1.18), thus preventing the virus from budding from the host cell. |
| antiviral drug | A substance used in the prophylaxis or therapy of virus diseases. |
| environmental contaminant | Any minor or unwanted substance introduced into the environment that can have undesired effects. |
| xenobiotic | A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| cyclohexenecarboxylate ester | |
| amino acid ester | Any carboxylic ester derivative of an amino acid. |
| primary amino compound | A compound formally derived from ammonia by replacing one hydrogen atom by an organyl group. |
| acetamides | Compounds with the general formula RNHC(=O)CH3. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 0.0074 | 0.0013 | 10.1577 | 42.8575 | AID1259253 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 0.7079 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Neuraminidase | Influenza A virus (A/Turkey/651242/2006(H5N1)) | IC50 (µMol) | 0.1104 | 0.0003 | 0.3103 | 2.8247 | AID1401152; AID560872 |
| Neuraminidase | Influenza A virus (A/Turkey/651242/2006(H5N1)) | Ki | 0.0079 | 0.0010 | 0.0044 | 0.0079 | AID560877 |
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | IC50 (µMol) | 13.0076 | 0.0000 | 0.5035 | 10.0000 | AID1059386; AID1059387; AID1064127; AID1064128; AID1064131; AID1064132; AID1073042; AID1073043; AID1073044; AID1073045; AID1156845; AID1266207; AID1266208; AID1266209; AID1266210; AID1401148; AID1401151; AID1588930; AID294072; AID384920; AID443293; AID443294; AID443295; AID443296; AID455703; AID527157; AID527158; AID527159; AID527160; AID532116; AID542945; AID542946; AID542947; AID542948; AID542949; AID542950; AID542951; AID542952; AID542953; AID542954; AID542955; AID542956; AID542957; AID542958; AID542959; AID542960; AID542961; AID542962; AID542963; AID542964; AID542965; AID542966; AID542967; AID542968; AID542969; AID542970; AID542971; AID542995; AID542996; AID542997; AID542998; AID542999; AID543000; AID543001; AID543002; AID543003; AID543004; AID543006; AID543007; AID543183; AID543184; AID543186; AID543187; AID560874; AID561142; AID561144; AID591600; AID636870; AID648767; AID648768; AID753435; AID753436 |
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | Ki | 0.0005 | 0.0001 | 1.7868 | 7.7000 | AID314411; AID560879 |
| Neuraminidase | Influenza A virus (A/duck/Laos/25/2006(H5N1)) | IC50 (µMol) | 2.0317 | 0.0001 | 1.1047 | 6.0950 | AID1401149; AID560875; AID561145 |
| Neuraminidase | Influenza A virus (A/duck/Laos/25/2006(H5N1)) | Ki | 0.0011 | 0.0005 | 0.0008 | 0.0011 | AID560880 |
| Neuraminidase | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | IC50 (µMol) | 1.1344 | 0.0005 | 0.9767 | 10.0000 | AID1401150; AID147493; AID1502944; AID1588927; AID1588929; AID532114 |
| Neuraminidase | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | Ki | 12.1000 | 0.0100 | 0.4350 | 0.8600 | AID1365369 |
| Neuraminidase | Influenza A virus (A/USSR/90/1977(H1N1)) | IC50 (µMol) | 27.1760 | 0.0014 | 0.0055 | 0.0130 | AID1167295; AID1167296; AID1186763; AID1186764 |
| Neuraminidase | Influenza B virus (B/Lee/1940) | IC50 (µMol) | 0.0050 | 0.0010 | 0.4028 | 10.0000 | AID147494 |
| Neuraminidase | Influenza B virus (B/Lee/1940) | Ki | 0.0011 | 0.0001 | 0.0010 | 0.0025 | AID314410 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | IC50 (µMol) | 1,300.0000 | 0.0002 | 2.3185 | 10.0000 | AID582049 |
| Sialidase | Clostridium perfringens | IC50 (µMol) | 61.1000 | 0.0010 | 2.4572 | 9.8000 | AID1372135 |
| Acyl-CoA desaturase 1 | Mus musculus (house mouse) | IC50 (µMol) | 0.0080 | 0.0010 | 0.6830 | 3.4000 | AID1064128 |
| Neuraminidase | Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) | IC50 (µMol) | 0.0043 | 0.0007 | 0.0025 | 0.0049 | AID560873; AID561143 |
| Neuraminidase | Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) | Ki | 0.0049 | 0.0004 | 0.0027 | 0.0049 | AID560878 |
| Neuraminidase | Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) | IC50 (µMol) | 0.0003 | 0.0002 | 0.0013 | 0.0048 | AID560871; AID561141 |
| Neuraminidase | Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) | Ki | 0.0001 | 0.0001 | 0.0003 | 0.0005 | AID560876 |
| Neuraminidase | Influenza A virus (A/Singapore/1/1957(H2N2)) | IC50 (µMol) | 0.0030 | 0.0010 | 0.0050 | 0.0170 | AID1795726 |
| Neuraminidase | Influenza A virus (A/Aichi/2/1968(H3N2)) | IC50 (µMol) | 0.0016 | 0.0016 | 0.0021 | 0.0027 | AID532115 |
| Sialidase-4 | Homo sapiens (human) | IC50 (µMol) | 3,666.6667 | 8.3000 | 8.3000 | 8.3000 | AID1405015; AID1889679; AID532109 |
| Sialidase-3 | Homo sapiens (human) | IC50 (µMol) | 5,250.0000 | 2.4000 | 5.9980 | 8.1700 | AID1405014; AID1889678; AID532108; AID539786 |
| Sialidase-2 | Homo sapiens (human) | IC50 (µMol) | 2,333.3333 | 3.9000 | 6.7333 | 7.8000 | AID1405013; AID1889677; AID532107 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | Km | 4,200.0000 | 0.0140 | 3.7172 | 10.0000 | AID581725 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID565049 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells selected at 31 uM of oseltamivir after 8 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID443832 | Antiviral activity against Influenza B virus (B/Hong Kong/5/72) assessed as cell viability by cell-based MTS assay | 2009 | Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19 | Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study. |
| AID1553317 | Antiviral activity against Influenza A virus A/JiangXi-DongHu/312/2006(H3N2) infected in human A549 cells assessed as inhibition of virus plaque formation by CPE reduction assay | 2019 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18 | Incorporation of privileged structures into 3-O-β-chacotriosyl ursolic acid can enhance inhibiting the entry of the H5N1 virus. |
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | |||
| AID542957 | Inhibition of Influenza A virus (A/Aichi/2/1968(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID510177 | Cytotoxicity against african green monkey Vero cells after 48 hrs | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities. |
| AID565272 | Ratio of IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V and H274Y mutant to IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID561129 | Antiviral activity against Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) infected in BALB/c mouse assessed as decrease in viral load in brain at 20 mg/kg, po BID for 5 days measured on day 9 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID387575 | Cytotoxicity against MDCK cells assessed as alteration in cell morphology by MTS assay | 2008 | Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18 | Synthesis and antiviral evaluation of acyclic azanucleosides developed from sulfanilamide as a lead structure. |
| AID455703 | Noncompetitive inhibition of recombinant influenza A virus rvH1N1 A/Bervig_Mission/1/18 neuraminidase | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. |
| AID565265 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID286172 | Antiviral activity against 10 EID50 influenza A/Vietnam/1203/04 H5N1 virus inoculated ferrets assessed as day of death at 5 mg/kg after 4 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID581718 | AUC (0 to infinity) ratio in brain to plasma in perfused Sprague-Dawley rat at 30 mg/kg, iv | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1222258 | AUC(0 to 24 hrs) in adult fed Sprague-Dawley rat at 30 mg/kg, po administered as 125 mM aqueous Gly-Sar solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID567617 | Antiviral activity against influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID565466 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID658749 | Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | 2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies. |
| AID542955 | Inhibition of Influenza A virus (A/Yamagata/83/2006(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1418310 | Inhibition of wild type Influenza A virus (A/chicken/Hubei/327/2004(H5N1)) M2 proton channel V27A/S31N mutant expressed in yeast after 46 to 48 hrs by yeast growth restoration assay | 2018 | European journal of medicinal chemistry, Nov-05, Volume: 159 | Synthesis and structure-activity relationship study of arylsulfonamides as novel potent H5N1 inhibitors. |
| AID565054 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 25 nM of oseltamivir after 3 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID634759 | Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID611763 | Antiviral activity against Sindbis virus infected in Vero cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID768189 | Antiviral activity against influenza A virus H1N1 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies. |
| AID1204717 | Total plasma concentration in CD1 mouse at 30 mg/kg, po measured at 60 mins by reversed-phase UPLC/MS analysis | 2015 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12 | Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay. |
| AID567605 | Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID733267 | Antiviral activity against Influenza B virus (B/Panama/45/1990) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition. |
| AID1222302 | AUC(0 to infinity) in adult fasted Sprague-Dawley rat at 30 mg/kg, po administered as water solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID582070 | Prodrug conversion in commercial liver S9 fractions assessed as oseltamivir carboxylate generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID766686 | Antiviral activity against Influenza A virus H3N3 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity | 2013 | European journal of medicinal chemistry, Sep, Volume: 67 | Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity. |
| AID561123 | Antiviral activity against Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) infected in BALB/c mouse assessed as decrease in viral load in lung at 20 mg/kg, po BID for 5 days measured on day 9 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID542964 | Inhibition of Influenza A virus (A/Wisconsin/67/2005(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1183510 | Antiviral activity against Influenza A virus A/New York/18/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay | 2014 | Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15 | Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. |
| AID542557 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) H274Y mutant infected in BALB/c mouse assessed as reduction in body weight at 10 mg/kg, po administered 48 hrs postinfection for 5 days measured on day 5 (Rvb = 22.2 %) | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID674367 | Antiviral activity against influenza A virus A/Hanfang/359/95 (H3N2) assessed as inhibition of virus-induced cytopathic effect in cell-based assay | 2012 | Journal of natural products, Jun-22, Volume: 75, Issue:6 | Alkaloids from the root of Isatis indigotica. |
| AID1502944 | Inhibition of neuraminidase activity in Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells using 4-MU-NANA as substrate pretreated for 30 mins followed by substrate addition measured after 2 hrs by fluorescence assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | C-Methylated Flavonoid Glycosides from Pentarhizidium orientale Rhizomes and Their Inhibitory Effects on the H1N1 Influenza Virus. |
| AID648767 | Inhibition of Influenza A virus H7N1 N1 neuraminidase expressed in baculovirus using 2'-(4-Methylumbelliferyl)-alpha-D-acetyl neuraminic acid as substrate incubated for 2 hrs prior to substrate addition measured after 5 hrs by fluorimetry | 2012 | Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6 | Synthesis and in vitro study of novel neuraminidase inhibitors against avian influenza virus. |
| AID286181 | Survival of 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus inoculated ferrets at 25 mg/kg after 24 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID581707 | Cmax in perfused Sprague-Dawley rat cerebrospinal fluid at 1000 mg/kg, po | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID581523 | Prodrug conversion in 42 days old female rat brain S9 fractions assessed as paranitrophenol generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1771093 | Cytotoxicity against dog MDCK cells assessed as decrease in cell viability by CCK8 assay | |||
| AID567595 | Antiviral activity against influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID582045 | Permeability from basolateral to apical side of pig LLC-PK1 cells over expressing human MDR1 | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID634833 | Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID567710 | Ratio of IC50 for influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID565241 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M and H274Y mutant infected in MDCK cells selected at 78 uM of oseltamivir after 8 passage after 48 hrs by hemagg | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID565478 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/12 | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID560892 | Antiviral activity against Influenza A virus (A/Turkey/651242/2006(H5N1)) infected in BALB/c mouse assessed as virus-induced change body weight at 20 mg/kg, po BID for 5 days measured on day 6 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID542950 | Inhibition of Influenza A virus (A/Yamagata/57/2002(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID582037 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 7000 uM in presence of P-gp inhibitor elacridar | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1077000 | Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus A/hanfang/359/95(H3N2) | 2014 | European journal of medicinal chemistry, Apr-09, Volume: 76 | 1,2,3-Triazole-containing derivatives of rupestonic acid: click-chemical synthesis and antiviral activities against influenza viruses. |
| AID1073033 | Inhibition of Clostridium perfringens neuraminidase by chemiluminescence based assay | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | Computer-guided approach to access the anti-influenza activity of licorice constituents. |
| AID582073 | Prodrug conversion in 42 days old male rat brain S9 fractions assessed as conversion of oseltamivir to oseltamivir carboxylate | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1409726 | Cytotoxicity against MDCK cells after 72 hrs by crystal violet staining based spectrophotometric method | 2018 | ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3 | Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants. |
| AID582048 | Efflux ratio of permeability from apical to basolateral side over basolateral to apical side in pig LLC-PK1 cells over expressing human MDR1 in presence of P-gp inhibitor elacridar | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | |||
| AID1222298 | Inhibition of human PEPT1 expressed in CHOK1 cells assessed as Gly-Sar uptake at 0.3 to 10 mM after 10 mins by HPLC coupled with radiodetection analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1365376 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity treated immediately after virus infection and measured after 48 hrs by SRB assay | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. |
| AID1204726 | Half life in CD1 mouse at 30 mg/kg, po | 2015 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12 | Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay. |
| AID581682 | Ratio of AUC (0 to infinity) after iv dose to AUC (0 to 8 hrs) after po dose in non-perfused Sprague-Dawley rat cerebrospinal fluid at 30 mg/kg | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID515132 | Inhibition of Influenza B virus B/Gifu/11/2005 wild type neuraminidase expressed in Sf21 insect cells preincubated for 30 mins measured after 60 mins by MUNANA based assay | 2010 | Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17 | Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. |
| AID560872 | Inhibition of Influenza A virus (A/Turkey/651242/2006(H5N1)) neuraminidase by fluorometric assay | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID565249 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 1250 nM of compound after 6 passage after 48 hrs by hemagglutininin tit | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1432501 | Cytotoxicity against MDCK cells after 48 hrs by by Reed and Muench analysis | 2017 | Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6 | Structure-activity relationship studies of 1-(1'-hydroxyalkyl)rupestonic acid methyl esters against influenza viruses. |
| AID286191 | Inhibition of influenza A/Vietnam/1203/04 virus replication in ferrets upper respiratory tract at 10 mg/kg twice daily after 24 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID542984 | Inhibition of Influenza B virus (B/Shanghai/361/2002(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567706 | Ratio of IC50 for influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567702 | Ratio of IC50 for influenza A (A/North Carolina/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme expressing wild type enzyme by NA-star substrate based chemi | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID634755 | Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID1222310 | AUC(0 to infinity) in adult fasted Sprague-Dawley rat at 30 mg/kg, po administered as 125 mM aqueous Gly-Sar solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID634831 | Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID294072 | Inhibition of Influenza A virus type A H3N2 neuraminidase | 2007 | Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7 | Design, synthesis, inhibitory activity, and SAR studies of pyrrolidine derivatives as neuraminidase inhibitors. |
| AID416779 | Cytotoxicity against MDCK cells by MTS assay | 2009 | Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7 | Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus. |
| AID561137 | Antiviral activity against Influenza A virus (A/Turkey/651242/2006(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in IL1alpha production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1222273 | Tmax in healthy human at 150 mg, po administered as single dose by HPLC-tandem mass spectrometry under fasting conditions | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID542579 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) infected in BALB/c mouse assessed as reduction in body weight at 1 mg/kg, po administered 48 hrs postinfection for 5 days measured on day 5 (Rvb = 17.4 %) | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID611770 | Cytotoxicity against dog MDCK cells assessed as alteration of cell morphology after 3 days by microscopy | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID384920 | Inhibition of influenza virus neuraminidase | 2008 | European journal of medicinal chemistry, Mar, Volume: 43, Issue:3 | QSAR study of neuraminidase inhibitors based on heuristic method and radial basis function network. |
| AID542994 | Inhibition of Influenza B virus (B/Yamagata/113/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID658606 | Cytotoxicity against MDCK cells assessed as cell viability by colorimetric formazan-based MTS assay | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | 2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies. |
| AID565465 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID237325 | Half-life determined after administration of compound dosed at 5 mg equiv/kg (iv) and 10 mg/equiv/kg (oral) in rat | 2005 | Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12 | Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors. |
| AID542992 | Inhibition of Influenza B virus (B/Tokushima/1/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1222305 | AUC(0 to 6 hrs) in adult fasted Sprague-Dawley rat at 30 mg/kg, po administered as solution in bovine milk by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID542983 | Inhibition of Influenza B virus (B/Mie/1/1993(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1498124 | Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity by MTS assay | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12 | Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs. |
| AID1156846 | Inhibition of Influenza A H1N1 virus neuraminidase at 100 nM after 1 hr by spectrofluorimetry using 2-(4-meythylumbelliferyl)-alpha-D-acetylneuramic acid as substrate | 2014 | European journal of medicinal chemistry, Aug-18, Volume: 83 | Design and synthesis of 6-oxo-1,4,5,6-tetrahydropyrimidine-5-carboxylate derivatives as neuraminidase inhibitors. |
| AID1073040 | Antiviral activity against Influenza A virus (A/Hong Kong/1/1968(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | Computer-guided approach to access the anti-influenza activity of licorice constituents. |
| AID1731309 | Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 48 hrs by crystal violet staining based assay | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors. |
| AID1401151 | Inhibition of Influenza A virus A/Anhui/1/2013(H7N9) neuraminidase 150 cavity at 10 uM using MUNANA as substrate preincubated for 5 to 15 mins followed by substrate addition measured after 30 mins by fluorescence assay relative to control | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Synthesis and biological evaluation of NH |
| AID567610 | Antiviral activity against influenza A (A/New York/18/2009 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID561130 | Antiviral activity against Influenza A virus (A/whooper swan/Mongolia/1/2009(H5N1)) infected in BALB/c mouse assessed as decrease in viral load in brain at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID561345 | Antiviral activity against Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in IFNalpha production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1365384 | Inhibition of neuraminidase in influenza A virus (A/Puerto Rico/8/1934(H1N1)) assessed as remaining enzyme activity at 0.1 ug/ml pre-incubated for 30 mins before NA-Star substrate addition for 30 mins by luminescence based assay | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. |
| AID539955 | Antiviral activity against influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days | 2010 | European journal of medicinal chemistry, Nov, Volume: 45, Issue:11 | Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones. |
| AID581685 | Ratio of AUC (0 to infinity) after iv dose to AUC (0 to 8 hrs) after po dose in perfused Sprague-Dawley rat cerebrospinal fluid at 30 mg/kg | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID542578 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) infected in BALB/c mouse assessed as reduction in body weight at 1 mg/kg, po administered 4 hrs before infection for 5 days measured on day 5 (Rvb = 17.4 %) | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID561143 | Inhibition of Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) neuraminidase isolated from virus-infected BALB/c mouse by fluorometric assay | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1222291 | Drug uptake in CHOK1 cells at 100 uM after 10 mins by HPLC coupled with radiodetection analysis in presence of PEPT1 inhibitor cefadroxil | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID527160 | Inhibition of oseltamivir-resistant Influenza A virus (A/California/08/2009(H1N1)) neuraminidase H274Y mutant expressed in human 293T cells after 30 mins by spectrofluorimetric analysis | 2010 | Journal of natural products, Oct-22, Volume: 73, Issue:10 | C-Methylated Flavonoids from Cleistocalyx operculatus and Their Inhibitory Effects on Novel Influenza A (H1N1) Neuraminidase. |
| AID1204731 | AUC in CD1 mouse at 30 mg/kg, po | 2015 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12 | Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay. |
| AID1386762 | Inhibition of Influenza A virus (A/Puerto Rico/8/1934(H1N1)) neuraminidase at 0.1 to 1000 uM by chemiluminescence based assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. |
| AID515123 | Fold resistance, ratio of IC50 for Influenza B virus (B/Perth/211/2001) recombinant wild type neuraminidase to IC50 for Influenza B virus (B/Perth/211/2001) recombinant neuraminidase E197 mutant | 2010 | Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17 | Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. |
| AID283463 | Lowering of Arterial oxygen saturation decline in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 20 mg/kg/day, po twice daily for 5 days administered 1 hr after infection measured on day 11 relative to carboxymethyl ce | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. |
| AID558688 | Half life in MDCK cells expressing human ST6Gal 1 gene in hollow fiber model system at 1 ng/ml administered as 1 hr infusion every 12 hrs by LC-MS-MS | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. |
| AID1473441 | Synergistic antiviral activity against Influenza A virus (A/WSN/33(H1N1)) infected in MDCK cells expressing ST6Gal-1 assessed as reduction in virus-induced cytopathic effect after 44 to 48 hrs in presence of 1:10 3-{[(5-Cyclopropyl-1,2-oxazol-3-yl)methyl] | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses. |
| AID567604 | Antiviral activity against influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1056522 | Antiviral activity against Influenza virus A/Hanfang/359/95 (H3N2) | 2013 | Journal of natural products, Dec-27, Volume: 76, Issue:12 | Homosecoiridoid alkaloids with amino acid units from the flower buds of Lonicera japonica. |
| AID236746 | Maximum plasma concentration determined after administration of compound dosed at 5 mg equiv/kg (iv) and 10 mg/equiv/kg (oral) in rat | 2005 | Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12 | Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors. |
| AID582053 | Prodrug conversion in 86 years old male human brain S9 fractions assessed as paranitrophenol generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID661916 | Inhibition of oseltamivir-resistant H1N1 swine influenza virus neuraminidase H274Y mutant using 4-MU-NANA as substrate by fluorescence assay | 2012 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11 | Xanthones from Polygala karensium inhibit neuraminidases from influenza A viruses. |
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | |||
| AID1767878 | Cytotoxicity against dog MDCK cells assessed as reduction in cell viability | 2021 | European journal of medicinal chemistry, Oct-15, Volume: 222 | Optimization and SAR research at the piperazine and phenyl rings of JNJ4796 as new anti-influenza A virus agents, part 1. |
| AID581521 | Prodrug conversion in 7 days old female rat liver S9 fractions assessed as paranitrophenol generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID567591 | Antiviral activity against influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID539953 | Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days | 2010 | European journal of medicinal chemistry, Nov, Volume: 45, Issue:11 | Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones. |
| AID542987 | Inhibition of Influenza B virus (B/Yamagata/85/2004(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1415635 | Cytotoxicity against MDCK cells after 48 hrs by MTT assay | 2017 | MedChemComm, May-01, Volume: 8, Issue:5 | Synthesis and |
| AID558678 | Antiviral activity against influenza virus (A/Sidney/5/97 (H3N2)) R292 infected in MDCK cells expressing human ST6Gal 1 gene in hollow fiber model system assessed as decrease in viral replication at 1 ng/ml administered as 1 hr infusion every 24 hrs for 6 | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. |
| AID1266210 | Inhibition of Influenza A virus H1N1 neuraminidase H275Y mutant | 2015 | Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24 | 1,2,3-Triazolyl-4-oxoquinolines: A feasible beginning for promising chemical structures to inhibit oseltamivir-resistant influenza A and B viruses. |
| AID561131 | Antiviral activity against Influenza A virus (A/whooper swan/Mongolia/1/2009(H5N1)) infected in BALB/c mouse assessed as decrease in viral load in brain at 20 mg/kg, po BID for 5 days measured on day 6 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID523886 | Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. |
| AID527159 | Inhibition of Influenza A virus (A/California/08/2009(H1N1)) wild type neuraminidase expressed in human 293T cells after 30 mins by spectrofluorimetric analysis | 2010 | Journal of natural products, Oct-22, Volume: 73, Issue:10 | C-Methylated Flavonoids from Cleistocalyx operculatus and Their Inhibitory Effects on Novel Influenza A (H1N1) Neuraminidase. |
| AID581717 | AUC (0 to infinity) ratio in brain to plasma in non-perfused Sprague-Dawley rat at 30 mg/kg, iv | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1222246 | Renal clearance in healthy human at 150 mg, po administered as single dose by HPLC-tandem mass spectrometry under fed conditions | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID455706 | Antiviral activity against influenza A virus H9N2 A/Chicken/Korea/MS96/96 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. |
| AID625285 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID581730 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 1665 uM | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1502946 | Antiviral activity against Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by MTT assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | C-Methylated Flavonoid Glycosides from Pentarhizidium orientale Rhizomes and Their Inhibitory Effects on the H1N1 Influenza Virus. |
| AID542951 | Inhibition of Influenza A virus (A/Saitama/78/2003(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | |||
| AID1365379 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity treated 4 hrs after virus infection and measured after 48 hrs by SRB assay | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. |
| AID1222288 | Drug uptake in CHOK1 cells expressing human PEPT1 by HPLC coupled with radiodetection analysis in presence of KH and Hanks' balanced salt solution | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1553315 | Antiviral activity against Influenza A virus A/Duck/Guangdong/99(H5N1) infected in human A549 cells assessed as inhibition of virus plaque formation by CPE reduction assay | 2019 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18 | Incorporation of privileged structures into 3-O-β-chacotriosyl ursolic acid can enhance inhibiting the entry of the H5N1 virus. |
| AID565050 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin A45S, K156E, P210Q, L313F mutant gene and neuraminidase H274Y mutant infected in MDCK cells selected at 31 uM of oseltamivir after 9 passage after 48 hrs b | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1553316 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in human A549 cells assessed as inhibition of virus plaque formation by CPE reduction assay | 2019 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18 | Incorporation of privileged structures into 3-O-β-chacotriosyl ursolic acid can enhance inhibiting the entry of the H5N1 virus. |
| AID561153 | Antiviral activity against Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in IL6 production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID567599 | Antiviral activity against influenza A (A/New York/18/2009 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID558677 | Antiviral activity against influenza virus (A/Sidney/5/97 (H3N2)) R292 infected in MDCK cells expressing human ST6Gal 1 gene in hollow fiber model system assessed as decrease in viral replication at 1 ng/ml administered as continuous infusion for 6 days m | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. |
| AID581708 | Cmax in perfused Sprague-Dawley rat brain at 1000 mg/kg, po | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID768212 | Cytotoxicity against MDCK cells assessed as cell viability after 4 days by MTS assay | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies. |
| AID1713960 | Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/Puerto Rico/8/34 (H1N1)) infected in MDCK cells | 2016 | Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22 | Biological evaluation of tetracationic compounds based on two 1,4-diazabicyclo[2.2.2]octane moieties connected by different linkers. |
| AID558676 | Antiviral activity against influenza virus (A/Sidney/5/97 (H3N2)) R292 infected in MDCK cells expressing human ST6Gal 1 gene in hollow fiber model system assessed as decrease in viral replication at 1000 ng/ml administered as continuous infusion for 6 day | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. |
| AID625289 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID581522 | Prodrug conversion in 7 days old male rat liver S9 fractions assessed as paranitrophenol generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID582042 | Permeability from apical to basolateral side of Spodoptera frugiperda Sf9 cells over expressing human MRP3 | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID515139 | Fold resistance, ratio of Ki for Influenza B virus B/Gifu/11/2005 wild type neuraminidase to Ki for Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant | 2010 | Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17 | Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. |
| AID1156845 | Inhibition of Influenza A H1N1 virus neuraminidase after 1 hr by spectrofluorimetry using 2-(4-meythylumbelliferyl)-alpha-D-acetylneuramic acid as substrate | 2014 | European journal of medicinal chemistry, Aug-18, Volume: 83 | Design and synthesis of 6-oxo-1,4,5,6-tetrahydropyrimidine-5-carboxylate derivatives as neuraminidase inhibitors. |
| AID561133 | Antiviral activity against Influenza A virus (A/Turkey/651242/2006(H5N1)) infected in BALB/c mouse assessed as decrease in viral load in brain at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1553314 | Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay | 2019 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18 | Incorporation of privileged structures into 3-O-β-chacotriosyl ursolic acid can enhance inhibiting the entry of the H5N1 virus. |
| AID542988 | Inhibition of Influenza B virus (B/Yamagata/87/2004(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1222254 | AUC(0 to infinity) in adult fed Sprague-Dawley rat at 30 mg/kg, po administered as solution in bovine milk by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID542977 | Inhibition of Influenza B virus (B/Akita/9/2003(Victoria)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1222297 | Drug uptake in CHOK1 cells expressing human PEPT1 at 100 uM at 4 degC after 10 mins by HPLC coupled with radiodetection analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1438094 | Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) expressing M2 proton channel S31N mutant infected in MDCK cells assessed as reduction in cytopathic effect after 48 hrs by crystal violet staining-based microscopic analysis | 2017 | Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5 | Binding and Proton Blockage by Amantadine Variants of the Influenza M2 |
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | |||
| AID1201117 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis | 2015 | European journal of medicinal chemistry, Apr-13, Volume: 94 | A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives. |
| AID561144 | Inhibition of Influenza A virus (A/whooper swan/Mongolia/1/2009(H5N1)) neuraminidase isolated from virus-infected BALB/c mouse by fluorometric assay | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID542566 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) H274Y mutant infected in BALB/c mouse assessed as lung viral titer at 10 mg/kg, po administered 48 hrs postinfection for 5 days measured on day 4 (Rvb = 1 x 10'6 +/- 0.3 x 10'6 PF | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID1409722 | Antiviral activity against Influenza A virus (A/Hong Kong/68(H3N2)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect by crystal violet staining based light-microscopic analysis | 2018 | ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3 | Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants. |
| AID542554 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) infected in BALB/c mouse assessed as lung viral titer at 10 mg/kg, po administered 48 hrs postinfection for 5 days measured on day 4 (Rvb = 1.9 x 10'6 +/- 0.1 x 10'6 PFU) | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID581684 | Ratio of AUC (0 to infinity) after iv dose to AUC (0 to 8 hrs) after po dose in perfused Sprague-Dawley rat plasma at 30 mg/kg | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID548443 | Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | 4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation. |
| AID1460756 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in Kunming mouse assessed as intact columnar epithelium in bronchiole without inflammatory cell infiltration at 20 mg/kg/day, po qd for 4 days by hematoxylin and eosin staini | 2017 | Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7 | Boronic Acid Modifications Enhance the Anti-Influenza A Virus Activities of Novel Quindoline Derivatives. |
| AID1365380 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity treated 7 hrs after virus infection and measured after 48 hrs by SRB assay | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. |
| AID527169 | Cytotoxicity against MDCK cells at 97.56 uM after 48 hrs by neutral red dye assay | 2010 | Journal of natural products, Oct-22, Volume: 73, Issue:10 | C-Methylated Flavonoids from Cleistocalyx operculatus and Their Inhibitory Effects on Novel Influenza A (H1N1) Neuraminidase. |
| AID1365371 | Antiviral activity against Influenza B virus (B/Lee/40) infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 48 hrs by SRB assay | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. |
| AID567598 | Antiviral activity against influenza A (A/North Carolina/02/2009 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID581738 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 1000 uM | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1505282 | Antiviral activity against Influenza A virus (A/PR/8/34 (H1N1)(NA-H274Y)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 48 hrs by microscopic analysis | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12 | Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses. |
| AID527158 | Inhibition of Influenza A virus (A/Sw/Kor/CAH1/04 (H1N1) KCTC 11165BP neuraminidase after 30 mins by spectrofluorimetric analysis | 2010 | Journal of natural products, Oct-22, Volume: 73, Issue:10 | C-Methylated Flavonoids from Cleistocalyx operculatus and Their Inhibitory Effects on Novel Influenza A (H1N1) Neuraminidase. |
| AID1858129 | Antiviral activity against group 2 influenza A virus H3N2 (A/Hong Kong-11/1968) infected in human A549 cells assessed as inhibition of viral entry preincubated with compound for 30 mins followed by viral infection for 1 hour further incubated for 48 hrs w | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Synthesis, Optimization, and Structure-Activity Relationships of Imidazo[1,2- |
| AID542996 | Inhibition of Influenza A virus (A/duck/Hokkaido/84/2002(H5N3)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1113454 | Antiviral activity against Unidentified Influenza A virus (H1N1) infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay | 2013 | Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4 | Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)- |
| AID565477 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1064132 | Inhibition of Influenza A virus H5N1 neuraminidase using MUNANA as substrate preincubated for 30 mins measured after 2 hrs | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | Bifunctional thiosialosides inhibit influenza virus. |
| AID658750 | Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | 2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies. |
| AID542989 | Inhibition of Influenza B virus (B/Aichi/186/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID443297 | Inhibition of oseltamivir-resistant Influenza Virus A/342/0 (H1N1) neuraminidase at 100 nM | 2010 | Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2 | Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. |
| AID515124 | Inhibition of Influenza B virus (B/Perth/211/2001) wild type recombinant neuraminidase expressed in Sf21 insect cells preincubated for 30 mins measured after 60 mins by MUNANA based assay | 2010 | Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17 | Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. |
| AID625283 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID542563 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) H274Y mutant infected in BALB/c mouse assessed as time to death at 1 mg/kg, po administered 4 hrs before infection on day 5 (Rvb = 5.1 days) | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID766706 | Cytotoxicity against MDCK cells assessed as morphological changes | 2013 | European journal of medicinal chemistry, Sep, Volume: 67 | Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity. |
| AID565254 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 1 nM of compound after 1 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1222306 | AUC(0 to infinity) in adult fasted Sprague-Dawley rat at 30 mg/kg, po administered as solution in bovine milk by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID763864 | Antiviral activity against Influenza A virus (A/Perth/16/2009(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones. |
| AID286178 | Antiviral activity against 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus inoculated ferrets assessed as inhibition of virus spread in spleen at 5 mg/kg after 4 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID561148 | Antiviral activity against Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in TNFalpha production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1474167 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID565239 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant infected in MDCK cells selected at 3,125 nM of oseltamivir after 6 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1767879 | Selectivity index, ratio of CC50 for cytotoxicity against dog MDCK cells to IC50 for antiviral activity against Influenza A virus HINI infected in dog MDCK cells | 2021 | European journal of medicinal chemistry, Oct-15, Volume: 222 | Optimization and SAR research at the piperazine and phenyl rings of JNJ4796 as new anti-influenza A virus agents, part 1. |
| AID1266208 | Inhibition of oseltamivir-resistant Influenza A virus H3N2 neuraminidase E119V mutant | 2015 | Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24 | 1,2,3-Triazolyl-4-oxoquinolines: A feasible beginning for promising chemical structures to inhibit oseltamivir-resistant influenza A and B viruses. |
| AID1405014 | Inhibition of MBP-fused recombinant human neuraminidase 3 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence analysis | 2018 | Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19 | Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity. |
| AID1405016 | Inhibition of recombinant His6-tagged human neuraminidase 1 expressed in HEK293 cells using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured every 1 min for 30 mins by fluorescence analysis | 2018 | Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19 | Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity. |
| AID542976 | Inhibition of Influenza B virus (B/Yamagata/15/2002(Victoria)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1160748 | Antiviral activity against Influenza A virus H3N2 VR1679 infected in MDCK cells assessed as inhibition of viral nucleoprotein production at 10 uM after 6 hrs by immunostaining-based confocal microscopy | 2014 | ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8 | Identification and synthesis of quinolizidines with anti-influenza a virus activity. |
| AID567590 | Antiviral activity against influenza A (A/Singapore/91/2009 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID581686 | Ratio of AUC (0 to infinity) after iv dose to AUC (0 to 8 hrs) after po dose in perfused Sprague-Dawley rat brain at 30 mg/kg | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID416781 | Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method | 2009 | Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7 | Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus. |
| AID565271 | Ratio of IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V mutant to IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID560881 | Antiviral activity against Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) infected in BALB/c mouse assessed as survival rate at 20 mg/kg, po BID for 5 days measured post last dose | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID539948 | Cytotoxicity against MDCK cells by MTS assay | 2010 | European journal of medicinal chemistry, Nov, Volume: 45, Issue:11 | Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones. |
| AID543190 | Inhibition of Influenza B virus (B/Yokohama/UT3318/2005)) neuraminidase N294S mutant after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1771096 | Antiviral activity against Influenza A virus H5N1 infected in human A549 cells assessed as inhibition of viral replication by TCID50 assay | |||
| AID392528 | Antiviral activity against influenza H2N2 virus | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2 | Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. |
| AID582040 | Permeability from apical to basolateral side of Spodoptera frugiperda Sf9 cells over expressing human MRP1 | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1280362 | Antiviral activity against amantadine-resistant influenza A virus JX/312 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus. |
| AID515137 | Fold resistance, ratio of Ki for Influenza B virus (B/Perth/211/2001) recombinant wild type neuraminidase to Ki for Influenza B virus (B/Perth/211/2001) recombinant neuraminidase E197 mutant | 2010 | Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17 | Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. |
| AID581525 | Prodrug conversion in 42 days old male rat brain S9 fractions assessed as paranitrophenol generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1858133 | Selectivity index, ratio of CC50 for human A549 cells to EC50 for group 2 influenza A virus H3N2 (A/Victoria361/2011) infected in human A549 cells | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Synthesis, Optimization, and Structure-Activity Relationships of Imidazo[1,2- |
| AID350634 | Antiviral activity against Influenza A virus (A/Viet Nam/1203/2004(H5N1)) in MDCK cells assessed as inhibition of viral replication at 100 uM after 18 hrs by transmission electron microscopy | 2009 | Journal of medicinal chemistry, May-14, Volume: 52, Issue:9 | A novel small-molecule inhibitor of the avian influenza H5N1 virus determined through computational screening against the neuraminidase. |
| AID560876 | Inhibition of Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) neuraminidase by by Michaelis-Menten equation analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID625284 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID515134 | Fold resistance, ratio of IC50 for Influenza B virus B/Gifu/11/2005 wild type neuraminidase preincubated for 30 mins to IC50 for Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant preincubated for 30 mins | 2010 | Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17 | Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. |
| AID560893 | Antiviral activity against Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) infected in BALB/c mouse assessed as virus-induced change body weight at 20 mg/kg, po BID for 5 days measured on day 6 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID565469 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID581518 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 335 uM | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID565473 | Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID543002 | Inhibition of Influenza A virus (A/duck/Memphis/546/1974(H11N9)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1385613 | Cytotoxicity against MDCK cells measured after 48 hrs | 2018 | Journal of natural products, 08-24, Volume: 81, Issue:8 | Minor Nortriterpenoids from the Twigs and Leaves of Rhododendron latoucheae. |
| AID561152 | Antiviral activity against Influenza A virus (A/Turkey/651242/2006(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in IL6 production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID733268 | Antiviral activity against Influenza A virus (A/Hong kong/8/1968(H2N3)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition. |
| AID1427857 | Antiviral activity against Influenza A virus A/95-359 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect | |||
| AID542559 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) H274Y mutant infected in BALB/c mouse assessed as mortality rate at 1 mg/kg, po administered 48 hrs postinfection for 5 days measured on day 5 (Rvb = 100 %) | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID1767880 | Antiviral activity against Oseltamivir resistant Influenza A virus (A/Tianjin-Jinnan/15/2009(H1N1) infected in dog MDCK cells assessed as inhibition of surface glycoprotein hemagglutinin | 2021 | European journal of medicinal chemistry, Oct-15, Volume: 222 | Optimization and SAR research at the piperazine and phenyl rings of JNJ4796 as new anti-influenza A virus agents, part 1. |
| AID542995 | Inhibition of Influenza A virus (A/R(duck/Mongolia/54/01-duck/Mongolia/47/01)(H5H1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID543006 | Inhibition of Influenza A virus (A/Kawasaki/IMS22A-954/2003(H3N2)) wild type neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID565053 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 5 nM of oseltamivir after 2 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1222285 | Drug uptake in CHOK1 cells incubated for 30s to 15 mins by HPLC coupled with radiodetection analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID561116 | Antiviral activity against Influenza A virus (A/whooper swan/Mongolia/1/2009(H5N1)) infected in BALB/c mouse assessed as virus-induced change body weight at 20 mg/kg, po BID for 5 days measured on day 9 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID542998 | Inhibition of Influenza A virus (A/duck/Alberta/60/1976(H12N5)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID625291 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1365372 | Antiviral activity against Influenza B virus (B/Maryland/1/59) infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 48 hrs by SRB assay | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. |
| AID582072 | Prodrug conversion in 7 days old female rat brain S9 fractions assessed as conversion of oseltamivir to oseltamivir carboxylate | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID634747 | Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID1077002 | Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus (A/Tianjinjinnan/15/2009/H1N1) | 2014 | European journal of medicinal chemistry, Apr-09, Volume: 76 | 1,2,3-Triazole-containing derivatives of rupestonic acid: click-chemical synthesis and antiviral activities against influenza viruses. |
| AID1222265 | AUC(0 to 5 hrs) in juvenile fasted Sprague-Dawley rat at 30 mg/kg, po administered as water solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID455704 | Cytotoxicity against MDCK cells after 48 hrs by MTT assay | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. |
| AID532106 | Inhibition of human NEU1 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. |
| AID542960 | Inhibition of Influenza A virus (A/Wellington/1/2004(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1502947 | Cytotoxicity against MDCK cells after 2 days by MTT assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | C-Methylated Flavonoid Glycosides from Pentarhizidium orientale Rhizomes and Their Inhibitory Effects on the H1N1 Influenza Virus. |
| AID712809 | Antiviral activity against amantadine-sensitive Influenza A virus (A/FM/1/47 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis | 2012 | ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12 | Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds. |
| AID1266207 | Inhibition of oseltamivir-resistant Influenza A virus H3N2 neuraminidase | 2015 | Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24 | 1,2,3-Triazolyl-4-oxoquinolines: A feasible beginning for promising chemical structures to inhibit oseltamivir-resistant influenza A and B viruses. |
| AID286198 | Inhibition of 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus replication in ferrets brain at 25 mg/kg after 24 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID634837 | Antiviral activity against Human immunodeficiency virus 2 infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID1773429 | Antiviral activity against Influenza A virus H1N1 (A/PR/8/34) infected in MDCK cells assessed as reduction in virus titer treated 1 hr post viral infection followed by replacement with fresh medium with compounds and measured after 72 hrs by MTT assay | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Novel betulin dicarboxylic acid ester derivatives as potent antiviral agents: Design, synthesis, biological evaluation, structure-activity relationship and in-silico study. |
| AID1222251 | Tmax in adult fed Sprague-Dawley rat at 30 mg/kg, po administered as solution in bovine milk by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID515131 | Fold resistance, ratio of IC50 for Influenza B virus B/Gifu/11/2005 wild type neuraminidase to IC50 for Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant | 2010 | Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17 | Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. |
| AID1767881 | Selectivity index, ratio of CC50 for cytotoxicity against dog MDCK cells to IC50 for antiviral activity against Oseltamivir resistant Influenza A virus (A/Tianjin-Jinnan/15/2009(H1N1)) infected in dog MDCK cells | 2021 | European journal of medicinal chemistry, Oct-15, Volume: 222 | Optimization and SAR research at the piperazine and phenyl rings of JNJ4796 as new anti-influenza A virus agents, part 1. |
| AID1771092 | Antiviral activity against Influenza A virus H5N1 (A/chicken/Hubei/327/2004(H5N1)) infected in dog MDCK cells assessed as inhibition of virus replication by plaque reduction assay | |||
| AID565051 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin A45S, K156E, P210Q, L313F mutant gene and neuraminidase H274Y mutant infected in MDCK cells selected at 781 uM of oseltamivir after 10 passage after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID581531 | Cmax in perfused Sprague-Dawley rat plasma at 30 mg/kg, iv | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID582047 | Efflux ratio of permeability from apical to basolateral side over basolateral to apical side in pig LLC-PK1 cells over expressing human MDR1 | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1849916 | Inhibition of Influenza virus neuraminidase | 2021 | European journal of medicinal chemistry, Jan-15, Volume: 210 | Chemistry, biosynthesis and biological activity of terpenoids and meroterpenoids in bacteria and fungi isolated from different marine habitats. |
| AID581674 | Cmax in perfused Sprague-Dawley rat brain at 30 mg/kg, iv | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1636440 | Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA | 2016 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16 | Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. |
| AID733269 | Antiviral activity against Influenza A virus (A/Taiwan/1/1986(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition. |
| AID1404181 | Antiviral activity against Influenza A virus H3N2 A/Hong Kong/68 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs | |||
| AID1401152 | Inhibition of Influenza A virus A/Anhui/1/2005(H5N1) neuraminidase using MUNANA as substrate preincubated for 5 to 15 mins followed by substrate addition measured after 30 mins by fluorescence assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Synthesis and biological evaluation of NH |
| AID558683 | Antiviral activity against influenza virus (A/Sidney/5/97 (H3N2)) R292 infected in MDCK cells expressing human ST6Gal 1 gene in hollow fiber model system assessed as decrease in hemagglutinination units at 1 ng/ml administered as 1 hr infusion every 12 hr | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. |
| AID567618 | Antiviral activity against influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567726 | Ratio of IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID561151 | Antiviral activity against Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in IL6 production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID565475 | Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | |||
| AID561124 | Antiviral activity against Influenza A virus (A/whooper swan/Mongolia/1/2009(H5N1)) infected in BALB/c mouse assessed as decrease in viral load in lung at 20 mg/kg, po BID for 5 days measured on day 9 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID611772 | Cytotoxicity against human CEM cells assessed as growth inhibition after 3 days by coulter counting analysis | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID1222275 | AUC(0 to 24 hrs) in adult fed Sprague-Dawley rat at 30 mg/kg, po administered as water solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | |||
| AID1473449 | Synergistic antiviral activity against Influenza A virus (A/WSN/33(H1N1)) infected in MDCK cells expressing ST6Gal-1 assessed as reduction in virus-induced cytopathic effect after 44 to 48 hrs in presence of 1:1 3-{[(5-Cyclopropyl-1,2-oxazol-3-yl)methyl]a | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses. |
| AID1183522 | Antiviral activity against Influenza A virus A/Puerto Rico/8/34 infected in BALB/c mouse assessed as body weight loss at 30 mg/kg bid treated after 48 hrs of infection for 10 days | 2014 | Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15 | Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. |
| AID565256 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 25 nM of zanamivir after 3 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID567611 | Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID582062 | Prodrug conversion in 7 days old male rat liver S9 fractions assessed as oseltamivir carboxylate generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1222290 | Drug uptake in CHOK1 cells at 100 uM after 10 mins by HPLC coupled with radiodetection analysis in presence of PEPT1 inhibitor valacyclovir | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1660683 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in Kunming mouse assessed as decrease in lung TNFalpha level at 10 mg/kg/day, po starting 4 hrs after viral challenge and continued for 4 days by ELISA | 2020 | Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13 | Chemoreactive-Inspired Discovery of Influenza A Virus Dual Inhibitor to Block Hemagglutinin-Mediated Adsorption and Membrane Fusion. |
| AID634760 | Antiviral activity against Vesicular stomatitis virus infected in human Hela cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID1773419 | Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Novel betulin dicarboxylic acid ester derivatives as potent antiviral agents: Design, synthesis, biological evaluation, structure-activity relationship and in-silico study. |
| AID558681 | Antiviral activity against influenza virus (A/Sidney/5/97 (H3N2)) R292 infected in MDCK cells expressing human ST6Gal 1 gene in hollow fiber model system assessed as decrease in hemagglutinination units at 1 ng/ml administered as continuous infusion for 6 | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. |
| AID443295 | Inhibition of Influenza Virus A/Horneburg/IDT7489/08 (H1N1) neuraminidase | 2010 | Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2 | Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. |
| AID515128 | Selectivity ratio of IC50 for Influenza B virus (B/Perth/211/2001) recombinant neuraminidase E197 mutant to IC50 for Influenza B virus (B/Perth/211/2001) neuraminidase E197 mutant preincubated for 30 mins | 2010 | Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17 | Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. |
| AID582052 | Prodrug conversion assessed as oseltamivir carboxylate level in presence of Sf9 cell culture supernatant expressing human recombinant HCE2 after 30 mins | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID581705 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 162 uM | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1200483 | Antiviral activity against influenza A virus A/WSN/33 (H1N1) infected in MDCK cells assessed as reduction in cytopathic effect after 48 hrs by plaque assay | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin. |
| AID567720 | Ratio of IC50 for influenza A (A/North Carolina/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1858135 | Antiviral activity against group 2 influenza A virus H3N2 (A/Hong Kong-11/1968) infected in MDCK cells infected with supernatant of compound treated virus-producing human A549 cells assessed as reduction in viral titer at 1 to 10 uM treated for 48 hrs wit | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Synthesis, Optimization, and Structure-Activity Relationships of Imidazo[1,2- |
| AID712808 | Antiviral activity against Influenza A virus (A/Ishikawa/7/82 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis | 2012 | ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12 | Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds. |
| AID1064129 | Antiviral activity against Influenza A virus A/California/07/2009 (H1N1) infected in MDCK cells assessed as reduction in virus plaque formation after 5 days | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | Bifunctional thiosialosides inhibit influenza virus. |
| AID286176 | Antiviral activity against 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus inoculated ferrets assessed as inhibition of virus spread in brain at 5 mg/kg after 4 hrs of inoculum for 5days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID542986 | Inhibition of Influenza B virus (B/Shizuoka/58/2004(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1386750 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in HEK293T cells assessed as inhibition of viral replicon activity incubated for 30 hrs by dual-Glo luciferase assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. |
| AID542551 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) infected in BALB/c mouse assessed as time to death at 1 mg/kg, po administered 48 hrs postinfection for 5 days (Rvb = 5.8 days) | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID286195 | Inhibition of 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus replication in ferrets lungs at 25 mg/kg after 24 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID548437 | Cytotoxicity against MDCK cells assessed as cell viability by MTS assay | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | 4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation. |
| AID565244 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 1 nM of zanamivir after 1 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID567600 | Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1160745 | Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay | 2014 | ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8 | Identification and synthesis of quinolizidines with anti-influenza a virus activity. |
| AID1473422 | Antiviral activity against Influenza A virus (A/WSN/33(H1N1)) infected in MDCK cells expressing ST6Gal-1 assessed as reduction in plaque formation after 2 days by crystal violet staining based assay | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses. |
| AID1365369 | Inhibition of neuraminidase in influenza A virus (A/Puerto Rico/8/1934(H1N1)) pre-incubated for 30 mins before NA-Star substrate addition for 30 mins by luminescence based assay | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. |
| AID515125 | Inhibition of Influenza B virus (B/Perth/211/2001) recombinant neuraminidase E197 mutant expressed in Sf21 insect cells preincubated for 30 mins measured after 60 mins by MUNANA based assay | 2010 | Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17 | Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. |
| AID549516 | Inhibition of wild type H1N1 swine influenza virus neuraminidase activity expressed in HEK293T cells after 2 hrs by spectrofluorometry | 2011 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1 | Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata. |
| AID1143482 | Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in BALB/c mouse assessed as increase in survival rate at 2.6 umol/kg/day, po bid administered on day 0 prior to viral infection continued for day 1 to day 4 measured on day 14 | 2014 | European journal of medicinal chemistry, Jun-23, Volume: 81 | Tamiphosphor monoesters as effective anti-influenza agents. |
| AID1266206 | Inhibition of oseltamivir-resistant Influenza A virus H3N2 neuraminidase at 50 uM | 2015 | Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24 | 1,2,3-Triazolyl-4-oxoquinolines: A feasible beginning for promising chemical structures to inhibit oseltamivir-resistant influenza A and B viruses. |
| AID582069 | Prodrug conversion in commercial brain S9 fractions assessed as oseltamivir carboxylate generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1222260 | Cmax in juvenile breast-fed Sprague-Dawley rat at 30 mg/kg, po administered as water solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1222292 | Drug uptake in CHOK1 cells expressing human PEPT1 at 100 uM after 10 mins by HPLC coupled with radiodetection analysis in presence of PEPT1 inhibitor Trp-Gly | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1204714 | Total plasma concentration in CD1 mouse at 30 mg/kg, po measured at 20 mins by reversed-phase UPLC/MS analysis | 2015 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12 | Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay. |
| AID565471 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID582079 | Prodrug conversion in 86 years old male human brain S9 fractions assessed as conversion of oseltamivir to oseltamivir carboxylate | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID581725 | Activity of human MDR1-mediated drug permeability expressed in pig LLC-PK1 cells | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID286185 | Antiviral activity against 10 EID50 influenza A/Vietnam/1203/04 H5N1 virus inoculated ferrets assessed as increase in temperature at 5 mg/kg after 4 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID286192 | Inhibition of 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus replication in ferrets lungs at 10 mg/kg after 24 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID528272 | Non-competitive inhibition of influenza A virus H1N1 Neuraminidase using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid sodium salt hydrate substrate by Lineweaver burk plot | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22 | New stilbenoid with inhibitory activity on viral neuraminidases from Erythrina addisoniae. |
| AID582057 | Prodrug conversion in commercial liver S9 fractions assessed as paranitrophenol generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1418311 | Cytotoxicity in yeast assessed as reduction in cell proliferation | 2018 | European journal of medicinal chemistry, Nov-05, Volume: 159 | Synthesis and structure-activity relationship study of arylsulfonamides as novel potent H5N1 inhibitors. |
| AID1222294 | Drug uptake in CHOK1 cells expressing human PEPT1 at 100 uM after 10 mins by HPLC coupled with radiodetection analysis in presence of PEPT1 inhibitor cefadroxil | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1183509 | Antiviral activity against Influenza A virus A/Mexico/4108/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay | 2014 | Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15 | Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. |
| AID1073041 | Antiviral activity against Influenza A virus J/8178/09 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | Computer-guided approach to access the anti-influenza activity of licorice constituents. |
| AID1293611 | Cytotoxicity against MDCK cells assessed as decrease in cell viability after 48 hrs by MTT assay | 2016 | Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6 | 4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA-PB1 Protein-Protein Interaction: Structure-Activity Relationships Exploration with the Aid of Molecular Modeling. |
| AID1405019 | Inhibition of MBP-fused recombinant human neuraminidase 4 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured every 1 min for 30 mins by fluorescence analysis | 2018 | Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19 | Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity. |
| AID1201121 | Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis | 2015 | European journal of medicinal chemistry, Apr-13, Volume: 94 | A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives. |
| AID561115 | Antiviral activity against Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) infected in BALB/c mouse assessed as virus-induced change body weight at 20 mg/kg, po BID for 5 days measured on day 9 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID581735 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 175 uM | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1365382 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity treated 24 hrs after virus infection and measured after 48 hrs by SRB assay | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. |
| AID455708 | Selectivity index, ratio of CC50 for MDCK cells to EC50 for influenza virus H9N2 A/Chicken/Korea/MS96/96 | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. |
| AID1432502 | Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 40 hrs | 2017 | Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6 | Structure-activity relationship studies of 1-(1'-hydroxyalkyl)rupestonic acid methyl esters against influenza viruses. |
| AID561118 | Antiviral activity against Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) infected in BALB/c mouse assessed as virus-induced change body weight at 20 mg/kg, po BID for 5 days measured on day 15 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1156847 | Inhibition of Influenza A H1N1 virus neuraminidase at 20 nM after 1 hr by spectrofluorimetry using 2-(4-meythylumbelliferyl)-alpha-D-acetylneuramic acid as substrate | 2014 | European journal of medicinal chemistry, Aug-18, Volume: 83 | Design and synthesis of 6-oxo-1,4,5,6-tetrahydropyrimidine-5-carboxylate derivatives as neuraminidase inhibitors. |
| AID661913 | Inhibition of Influenza A virus H1N1 neuraminidase using 4-MU-NANA as substrate by fluorescence assay | 2012 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11 | Xanthones from Polygala karensium inhibit neuraminidases from influenza A viruses. |
| AID1222319 | Drug uptake in CHOK1 cells at 100 uM after 10 mins by HPLC coupled with radiodetection analysis in presence of PEPT1 inhibitor Trp-Gly | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1064131 | Inhibition of Influenza A virus H3N2 neuraminidase using MUNANA as substrate preincubated for 30 mins measured after 2 hrs | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | Bifunctional thiosialosides inhibit influenza virus. |
| AID1222299 | Cmax in adult fasted Sprague-Dawley rat at 30 mg/kg, po administered as water solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1578003 | Antiviral activity against Influenza A virus H1N1 infected in dog MDCK cells assessed as inhibition in virus-induced cytopathic effect incubated for 40 hrs | 2019 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19 | Novel amides modified rupestonic acid derivatives as anti-influenza virus reagents. |
| AID567707 | Ratio of IC50 for influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1293608 | Inhibition of Influenza A virus PR/8/34 6His-tagged PA (239 to 716 residues) interaction with GST-tagged PB1 (1 to 25 residues) expressed in Escherichia coli compound treated in PBS buffer measured after overnight incubation by ELISA | 2016 | Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6 | 4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA-PB1 Protein-Protein Interaction: Structure-Activity Relationships Exploration with the Aid of Molecular Modeling. |
| AID561344 | Antiviral activity against Influenza A virus (A/duck/Laos/25/2006(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in IL6 production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1222267 | Tmax in juvenile fasted Sprague-Dawley rat at 30 mg/kg, po administered as solution in bovine milk by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID542553 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) infected in BALB/c mouse assessed as lung viral titer at 1 mg/kg, po administered 48 hrs postinfection for 5 days measured on day 4 (Rvb = 1.9 x 10'6 +/- 0.1 x 10'6 PFU) | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | |||
| AID1222293 | Drug uptake in CHOK1 cells expressing human PEPT1 at 100 uM after 10 mins by HPLC coupled with radiodetection analysis in presence of PEPT1 inhibitor valacyclovir | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID565467 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1113453 | Antiviral activity against Influenza A virus H3N2 infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay | 2013 | Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4 | Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)- |
| AID236505 | Area under concentration time curve determined after administration of compound dosed at 5 mg equiv/kg (iv) and 10 mg/equiv/kg (oral) in rat | 2005 | Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12 | Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors. |
| AID763861 | Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/California/07/2009(H1N1)) | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones. |
| AID560873 | Inhibition of Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) neuraminidase by fluorometric assay | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID611764 | Antiviral activity against Punta Toro virus infected in Vero cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID565462 | Ratio of IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V and H274Y mutant to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID582043 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID648768 | Inhibition of Influenza A virus H7N3 N3 neuraminidase expressed in baculovirus using 2'-(4-Methylumbelliferyl)-alpha-D-acetyl neuraminic acid as substrate incubated for 2 hrs prior to substrate addition measured after 5 hrs by fluorimetry | 2012 | Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6 | Synthesis and in vitro study of novel neuraminidase inhibitors against avian influenza virus. |
| AID549517 | Inhibition of oseltamivir-resistant H1N1 swine influenza virus neuraminidase H274Y mutant activity expressed in HEK293T cells after 2 hrs by spectrofluorometry | 2011 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1 | Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata. |
| AID455705 | Antiviral activity against influenza A virus H1N1 A/PR/8/34 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. |
| AID286203 | Antiviral activity against 10^6 EID50 influenza A/turkey/15/06 H5N1 virus inoculated ferrets assessed as viral titer in brain at 10 mg/kg after 24 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID539786 | Inhibition of human neuraminidase 3 assessed as inhibition of GM3 hydrolysis | 2010 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24 | Inhibition of human neuraminidase 3 (NEU3) by C9-triazole derivatives of 2,3-didehydro-N-acetyl-neuraminic acid. |
| AID1606652 | Antiviral activity against Influenza A virus (A/PA/10/2010 (H3N2)) infected in BALB/c mouse assessed as increase in animal survival rate at 10 mg/kg, po administered via gavage starting at 8 hrs post infection and continuing BID for 6 days | 2020 | Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8 | Targeting Endoplasmic Reticulum α-Glucosidase I with a Single-Dose Iminosugar Treatment Protects against Lethal Influenza and Dengue Virus Infections. |
| AID1222250 | Cmax in adult fed Sprague-Dawley rat at 30 mg/kg, po administered as solution in bovine milk by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID567612 | Antiviral activity against influenza A (A/Singapore/91/2009 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID542993 | Inhibition of Influenza B virus (B/Yamagata/1/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1409725 | Antiviral activity against Influenza A virus A/WSN/33 H1N1 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect by crystal violet staining based light-microscopic analysis | 2018 | ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3 | Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants. |
| AID636870 | Inhibition of influenza A virus neuraminidase | 2011 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23 | The de-guanidinylated derivative of peramivir remains a potent inhibitor of influenza neuraminidase. |
| AID1160747 | Antiviral activity against Influenza A virus H3N2 VR1679 infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity after 48 hrs by CellTiter-Glo assay | 2014 | ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8 | Identification and synthesis of quinolizidines with anti-influenza a virus activity. |
| AID567712 | Ratio of IC50 for influenza A (A/New York/18/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID565261 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells selected at 78 uM of zanamivir after 8 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID286171 | Survival of 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus inoculated ferrets at 5 mg/kg after 4 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID1186763 | Inhibition of influenza A virus (A/California/07/2009(H1N1)) pdm09 neuraminidase using MUNANA substrate pre-incubated for 30 mins before substrate addition by fluorometric assay | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | Inhibitory potency of flavonoid derivatives on influenza virus neuraminidase. |
| AID510176 | Antiviral activity against parainfluenza-3 virus infected in Vero cells assessed as reduction of virus-induced cytopathic effect | 2010 | European journal of medicinal chemistry, Sep, Volume: 45, Issue:9 | A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities. |
| AID561139 | Antiviral activity against Influenza A virus (A/whooper swan/Mongolia/1/2009(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in IL1alpha production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID561353 | Antiviral activity against Influenza A virus (A/whooper swan/Mongolia/1/2009(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in MCP1 production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID581675 | Terminal half life in non-perfused Sprague-Dawley rat plasma at 30 mg/kg, iv | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID565046 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 250 nM of oseltamivir after 5 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1222244 | AUC(0 to infinity) in healthy human at 150 mg, po administered as single dose by HPLC-tandem mass spectrometry under fed conditions | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1385614 | Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus A/95-359 infected in MDCK cells | 2018 | Journal of natural products, 08-24, Volume: 81, Issue:8 | Minor Nortriterpenoids from the Twigs and Leaves of Rhododendron latoucheae. |
| AID1222284 | Drug uptake in CHOK1 cells expressing human PEPT1 at pH 6 by HPLC coupled with radiodetection analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID658607 | Cytotoxicity against MDCK cells assessed as minimum compound concentration required to causes microscopically detectable alteration of normal cell morphology | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | 2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies. |
| AID1160746 | Selectivity ratio of EC50 for Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells to EC50 for Influenza A virus H3N2 VR1679 infected in MDCK cells | 2014 | ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8 | Identification and synthesis of quinolizidines with anti-influenza a virus activity. |
| AID515136 | Selectivity ratio of IC50 for Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant to IC50 for Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant preincubated for 30 mins | 2010 | Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17 | Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. |
| AID1250470 | Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by crystal violet staining | 2015 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19 | Dicarabrol, a new dimeric sesquiterpene from Carpesium abrotanoides L. |
| AID283442 | Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. |
| AID565257 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 125 nM of zanamivir after 4 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1222253 | AUC(0 to 24 hrs) in adult fed Sprague-Dawley rat at 30 mg/kg, po administered as solution in bovine milk by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID567722 | Ratio of IC50 for influenza A (A/Singapore/91/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1889676 | Inhibition of human NEU1 | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Human Neuraminidases: Structures and Stereoselective Inhibitors. |
| AID1235020 | Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus (A/FM/1/47(H1N1))-induced cytopathic effect in MDCK cells | 2015 | Journal of natural products, Jul-24, Volume: 78, Issue:7 | Bioactive Sesquiterpenes and Lignans from the Fruits of Xanthium sibiricum. |
| AID581711 | Ratio of AUC (0 to infinity) after iv dose to AUC (0 to 8 hrs) after po dose in perfused Sprague-Dawley rat plasma at 1000 mg/kg | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID581731 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 3415 uM | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID582059 | Prodrug conversion in 7 days old female rat brain S9 fractions assessed as oseltamivir carboxylate generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID542580 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) infected in BALB/c mouse assessed as reduction in body weight at 10 mg/kg, po administered 48 hrs postinfection for 5 days measured on day 5 (Rvb = 17.4 %) | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID1222240 | Tmax in healthy human at 150 mg, po administered as single dose by HPLC-tandem mass spectrometry under fed conditions | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1372135 | Inhibition of Clostridium perfringenes neuraminidase activity using 4-methylumbelliferyl-1-alpha-D-N-acetylneuramic acid sodium salt hydrate as substrate by fluorescence based assay | 2017 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24 | Design, synthesis and biological evaluation of novel oseltamivir derivatives as potent neuraminidase inhibitors. |
| AID565460 | Ratio of IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M and H274Y mutant to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID581715 | Volume of distribution at steady state in Sprague-Dawley rat at 30 mg/kg, iv | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID581859 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 1665 uM in presence of P-gp inhibitor elacridar | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID286175 | Antiviral activity against 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus inoculated ferrets assessed as inhibition of viral replication in lungs at 5 mg/kg after 4 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID565251 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 31 uM of compound after 8 passage after 48 hrs by hemagglutininin titer | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID236132 | Bioavailability in rat (dose 5 mg equiv/kg i.v. and 10 mg/equiv/kg p.o.) | 2005 | Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12 | Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors. |
| AID712816 | Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis | 2012 | ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12 | Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds. |
| AID567725 | Ratio of IC50 for influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID582076 | Prodrug conversion in 7 days old female rat liver S9 fractions assessed as conversion of oseltamivir to oseltamivir carboxylate | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID567614 | Antiviral activity against influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1578006 | Selectivity index, ratio of TC50 for cytotoxicity against dog MDCK cells to IC50 for antiviral activity against Influenza A virus H3N2 infected in dog MDCK cells | 2019 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19 | Novel amides modified rupestonic acid derivatives as anti-influenza virus reagents. |
| AID1636357 | Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA | 2016 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16 | Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. |
| AID581712 | Ratio of AUC (0 to infinity) after iv dose to AUC (0 to 8 hrs) after po dose in perfused Sprague-Dawley rat cerebrospinal fluid at 1000 mg/kg | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1403783 | Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) harboring neuraminidase H275Y mutant infected in BALB/c mouse assessed as mouse survival at 0.96 umol/day, po for 5 consecutive days measured on day 10 post dose | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145 | Peramivir conjugates as orally available agents against influenza H275Y mutant. |
| AID558680 | Antiviral activity against influenza virus (A/Sidney/5/97 (H3N2)) R292 infected in MDCK cells expressing human ST6Gal 1 gene in hollow fiber model system assessed as decrease in viral replication at 1 ng/ml administered as 1 hr infusion every 8 hrs for 6 | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. |
| AID1201119 | Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis | 2015 | European journal of medicinal chemistry, Apr-13, Volume: 94 | A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives. |
| AID1293609 | Antiviral activity against Influenza A virus PR/8/34 infected in MDCK cells assessed as inhibition of plaque formation treated for 1 hr measured after 2 days by toluidine blue staining-based assay | 2016 | Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6 | 4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA-PB1 Protein-Protein Interaction: Structure-Activity Relationships Exploration with the Aid of Molecular Modeling. |
| AID1365370 | Antiviral activity against Influenza A virus (A/Victoria/3/1975(H3N2)) infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 48 hrs by SRB assay | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. |
| AID558686 | Half life in MDCK cells expressing human ST6Gal 1 gene in hollow fiber model system at 1 ng/ml administered as continuous infusion by LC-MS-MS | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. |
| AID1386752 | Cytotoxicity in MDCK cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer-Glo cell viability assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. |
| AID543003 | Inhibition of Influenza A virus (A/Yokohama/67/2006(clone 1)(H1N1)) wild type neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID565470 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase D198G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1226071 | Antiviral activity against oseltamivir/amantadine-resistant Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as protection against virus-induced cytocidal effect after 48 hrs by CellTiter-Glo assay | 2015 | ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3 | Phenolic diterpenoid derivatives as anti-influenza a virus agents. |
| AID1156848 | Inhibition of Influenza A H1N1 virus neuraminidase at 4 nM after 1 hr by spectrofluorimetry using 2-(4-meythylumbelliferyl)-alpha-D-acetylneuramic acid as substrate | 2014 | European journal of medicinal chemistry, Aug-18, Volume: 83 | Design and synthesis of 6-oxo-1,4,5,6-tetrahydropyrimidine-5-carboxylate derivatives as neuraminidase inhibitors. |
| AID658746 | Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | 2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies. |
| AID674871 | Antiviral activity against Influenza A virus (A/Guangdong-Luohu/219/2006(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect | 2012 | European journal of medicinal chemistry, Sep, Volume: 55 | Synthesis and antiviral activity of substituted bisaryl amide compounds as novel influenza virus inhibitors. |
| AID1201116 | Cytotoxicity against MDCK cells after 72 hrs by MTS assay | 2015 | European journal of medicinal chemistry, Apr-13, Volume: 94 | A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives. |
| AID1064127 | Inhibition of Influenza A virus A/California/07/2009 (H1N1) neuraminidase using MUNANA as substrate preincubated for 30 mins measured after 2 hrs | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | Bifunctional thiosialosides inhibit influenza virus. |
| AID1767877 | Antiviral activity against Influenza A virus (H1N1) infected in dog MDCK cells assessed as inhibition of surface glycoprotein hemagglutinin | 2021 | European journal of medicinal chemistry, Oct-15, Volume: 222 | Optimization and SAR research at the piperazine and phenyl rings of JNJ4796 as new anti-influenza A virus agents, part 1. |
| AID1505286 | Antiviral activity against Influenza A virus (A/duck/HK/Y280/97 (H9N2)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 48 hrs by microscopic analysis | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12 | Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses. |
| AID286187 | Antiviral activity against 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus inoculated ferrets assessed as weight loss at 10 mg/kg after 24 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID542956 | Inhibition of Influenza A virus (A/Singapore/1/1957(H2N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1365377 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity treated 1 hr after virus infection and measured after 48 hrs by SRB assay | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. |
| AID542560 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) H274Y mutant infected in BALB/c mouse assessed as mortality rate at 10 mg/kg, po administered 48 hrs postinfection for 5 days measured on day 5 (Rvb = 100 %) | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID1200496 | Antiviral activity against amantadine and ribavirin-resistant influenza A virus A/HuNan-huHui/1222/2010 (H3N2) strain | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin. |
| AID523882 | Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. |
| AID1183507 | Antiviral activity against Influenza A virus A/Puerto Rico/8/34 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay | 2014 | Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15 | Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. |
| AID1200482 | Antiviral activity against influenza A virus A/WSN/33 (H1N1) infected in MDCK cells assessed as reduction in cytopathic effect at 100 uM after 48 hrs by plaque assay | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin. |
| AID1470965 | Antiviral activity against Influenza A virus (A/Hong Kong/498/97(H3N2)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral replication preincubated for 36 hrs followed by reinfection in new monolayer of MDCK cells eve | 2017 | Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10 | Discovery of acylguanidine oseltamivir carboxylate derivatives as potent neuraminidase inhibitors. |
| AID763923 | Cytotoxicity against MDCK cells | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones. |
| AID753432 | Antiviral activity against Influenza A virus (A/chicken/Sandong/Li/2008(H9N2)) infected in chicken embryo fibroblast assessed as protection against virus-induced cytopathic effect after 2 days by MTS assay | 2013 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12 | Caffeic acid derivatives: a new type of influenza neuraminidase inhibitors. |
| AID1222315 | Drug uptake in CHOK1 cells expressing human PEPT1 at 100 uM at pH 4 to 8 after 10 mins by HPLC coupled with radiodetection analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID542947 | Inhibition of Influenza A virus (A/New Caledonia/20/1999(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1617144 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in human A549 cells assessed as reduction in virus neuraminidase level incubated for 24 hrs by fluorescence based assay | 2019 | Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21 | Design, Synthesis, and Biological Evaluation of Novel Indoles Targeting the Influenza PB2 Cap Binding Region. |
| AID1889677 | Inhibition of human NEU2 | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Human Neuraminidases: Structures and Stereoselective Inhibitors. |
| AID1222234 | Apparent oral clearance in healthy human at 150 mg, po administered as single dose by HPLC-tandem mass spectrometry under fasting conditions | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID542970 | Inhibition of Influenza A virus (A/Tokushima/1/2005(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID561114 | Antiviral activity against Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) infected in BALB/c mouse assessed as decrease in viral load in lung at 20 mg/kg, po BID for 5 days measured on day 9 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1771091 | Inhibition of Influenza A virus H5N1 neuraminidase | |||
| AID478323 | Antiviral activity against Influenza A virus H3N2 assessed as cell viability by cell based MTS assay | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9 | Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity. |
| AID1073042 | Inhibition of Influenza A virus (A/Hong Kong/1/1968(H3N2)) neuraminidase by chemiluminescence based assay | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | Computer-guided approach to access the anti-influenza activity of licorice constituents. |
| AID416783 | Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method | 2009 | Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7 | Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus. |
| AID542552 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) infected in BALB/c mouse assessed as lung viral titer at 1 mg/kg, po administered 4 hrs before infection for 5 days measured on day 4 (Rvb = 1.9 x 10'6 +/- 0.1 x 10'6 PFU) | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID1250471 | Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by crystal violet staining | 2015 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19 | Dicarabrol, a new dimeric sesquiterpene from Carpesium abrotanoides L. |
| AID1222236 | AUC(0 to infinity) in healthy human at 150 mg, po administered as single dose by HPLC-tandem mass spectrometry under fasting conditions | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID611760 | Antiviral activity against Coxsackievirus B4 infected in Vero cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID1731311 | Selectivity index, ratio of TC50 for MDCK cells to EC50 for antiviral activity against Influenza A virus A/Hebei Xinhua/SWL1106/2017 (H1N1) pdm09 infected in MDCK cells | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors. |
| AID565255 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 5 nM of zanamivir after 2 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID611766 | Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID1222301 | AUC(0 to 6 hrs) in adult fasted Sprague-Dawley rat at 30 mg/kg, po administered as water solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID661914 | Inhibition of Influenza A virus H9N2 neuraminidase using 4-MU-NANA as substrate by fluorescence assay | 2012 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11 | Xanthones from Polygala karensium inhibit neuraminidases from influenza A viruses. |
| AID565472 | Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1222256 | Tmax in adult fed Sprague-Dawley rat at 30 mg/kg, po administered as 125 mM aqueous Gly-Sar solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1222237 | Drug excretion in healthy human urine assessed as unchanged drug level at 150 mg, po administered as single dose by HPLC-tandem mass spectrometry under fasting conditions | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID625277 | FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI | 2011 | Drug discovery today, Aug, Volume: 16, Issue:15-16 | FDA-approved drug labeling for the study of drug-induced liver injury. |
| AID712796 | Cytotoxicity against dog MDCK cells assessed as cell morphology alterations | 2012 | ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12 | Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds. |
| AID542582 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) infected in BALB/c mouse assessed as mortality rate at 1 mg/kg, po administered 48 hrs postinfection for 5 days measured on day 5 (Rvb = 100 %) | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID528271 | Inhibition of influenza A virus H1N1 Neuraminidase using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid sodium salt hydrate substrate | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22 | New stilbenoid with inhibitory activity on viral neuraminidases from Erythrina addisoniae. |
| AID611758 | Antiviral activity against RSV infected in HeLa cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID581714 | Clearance in Sprague-Dawley rat at 30 mg/kg, iv | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID567704 | Ratio of IC50 for influenza A (A/Singapore/91/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID455707 | Selectivity index, ratio of CC50 for MDCK cells to EC50 for influenza virus H1N1 A/PR/8/34 | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. |
| AID1401146 | Inhibition of Influenza A virus A/Anhui/1/2005(H5N1) neuraminidase at 10 uM using MUNANA as substrate preincubated for 5 to 15 mins followed by substrate addition measured after 30 mins by fluorescence assay relative to control | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Synthesis and biological evaluation of NH |
| AID1071442 | Half life in Sprague-Dawley rat plasma | 2014 | Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3 | Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A. |
| AID1077001 | Antiviral activity against Influenza A virus A/hanfang/359/95(H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs | 2014 | European journal of medicinal chemistry, Apr-09, Volume: 76 | 1,2,3-Triazole-containing derivatives of rupestonic acid: click-chemical synthesis and antiviral activities against influenza viruses. |
| AID443830 | Antiviral activity against Influenza A virus (A/Hong Kong/7/87(H3N2)) assessed as cell viability by cell-based MTS assay | 2009 | Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19 | Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study. |
| AID1365385 | Inhibition of neuraminidase in influenza A virus (A/Puerto Rico/8/1934(H1N1)) assessed as remaining enzyme activity at 1 ug/ml pre-incubated for 30 mins before NA-Star substrate addition for 30 mins by luminescence based assay | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. |
| AID1386751 | Antiviral activity against influenza A virus Hong Kong/8/1968(H3N2) infected in HEK293T cells assessed as inhibition of viral replicon activity incubated for 30 hrs by dual-Glo luciferase assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. |
| AID1588928 | Inhibition of Influenza A virus (A/Babol/36/2005 (H3N2) neuraminidase expressed by HEK293 cells incubated for 1 hr using 4-MU-NANA substrate by spectrofluorometric assay | 2019 | Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17 | Total synthesis of dryocrassin ABBA and its analogues with potential inhibitory activity against drug-resistant neuraminidases. |
| AID1113452 | Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay | 2013 | Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4 | Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)- |
| AID1473440 | Synergistic antiviral activity against Influenza A virus (A/WSN/33(H1N1)) infected in MDCK cells expressing ST6Gal-1 assessed as reduction in virus-induced cytopathic effect after 44 to 48 hrs in presence of 1:5 3-{[(5-Cyclopropyl-1,2-oxazol-3-yl)methyl]a | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses. |
| AID565240 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M mutant infected in MDCK cells selected at 16 uM of oseltamivir after 7 passage after 48 hrs by hemagglutininin | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID567613 | Antiviral activity against influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1059383 | Antiviral activity against Influenza A virus (A/Chicken/Shandong/LY/08(H9N2)) infected in chicken embryo fibroblasts assessed as protection against virus-induced cytopathic effect preincubated for 1 hr followed by viral-infection measured after 2 days by | 2013 | Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24 | Further discovery of caffeic acid derivatives as novel influenza neuraminidase inhibitors. |
| AID1222311 | Cmax in adult fed Sprague-Dawley rat at 30 mg/kg, po administered as water solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID561128 | Antiviral activity against Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) infected in BALB/c mouse assessed as decrease in viral load in brain at 20 mg/kg, po BID for 5 days measured on day 9 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID392531 | Antiviral activity against influenza virus | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2 | Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. |
| AID565267 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID314411 | Inhibition of influenza A/N1/PR/8/34 neuraminidase | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5 | Synthesis of potent pyrrolidine influenza neuraminidase inhibitors. |
| AID542963 | Inhibition of Influenza A virus (A/Hiroshima/52/2005(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567721 | Ratio of IC50 for influenza A (A/New York/18/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID581729 | AUC (0 to 8 hrs) ratio in cerebrospinal fluid to plasma in perfused Sprague-Dawley rat at 1000 mg/kg, po | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID283448 | Cytotoxicity against MDCK cells | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. |
| AID542969 | Inhibition of Influenza A virus (A/Osaka/56/2004(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID456232 | Activity at human recombinant CES1 expressed in baculovirus-infected Spodoptera frugiperda Sf21 cells assessed as substrate hydrolysis by fluorescence assay | 2010 | Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1 | In silico prediction of human carboxylesterase-1 (hCES1) metabolism combining docking analyses and MD simulations. |
| AID1183518 | Antiviral activity against Influenza A virus A/Puerto Rico/8/34 infected in BALB/c mouse assessed as mouse survival at 1 to 10 mg/kg bid treated after 48 hrs of infection for 10 days | 2014 | Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15 | Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. |
| AID283440 | Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. |
| AID1578007 | Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition in virus-induced cytopathic effect incubated for 40 hrs | 2019 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19 | Novel amides modified rupestonic acid derivatives as anti-influenza virus reagents. |
| AID658751 | Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | 2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies. |
| AID515135 | Selectivity ratio of IC50 for Influenza B virus B/Gifu/11/2005 wild type neuraminidase to IC50 for Influenza B virus B/Gifu/11/2005 wild type neuraminidase preincubated for 30 mins | 2010 | Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17 | Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. |
| AID581745 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 618 uM in presence of P-gp inhibitor elacridar | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID286199 | Survival of 10^6 EID50 influenza A/turkey/15/06 H5N1 virus inoculated ferrets at 10 mg/kg twice daily after 24 hrs inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID543000 | Inhibition of Influenza A virus (A/seal/Massachusetts/1/1980(H7N7)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567718 | Ratio of IC50 for influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1578005 | Antiviral activity against Influenza A virus H3N2 infected in dog MDCK cells assessed as inhibition in virus-induced cytopathic effect incubated for 40 hrs | 2019 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19 | Novel amides modified rupestonic acid derivatives as anti-influenza virus reagents. |
| AID543182 | Ratio of IC50 for Influenza A virus (A/Kawasaki/IMS22A-954/2003(H3N2)) neuraminidase R292K mutant to IC50 for Influenza A virus (A/Kawasaki/IMS22A-954/2003(H3N2)) wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | |||
| AID1222282 | Drug uptake in CHOK1 cells expressing human PEPT1 at pH 5 by HPLC coupled with radiodetection analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID581726 | Activity of human MDR1-mediated permeability from apical to basolateral side in pig LLC-PK1 cells in presence of P-gp inhibitor elacridar | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID560886 | Antiviral activity against Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) infected in BALB/c mouse assessed as mean day to death at 20 mg/kg, po BID for 5 days measured post last dose | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID567708 | Ratio of IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1222304 | Tmax in adult fasted Sprague-Dawley rat at 30 mg/kg, po administered as solution in bovine milk by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID582031 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 6918 uM in presence of P-gp inhibitor elacridar | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1470964 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) harboring wild type neuraminidase assessed as inhibition of viral replication preincubated for 36 hrs followed by reinfection in new monolayer of MDCK cells every 1 hr for 12 hrs | 2017 | Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10 | Discovery of acylguanidine oseltamivir carboxylate derivatives as potent neuraminidase inhibitors. |
| AID561117 | Antiviral activity against Influenza A virus (A/duck/Laos/25/2006(H5N1)) infected in BALB/c mouse assessed as virus-induced change body weight at 20 mg/kg, po BID for 5 days measured on day 9 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID581520 | Prodrug conversion in 42 days old male rat liver S9 fractions assessed as paranitrophenol generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID542997 | Inhibition of Influenza A virus (A/turkey/Ontario/6,118/1968(H8N4)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID561127 | Antiviral activity against Influenza A virus (A/duck/Laos/25/2006(H5N1)) infected in BALB/c mouse assessed as decrease in viral load in brain at 20 mg/kg, po BID for 5 days measured on day 9 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID560878 | Inhibition of Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) neuraminidase by Michaelis-Menten equation analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID560884 | Antiviral activity against Influenza A virus (A/whooper swan/Mongolia/1/2009(H5N1)) infected in BALB/c mouse assessed as survival rate at 20 mg/kg, po BID for 5 days measured post last dose | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1234207 | Selectivity index, ratio of TC50 for African green monkey MDCK cells to IC50 for influenza A virus (A/Hanfang/359/95(H3N2)) | 2015 | Journal of natural products, Jul-24, Volume: 78, Issue:7 | Antiviral Matrine-Type Alkaloids from the Rhizomes of Sophora tonkinensis. |
| AID549515 | Inhibition of Influenza A H1N1 virus neuraminidase activity after 2 hrs by spectrofluorometry | 2011 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1 | Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata. |
| AID543183 | Inhibition of Influenza A virus (A/Yokohama/IMS9A-2029/2003(H3N2)) wild type neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID286173 | Antiviral activity against 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus inoculated ferrets assessed as day of death at 5 mg/kg after 4 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID1446880 | Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 40 hrs by CellTiter-Glo assay | 2017 | European journal of medicinal chemistry, Apr-21, Volume: 130 | Design, synthesis and biological evaluation of gentiopicroside derivatives as potential antiviral inhibitors. |
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | |||
| AID567593 | Antiviral activity against influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID565258 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 625 nM of zanamivir after 5 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1160752 | Antiviral activity against Influenza A virus H3N2 VR1679 infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity pretreated with compound before infection by time of addition assay | 2014 | ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8 | Identification and synthesis of quinolizidines with anti-influenza a virus activity. |
| AID542555 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) H274Y mutant infected in BALB/c mouse assessed as reduction in body weight at 1 mg/kg, po administered 4 hrs before infection for 5 days measured on day 5 (Rvb = 22.2 %) | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID1222241 | Terminal half life in healthy human at 150 mg, po administered as single dose by HPLC-tandem mass spectrometry under fed conditions | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID582030 | Cmax in perfused Sprague-Dawley rat cerebrospinal fluid at 30 mg/kg, iv | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1266212 | Inhibition of Influenza B virus neuraminidase R152K mutant | 2015 | Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24 | 1,2,3-Triazolyl-4-oxoquinolines: A feasible beginning for promising chemical structures to inhibit oseltamivir-resistant influenza A and B viruses. |
| AID582071 | Prodrug conversion in 7 days old male rat brain S9 fractions assessed as conversion of oseltamivir to oseltamivir carboxylate | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID611765 | Antiviral activity against Feline coronavirus infected in CRFK cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID523881 | Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. |
| AID1654868 | Antiviral activity against influenza A virus H3N2/95-359 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by Reed-Muench method | 2020 | Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11 | 2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action. |
| AID1654873 | Selectivity index, ratio of CC50 for cytotoxicity in MDCK cells to EC50 for Antiviral activity against influenza A virus H3N2/95-359 infected in MDCK cells | 2020 | Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11 | 2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action. |
| AID1160751 | Antiviral activity against Influenza A virus H3N2 VR1679 infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity compound treated 2 hrs post infection by time of addition assay | 2014 | ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8 | Identification and synthesis of quinolizidines with anti-influenza a virus activity. |
| AID515129 | Inhibition of Influenza B virus B/Gifu/11/2005 wild type neuraminidase expressed in Sf21 insect cells after 60 mins by MUNANA based assay | 2010 | Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17 | Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. |
| AID542982 | Inhibition of Influenza B virus (B/Saitama/01/2006(Victoria)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1505280 | Antiviral activity against Influenza A virus (A/WSN/33 (H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 48 hrs by microscopic analysis | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12 | Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses. |
| AID567589 | Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID581743 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 83 uM in presence of P-gp inhibitor elacridar | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1222264 | Tmax in juvenile fasted Sprague-Dawley rat at 30 mg/kg, po administered as water solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1222283 | Drug uptake in CHOK1 cells at pH 6 by HPLC coupled with radiodetection analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1440171 | Oral bioavailability in human | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Prodrug approach: An overview of recent cases. |
| AID286183 | Antiviral activity against 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus inoculated ferrets assessed as day of death at 25 mg/kg after 24 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID1113455 | Cytotoxicity against MDCK cells assessed as change in cellular morphology | 2013 | Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4 | Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)- |
| AID542966 | Inhibition of Influenza A virus (A/Yamagata/1/2002(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1386757 | Antiviral activity against oseltamivir-resistant Influenza A virus (H1N1) TJ/15 up to 100 uM | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. |
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | |||
| AID532124 | Inhibition of human NEU3 expressed in HEK293 cells assessed as hydrolysis of ganglioside GM3 by TLC method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. |
| AID286193 | Inhibition of 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus replication in ferrets liver at 10 mg/kg after 24 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID443828 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) assessed as cell viability by cell-based MTS assay | 2009 | Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19 | Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study. |
| AID1222259 | AUC(0 to infinity) in adult fed Sprague-Dawley rat at 30 mg/kg, po administered as 125 mM aqueous Gly-Sar solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1708993 | Inhibition of Influenza virus H5N1 neuraminidase | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Design, synthesis and biological evaluation of dihydrofurocoumarin derivatives as potent neuraminidase inhibitors. |
| AID515133 | Inhibition of Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant expressed in Sf21 insect cells preincubated for 30 mins measured after 60 mins by MUNANA based assay | 2010 | Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17 | Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. |
| AID558679 | Antiviral activity against influenza virus (A/Sidney/5/97 (H3N2)) R292 infected in MDCK cells expressing human ST6Gal 1 gene in hollow fiber model system assessed as decrease in viral replication at 1 ng/ml administered as 1 hr infusion every 12 hrs for 6 | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. |
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | |||
| AID1222289 | Drug uptake in CHOK1 cells expressing human PEPT2 by HPLC coupled with radiodetection analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1578004 | Selectivity index, ratio of TC50 for cytotoxicity against dog MDCK cells to IC50 for antiviral activity against Influenza A virus H1N1 infected in dog MDCK cells | 2019 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19 | Novel amides modified rupestonic acid derivatives as anti-influenza virus reagents. |
| AID1365381 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity treated 12 hrs after virus infection and measured after 48 hrs by SRB assay | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. |
| AID416784 | Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method | 2009 | Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7 | Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus. |
| AID1073044 | Inhibition of Influenza A virus (A/Puerto Rico/8/1934(H1N1)) neuraminidase by chemiluminescence based assay | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | Computer-guided approach to access the anti-influenza activity of licorice constituents. |
| AID1289285 | Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining-based microplate reader analysis | 2016 | Journal of natural products, Jan-22, Volume: 79, Issue:1 | Antiviral Merosesquiterpenoids Produced by the Antarctic Fungus Aspergillus ochraceopetaliformis SCSIO 05702. |
| AID565048 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells selected at 6250 nM of oseltamivir after 7 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID582060 | Prodrug conversion in 42 days old male rat brain S9 fractions assessed as oseltamivir carboxylate generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID283443 | Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by virus yield reduction assay | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. |
| AID561142 | Inhibition of Influenza A virus (A/Turkey/651242/2006(H5N1)) neuraminidase A119A mutant isolated from virus-infected BALB/c mouse by fluorometric assay | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID763860 | Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/duck/Minnesota/1525/1981(H5N1)) | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones. |
| AID1470962 | Inhibition of Influenza A virus (A/Hong Kong/498/97(H3N2)) neuraminidase using 4-MU-NANA as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence assay | 2017 | Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10 | Discovery of acylguanidine oseltamivir carboxylate derivatives as potent neuraminidase inhibitors. |
| AID147493 | Inhibitory activity against influenza A neuraminidase | 2001 | Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25 | Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity. |
| AID542945 | Inhibition of Influenza A virus (A/Puerto Rico/8/1934(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID565044 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 25 nM of oseltamivir after 3 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID565479 | Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledo | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID286179 | Antiviral activity against 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus inoculated ferrets assessed as inhibition of viral replication in small intestine at 5 mg/kg after 4 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID567592 | Antiviral activity against influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID560879 | Inhibition of Influenza A virus (A/whooper swan/Mongolia/1/2009(H5N1)) neuraminidase by Michaelis-Menten equation analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1222270 | Tmax in juvenile fasted Sprague-Dawley rat at 30 mg/kg, po administered as 125 mM aqueous Gly-Sar solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID561352 | Antiviral activity against Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in MCP1 production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1858136 | Antiviral activity against group 2 influenza A virus H3N2 (A/Victoria/361/2011) infected in MDCK cells infected with supernatant of compound treated virus-producing human A549 cells assessed as reduction in viral titer at 1 to 10 uM treated for 48 hrs wit | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Synthesis, Optimization, and Structure-Activity Relationships of Imidazo[1,2- |
| AID283441 | Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by virus yield reduction assay | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. |
| AID1059386 | Inhibition of influenza A virus A/duck/China/QJ/01(H5N1) neuraminidase using 4-MU-NANA as substrate incubated for 5 mins prior to substrate addition measured after 30 to 60 mins by fluorescence assay | 2013 | Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24 | Further discovery of caffeic acid derivatives as novel influenza neuraminidase inhibitors. |
| AID768187 | Antiviral activity against influenza B virus infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies. |
| AID565270 | Ratio of IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M and H274Y mutant to IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID350631 | Antiviral activity against influenza A virus H1N1 A/HK/54/98 in MDCK cells assessed as inhibition of viral replication after 48 hrs by hemagglutinination assay | 2009 | Journal of medicinal chemistry, May-14, Volume: 52, Issue:9 | A novel small-molecule inhibitor of the avian influenza H5N1 virus determined through computational screening against the neuraminidase. |
| AID1889679 | Inhibition of human NEU4 | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Human Neuraminidases: Structures and Stereoselective Inhibitors. |
| AID561149 | Antiviral activity against Influenza A virus (A/whooper swan/Mongolia/1/2009(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in TNFalpha production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1204729 | Cmax in CD1 mouse at 30 mg/kg, po | 2015 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12 | Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay. |
| AID1293615 | Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus PR/8/34 infected in MDCK cells | 2016 | Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6 | 4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA-PB1 Protein-Protein Interaction: Structure-Activity Relationships Exploration with the Aid of Molecular Modeling. |
| AID582077 | Prodrug conversion in 42 days old male rat liver S9 fractions assessed as conversion of oseltamivir to oseltamivir carboxylate | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1235018 | Cytotoxicity against MDCK cells assessed as growth inhibition by CPE assay | 2015 | Journal of natural products, Jul-24, Volume: 78, Issue:7 | Bioactive Sesquiterpenes and Lignans from the Fruits of Xanthium sibiricum. |
| AID674873 | Antiviral activity against Influenza B virus (strain B/Jifang/13/97) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect | 2012 | European journal of medicinal chemistry, Sep, Volume: 55 | Synthesis and antiviral activity of substituted bisaryl amide compounds as novel influenza virus inhibitors. |
| AID581524 | Prodrug conversion in 7 days old female rat brain S9 fractions assessed as paranitrophenol generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1280364 | Antiviral activity against influenza B virus B/SZ/155 infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus. |
| AID581744 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 335 uM in presence of P-gp inhibitor elacridar | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1858130 | Antiviral activity against group 2 influenza A virus H3N2 (A/Victoria/361/2011) infected in human A549 cells assessed as inhibition of viral entry preincubated with compound for 30 mins followed by viral infection for 1 hour further incubated for 48 hrs w | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Synthesis, Optimization, and Structure-Activity Relationships of Imidazo[1,2- |
| AID542961 | Inhibition of Influenza A virus (A/California/07/2004(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID625286 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1156850 | Inhibition of Influenza A H1N1 virus neuraminidase at 0.16 nM after 1 hr by spectrofluorimetry using 2-(4-meythylumbelliferyl)-alpha-D-acetylneuramic acid as substrate | 2014 | European journal of medicinal chemistry, Aug-18, Volume: 83 | Design and synthesis of 6-oxo-1,4,5,6-tetrahydropyrimidine-5-carboxylate derivatives as neuraminidase inhibitors. |
| AID1222242 | Apparent oral clearance in healthy human at 150 mg, po administered as single dose by HPLC-tandem mass spectrometry under fed conditions | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1857995 | Inhibition of influenza virus neuraminidase | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Sialidase Inhibitors with Different Mechanisms. |
| AID286189 | Antiviral activity against 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus inoculated ferrets assessed as increase in temperature at 10 mg/kg after 24 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID581679 | Terminal half life in perfused Sprague-Dawley rat cerebrospinal fluid at 30 mg/kg, iv | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID567587 | Antiviral activity against influenza A (A/North Carolina/02/2009 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1204734 | Oral bioavailability in CD1 mouse at 30 mg/kg | 2015 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12 | Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay. |
| AID147494 | Inhibitory activity against influenza B neuraminidase | 2001 | Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25 | Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity. |
| AID582039 | Permeability from apical to basolateral side of Spodoptera frugiperda Sf9 cells over expressing human BCRP1 | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1222255 | Cmax in adult fed Sprague-Dawley rat at 30 mg/kg, po administered as 125 mM aqueous Gly-Sar solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID543004 | Inhibition of Influenza A virus (A/Yokohama/67/2006(clone 11)(H1N1)) neuraminidase H274Y mutant after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1405012 | Inhibition of recombinant His6-tagged human neuraminidase 1 expressed in HEK293 cells using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence analysis | 2018 | Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19 | Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity. |
| AID1612770 | Cytotoxicity against MDCK cells after 40 hrs by CellTiter-Glo assay | 2019 | European journal of medicinal chemistry, Feb-01, Volume: 163 | Synthesis, structure activity relationship and in vitro anti-influenza virus activity of novel polyphenol-pentacyclic triterpene conjugates. |
| AID532108 | Inhibition of human NEU3 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. |
| AID542564 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) H274Y mutant infected in BALB/c mouse assessed as lung viral titer at 1 mg/kg, po administered 4 hrs before infection for 5 days measured on day 4 (Rvb = 1 x 10'6 +/- 0.3 x 10'6 P | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID1234206 | Antiviral activity against influenza A virus (A/Hanfang/359/95(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenic effect dosed 1 hr after viral adsorption | 2015 | Journal of natural products, Jul-24, Volume: 78, Issue:7 | Antiviral Matrine-Type Alkaloids from the Rhizomes of Sophora tonkinensis. |
| AID1405013 | Inhibition of MBP-fused recombinant human neuraminidase 2 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence analysis | 2018 | Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19 | Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity. |
| AID1266218 | Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus | 2015 | Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24 | 1,2,3-Triazolyl-4-oxoquinolines: A feasible beginning for promising chemical structures to inhibit oseltamivir-resistant influenza A and B viruses. |
| AID565269 | Ratio of IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase H274Y mutant to IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1384747 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in C57BL/6J mouse assessed as decrease in viral load in bronchoalveolar lavage at 8 mg/mouse/day, ip qd treated up to day 2 starting at 5 to 10 mins post infection relative | 2018 | Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16 | From Naproxen Repurposing to Naproxen Analogues and Their Antiviral Activity against Influenza A Virus. |
| AID543007 | Inhibition of Influenza A virus (A/Kawasaki/IMS22A-954/2003(H3N2)) neuraminidase R292K mutant after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID565263 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K205EQ mutant gene and neuraminidase E119G mutant infected in MDCK cells selected at 1950 uM of zanamivir after 10 passage after 48 hrs by hemagglutinini | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID567724 | Ratio of IC50 for influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567606 | Antiviral activity against influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1222266 | Cmax in juvenile fasted Sprague-Dawley rat at 30 mg/kg, po administered as solution in bovine milk by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1073037 | Cytotoxicity against MDCK cells after 72 hrs | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | Computer-guided approach to access the anti-influenza activity of licorice constituents. |
| AID565468 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID561134 | Antiviral activity against Influenza A virus (A/Turkey/651242/2006(H5N1)) infected in BALB/c mouse assessed as decrease in viral load in brain at 20 mg/kg, po BID for 5 days measured on day 6 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID558689 | Half life in MDCK cells expressing human ST6Gal 1 gene in hollow fiber model system at 1 ng/ml administered as 1 hr infusion every 8 hrs by LC-MS-MS | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. |
| AID582063 | Prodrug conversion in 7 days old female rat liver S9 fractions assessed as oseltamivir carboxylate generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID582055 | Prodrug conversion in human liver S9 fractions assessed as paranitrophenol generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1401149 | Inhibition of Influenza A virus A/Anhui/1/2005(H5N1) neuraminidase H274Y mutant using MUNANA as substrate preincubated for 5 to 15 mins followed by substrate addition measured after 30 mins by fluorescence assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Synthesis and biological evaluation of NH |
| AID478322 | Antiviral activity against Influenza A virus H3N2 assessed as inhibition of viral induced cytopathic effect | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9 | Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity. |
| AID1293610 | Cytotoxicity against HEK293T cells assessed as decrease in cell viability after 24 hrs by MTT assay | 2016 | Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6 | 4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA-PB1 Protein-Protein Interaction: Structure-Activity Relationships Exploration with the Aid of Molecular Modeling. |
| AID527157 | Inhibition of Influenza A virus (A/chicken/Korea/01310/2001 (H9N2)) neuraminidase after 30 mins by spectrofluorimetric analysis | 2010 | Journal of natural products, Oct-22, Volume: 73, Issue:10 | C-Methylated Flavonoids from Cleistocalyx operculatus and Their Inhibitory Effects on Novel Influenza A (H1N1) Neuraminidase. |
| AID582064 | Prodrug conversion in 42 days old male rat liver S9 fractions assessed as oseltamivir carboxylate generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID561120 | Antiviral activity against Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) infected in BALB/c mouse assessed as virus-induced change body weight at 20 mg/kg, po BID for 5 days measured on day 15 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID539949 | Cytotoxicity against MDCK cells assessed as minimum concentration required to cause microscopically detectable alteration after 2 days | 2010 | European journal of medicinal chemistry, Nov, Volume: 45, Issue:11 | Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones. |
| AID582035 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 700 uM in presence of P-gp inhibitor elacridar | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1222261 | Tmax in juvenile breast-fed Sprague-Dawley rat at 30 mg/kg, po administered as water solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1473447 | Synergistic antiviral activity against Influenza A virus (A/WSN/33(H1N1)) infected in MDCK cells expressing ST6Gal-1 assessed as reduction in virus-induced cytopathic effect after 44 to 48 hrs in presence of 10:1 3-{[(5-Cyclopropyl-1,2-oxazol-3-yl)methyl] | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses. |
| AID611627 | Antiviral activity against HIV 1 3B infected in CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopy | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID565047 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells selected at 1250 nM of oseltamivir after 6 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID567603 | Antiviral activity against influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID478320 | Antiviral activity against influenza A virus H1N1 assessed as inhibition of viral induced cytopathic effect | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9 | Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity. |
| AID646596 | Inhibition of viral neuraminidase after 20 mins by fluorescence assay | 2012 | Journal of natural products, Jan-27, Volume: 75, Issue:1 | p-Terphenyl and diterpenoid metabolites from endophytic Aspergillus sp. YXf3. |
| AID1365387 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity at 1 ug/ml pre-incubated for 1 hr with virus before virus infection of cells and measured after 48 hr | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. |
| AID543187 | Inhibition of Influenza A virus (A/Kawasaki/MS31A-1030/2002(H3N2)) neuraminidase N294S mutant after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1222238 | Renal clearance in healthy human at 150 mg, po administered as single dose by HPLC-tandem mass spectrometry under fasting conditions | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID560885 | Antiviral activity against Influenza A virus (A/duck/Laos/25/2006(H5N1)) infected in BALB/c mouse assessed as survival rate at 20 mg/kg, po BID for 5 days measured post last dose | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID286196 | Inhibition of 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus replication in ferrets liver at 25 mg/kg after 24 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID1384743 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in C57BL/6J mouse assessed as increase in mouse survival at 8 mg/mouse/day, ip qd treated up to day 2 starting at 5 to 10 mins post infection measured at day 12 | 2018 | Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16 | From Naproxen Repurposing to Naproxen Analogues and Their Antiviral Activity against Influenza A Virus. |
| AID611768 | Antiviral activity against Influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID567608 | Antiviral activity against influenza A (A/Washington/10/2008 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1077003 | Antiviral activity against oseltamivir-resistant Influenza A virus (A/Tianjinjinnan/15/2009/H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs | 2014 | European journal of medicinal chemistry, Apr-09, Volume: 76 | 1,2,3-Triazole-containing derivatives of rupestonic acid: click-chemical synthesis and antiviral activities against influenza viruses. |
| AID283455 | Reduction of lung viral titre in BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 20 mg/kg/day, po twice daily for 5 days administered 1 hr after infection measured on day 1 relative to carboxymethyl cellulose | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. |
| AID1588929 | Inhibition of Influenza A virus (A/Anhui/1/2005(H5N1)) neuraminidase expressed by HEK293 cells incubated for 1 hr using 4-MU-NANA substrate by spectrofluorometric assay | 2019 | Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17 | Total synthesis of dryocrassin ABBA and its analogues with potential inhibitory activity against drug-resistant neuraminidases. |
| AID515122 | Inhibition of Influenza B virus (B/Perth/211/2001) recombinant neuraminidase E197 mutant expressed in Sf21 insect cells after 60 mins by MUNANA based assay | 2010 | Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17 | Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. |
| AID565238 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 625 nM of oseltamivir after 5 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID443831 | Antiviral activity against Influenza B virus (B/Hong Kong/5/72) assessed as inhibition of virus-induced cytopathic effect by cell-based assay | 2009 | Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19 | Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study. |
| AID1201120 | Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay | 2015 | European journal of medicinal chemistry, Apr-13, Volume: 94 | A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives. |
| AID1222300 | Tmax in adult fasted Sprague-Dawley rat at 30 mg/kg, po administered as water solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID611761 | Antiviral activity against Parainfluenza virus 3 infected in Vero cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID561350 | Antiviral activity against Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in MCP1 production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1578002 | Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs | 2019 | Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19 | Novel amides modified rupestonic acid derivatives as anti-influenza virus reagents. |
| AID1858137 | Antiviral activity against group 2 influenza A virus LPAI H7N7 (A/Netherlands/219/2003) infected in MDCK cells infected with supernatant of compound treated virus-producing human A549 cells assessed as reduction in viral titer at 1 to 10 uM treated for 48 | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Synthesis, Optimization, and Structure-Activity Relationships of Imidazo[1,2- |
| AID582050 | Prodrug conversion in 42 days old female rat liver S9 fractions assessed as paranitrophenol generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1502945 | Inhibition of neuraminidase activity in H9N2 A/chicken/Korea/01210/2001 infected in MDCK cells using 4-MU-NANA as substrate pretreated for 30 mins followed by substrate addition measured after 2 hrs by fluorescence assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | C-Methylated Flavonoid Glycosides from Pentarhizidium orientale Rhizomes and Their Inhibitory Effects on the H1N1 Influenza Virus. |
| AID1470968 | Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/Puerto Rico/8/1934(H1N1)) harboring neuraminidase H259Y mutant | 2017 | Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10 | Discovery of acylguanidine oseltamivir carboxylate derivatives as potent neuraminidase inhibitors. |
| AID443827 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) assessed as inhibition of virus-induced cytopathic effect by cell-based assay | 2009 | Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19 | Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study. |
| AID1222287 | Drug uptake in CHOK1 cells by HPLC coupled with radiodetection analysis in presence of KH and Hanks' balanced salt solution | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID283445 | Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. |
| AID634757 | Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID1222243 | AUC(0 to 24 hrs) in healthy human at 150 mg, po administered as single dose by HPLC-tandem mass spectrometry under fed conditions | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1266213 | Ratio of IC50 for oseltamivir-resistant Influenza A virus H3N2 wild type neuraminidase to IC50 for oseltamivir-resistant Influenza A virus H3N2 neuraminidase E119V mutant | 2015 | Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24 | 1,2,3-Triazolyl-4-oxoquinolines: A feasible beginning for promising chemical structures to inhibit oseltamivir-resistant influenza A and B viruses. |
| AID1183505 | Antiviral activity against Influenza A virus A/Georgia/20/2006 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay | 2014 | Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15 | Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. |
| AID1222272 | Cmax in healthy human at 150 mg, po administered as single dose by HPLC-tandem mass spectrometry under fasting conditions | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID733264 | Antiviral activity against Influenza B virus (B/Brisbane/60/2008) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition. |
| AID392530 | Antiviral activity against influenza H5N1 virus | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2 | Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. |
| AID560882 | Antiviral activity against Influenza A virus (A/Turkey/651242/2006(H5N1)) infected in BALB/c mouse assessed as survival rate at 20 mg/kg, po BID for 5 days measured post last dose | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID733265 | Antiviral activity against Influenza B virus (B/Lee/40) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition. |
| AID674875 | Antiviral activity against Influenza A virus (A/Tianjin-Jinnan/15/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect | 2012 | European journal of medicinal chemistry, Sep, Volume: 55 | Synthesis and antiviral activity of substituted bisaryl amide compounds as novel influenza virus inhibitors. |
| AID1077006 | Cytotoxicity against MDCK cells after 48 hrs | 2014 | European journal of medicinal chemistry, Apr-09, Volume: 76 | 1,2,3-Triazole-containing derivatives of rupestonic acid: click-chemical synthesis and antiviral activities against influenza viruses. |
| AID674874 | Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza B virus (strain B/Jifang/13/97) | 2012 | European journal of medicinal chemistry, Sep, Volume: 55 | Synthesis and antiviral activity of substituted bisaryl amide compounds as novel influenza virus inhibitors. |
| AID567602 | Antiviral activity against influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID634758 | Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID565262 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K205EQ mutant gene and neuraminidase E119G mutant infected in MDCK cells selected at 390 uM of zanamivir after 9 passage after 48 hrs by hemagglutininin | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID543185 | Ratio of IC50 for Influenza A virus (A/Yokohama/IMS9A-2029/2003(H3N2)) neuraminidase E119V mutant to IC50 for Influenza A virus (A/Yokohama/IMS9A-2029/2003(H3N2)) wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID661915 | Inhibition of wild type H1N1 swine influenza virus neuraminidase using 4-MU-NANA as substrate by fluorescence assay | 2012 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11 | Xanthones from Polygala karensium inhibit neuraminidases from influenza A viruses. |
| AID1404182 | Antiviral activity against Influenza A virus H1N1 A/Jena/8178/09 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs | |||
| AID1386763 | Inhibition of influenza A virus Hong Kong/8/1968(H3N2) neuraminidase at 0.1 to 1000 uM by chemiluminescence based assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. |
| AID542562 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) H274Y mutant infected in BALB/c mouse assessed as time to death at 10 mg/kg, po administered 48 hrs postinfection for 5 days (Rvb = 5.1 days) | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID582075 | Prodrug conversion in 7 days old male rat liver S9 fractions assessed as conversion of oseltamivir to oseltamivir carboxylate | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1427859 | Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus (A/95-359) infected in MDCK cells | |||
| AID591600 | Inhibition of influenza A virus neuraminidase assessed as cleavage of MUNANA substrate by fluorescence assay | 2011 | Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7 | Design, synthesis and biological activity of thiazolidine-4-carboxylic acid derivatives as novel influenza neuraminidase inhibitors. |
| AID560874 | Inhibition of Influenza A virus (A/whooper swan/Mongolia/1/2009(H5N1)) neuraminidase by fluorometric assay | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1222308 | Tmax in adult fasted Sprague-Dawley rat at 30 mg/kg, po administered as 125 mM aqueous Gly-Sar solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1317960 | Inhibition of Influenza A virus (A/California/07/2009(H1N1)) recombinant wild type N-terminal FLAG-tagged neuraminidase ectodomain (82 to 469 residues) transfected in Drosophila Schneider S2 cells using 4-MUNANA as substrate after 20 mins by fluorometric | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121 | Kinetic, thermodynamic and structural analysis of tamiphosphor binding to neuraminidase of H1N1 (2009) pandemic influenza. |
| AID560877 | Inhibition of Influenza A virus (A/Turkey/651242/2006(H5N1)) neuraminidase by Michaelis-Menten equation analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID567717 | Ratio of IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1266215 | Ratio of IC50 for Influenza B virus wild type neuraminidase to IC50 for Influenza B virus neuraminidase R152K mutant | 2015 | Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24 | 1,2,3-Triazolyl-4-oxoquinolines: A feasible beginning for promising chemical structures to inhibit oseltamivir-resistant influenza A and B viruses. |
| AID515140 | Fold resistance, ratio of Ki for Influenza B virus B/Gifu/11/2005 wild type neuraminidase preincubated for 30 mins to Ki for Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant preincubated for 30 mins | 2010 | Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17 | Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. |
| AID561354 | Antiviral activity against Influenza A virus (A/duck/Laos/25/2006(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in MCP1 production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID561119 | Antiviral activity against Influenza A virus (A/duck/Laos/25/2006(H5N1)) infected in BALB/c mouse assessed as decrease in viral load in lung at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID582061 | Prodrug conversion in 42 days old female rat brain S9 fractions assessed as oseltamivir carboxylate generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID523885 | Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. |
| AID1889678 | Inhibition of human NEU3 | 2022 | Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4 | Human Neuraminidases: Structures and Stereoselective Inhibitors. |
| AID582074 | Prodrug conversion in 42 days old female rat brain S9 fractions assessed as conversion of oseltamivir to oseltamivir carboxylate | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1438096 | Cytotoxicity against MDCK cells measured after 72 hrs et staining-based microscopic analysis | 2017 | Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5 | Binding and Proton Blockage by Amantadine Variants of the Influenza M2 |
| AID565248 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 250 nM of zanamivir after 5 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID565250 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 6250 nM of compound after 7 passage after 48 hrs by hemagglutininin tit | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1222309 | AUC(0 to 6 hrs) in adult fasted Sprague-Dawley rat at 30 mg/kg, po administered as 125 mM aqueous Gly-Sar solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1073043 | Inhibition of oseltamivir-resistant Influenza A virus H1N1 B/55/08 neuraminidase by chemiluminescence based assay | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | Computer-guided approach to access the anti-influenza activity of licorice constituents. |
| AID1660674 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in Kunming mouse assessed as mouse survival at 10 mg/kg/day, po starting 4 hrs after viral challenge and continued for 7 days by plaque assay | 2020 | Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13 | Chemoreactive-Inspired Discovery of Influenza A Virus Dual Inhibitor to Block Hemagglutinin-Mediated Adsorption and Membrane Fusion. |
| AID543005 | Ratio of IC50 for Influenza A virus (A/Yokohama/67/2006(clone 11)(H1N1)) neuraminidase H274Y mutant to IC50 for Influenza A virus (A/Yokohama/67/2006(clone 1)(H1N1)) wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID753431 | Cytotoxicity against chicken embryo fibroblast after 2 days by MTS assay | 2013 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12 | Caffeic acid derivatives: a new type of influenza neuraminidase inhibitors. |
| AID387576 | Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTS assay | 2008 | Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18 | Synthesis and antiviral evaluation of acyclic azanucleosides developed from sulfanilamide as a lead structure. |
| AID286182 | Antiviral activity against 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus inoculated ferrets assessed as day of death at 10 mg/kg after 24 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID542974 | Inhibition of Influenza B virus (B/Ohio/01/2005(Victoria)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID561346 | Antiviral activity against Influenza A virus (A/Turkey/651242/2006(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in IFNalpha production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID286184 | Antiviral activity against 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus inoculated ferrets assessed as maximal change in weight loss at 5 mg/kg after 4 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID1505281 | Antiviral activity against Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 48 hrs by microscopic analysis | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12 | Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses. |
| AID567609 | Antiviral activity against influenza A (A/North Carolina/02/2009 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID581680 | Terminal half life in perfused Sprague-Dawley rat brain at 30 mg/kg, iv | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1059382 | Cytotoxicity against chicken embryo fibroblasts infected with Influenza A virus (A/Chicken/Shandong/LY/08(H9N2)) preincubated for 1 hr followed by viral-infection measured after 2 days by MTS assay | 2013 | Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24 | Further discovery of caffeic acid derivatives as novel influenza neuraminidase inhibitors. |
| AID581519 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 83 uM | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID286200 | Antiviral activity against 10^6 EID50 influenza A/turkey/15/06 H5N1 virus inoculated ferrets assessed as weight loss at 10 mg/kg twice daily after 24 hrs inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID532115 | Inhibition of human influenza A virus A/Aichi/2/1968(H3N2) neuraminidase by fluorometric method using 4MU-NeuAc substrate | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. |
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | |||
| AID542959 | Inhibition of Influenza A virus (A/Wyoming/03/2003(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1222248 | AUC(0 to 6 hrs) in adult fed Sprague-Dawley rat at 30 mg/kg, po administered as water solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID558685 | AUC (0 to 24 hrs) in MDCK cells expressing human ST6Gal 1 gene in hollow fiber model system at 1 ng/ml administered as continuous infusion by LC-MS-MS | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. |
| AID1077005 | Antiviral activity against Influenza A virus (A/FM/1/1947(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs | 2014 | European journal of medicinal chemistry, Apr-09, Volume: 76 | 1,2,3-Triazole-containing derivatives of rupestonic acid: click-chemical synthesis and antiviral activities against influenza viruses. |
| AID582066 | Prodrug conversion in 86 years old male human brain S9 fractions assessed as oseltamivir carboxylate generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID561140 | Antiviral activity against Influenza A virus (A/duck/Laos/25/2006(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in IL1alpha production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID567601 | Antiviral activity against influenza A (A/Singapore/91/2009 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID532116 | Inhibition of human influenza A virus A/DK/HK/313/4/78(H5N3) neuraminidase by fluorometric method using 4MU-NeuAc substrate | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. |
| AID561147 | Antiviral activity against Influenza A virus (A/Turkey/651242/2006(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in TNFalpha production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID532114 | Inhibition of human Influenza A virus A/PR/8/34(H1N1) neuraminidase by fluorometric method using 4MU-NeuAc substrate | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. |
| AID478321 | Antiviral activity against influenza A virus H1N1 assessed as cell viability by cell based MTS assay | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9 | Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity. |
| AID1222263 | Cmax in juvenile fasted Sprague-Dawley rat at 30 mg/kg, po administered as water solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1222245 | Drug excretion in healthy human urine assessed as unchanged drug level at 150 mg, po administered as single dose by HPLC-tandem mass spectrometry under fed conditions | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1160750 | Antiviral activity against Influenza A virus H3N2 VR1679 infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity compound treated 6 hrs post infection by time of addition assay | 2014 | ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8 | Identification and synthesis of quinolizidines with anti-influenza a virus activity. |
| AID1473437 | Synergistic antiviral activity against Influenza A virus (A/WSN/33(H1N1)) infected in MDCK cells expressing ST6Gal-1 assessed as reduction in virus-induced cytopathic effect after 44 to 48 hrs in presence of 10:1 3-{[(5-Cyclopropyl-1,2-oxazol-3-yl)methyl] | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses. |
| AID567586 | Antiviral activity against influenza A (A/Washington/10/2008 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1186765 | Inhibition of influenza B virus (B/Brisbane/60/2008) neuraminidase using MUNANA substrate pre-incubated for 30 mins before substrate addition by fluorometric assay | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | Inhibitory potency of flavonoid derivatives on influenza virus neuraminidase. |
| AID1438095 | Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) expressing wild-type M2 proton channel infected in MDCK cells assessed as reduction in cytopathic effect after 48 hrs by crystal violet staining-based microscopic analysis | 2017 | Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5 | Binding and Proton Blockage by Amantadine Variants of the Influenza M2 |
| AID1498141 | Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced visual cytopathicity | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12 | Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs. |
| AID567713 | Ratio of IC50 for influenza A (A/Singapore/91/2009 (H1N1))virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID314410 | Inhibition of influenza B/Memphis/3/89 neuraminidase | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5 | Synthesis of potent pyrrolidine influenza neuraminidase inhibitors. |
| AID1266211 | Inhibition of Influenza B virus wild type neuraminidase | 2015 | Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24 | 1,2,3-Triazolyl-4-oxoquinolines: A feasible beginning for promising chemical structures to inhibit oseltamivir-resistant influenza A and B viruses. |
| AID581681 | Ratio of AUC (0 to infinity) after iv dose to AUC (0 to 8 hrs) after po dose in non-perfused Sprague-Dawley rat plasma at 30 mg/kg | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID548441 | Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | 4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation. |
| AID611762 | Antiviral activity against Mammalian orthoreovirus 1 infected in Vero cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID1059387 | Inhibition of Influenza A virus (A/Chicken/Shandong/LY/08(H9N2)) neuraminidase using 4-MU-NANA as substrate incubated for 5 mins prior to substrate addition measured after 30 to 60 mins by fluorescence assay | 2013 | Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24 | Further discovery of caffeic acid derivatives as novel influenza neuraminidase inhibitors. |
| AID539956 | Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as cell viability after 2 days by MTS assay | 2010 | European journal of medicinal chemistry, Nov, Volume: 45, Issue:11 | Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones. |
| AID582046 | Permeability from basolateral to apical side of pig LLC-PK1 cells over expressing human MDR1 in presence of P-gp inhibitor elacridar | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID286186 | Antiviral activity against 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus inoculated ferrets assessed as increase in temperature at 5 mg/kg after 4 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID283444 | Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. |
| AID515121 | Inhibition of Influenza B virus (B/Perth/211/2001) recombinant wild type neuraminidase expressed in Sf21 insect cells after 60 mins by MUNANA based assay | 2010 | Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17 | Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. |
| AID763865 | Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones. |
| AID1201115 | Cytotoxicity against MDCK cells after 72 hrs by microscopic analysis | 2015 | European journal of medicinal chemistry, Apr-13, Volume: 94 | A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives. |
| AID286177 | Antiviral activity against 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus inoculated ferrets assessed as inhibition of virus spread in liver at 5 mg/kg after 4 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID286180 | Survival of 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus inoculated ferrets at 10 mg/kg after 24 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID1280344 | Antiviral activity against Influenza A virus A/WSN/1933 (H1N1) infected in MDCK cells assessed as protection against virus induced cytopathic effect after 40 hrs by Celltiter-Glo assay | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus. |
| AID548438 | Cytotoxicity against MDCK cells assessed as altered cell morphology | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | 4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation. |
| AID286174 | Antiviral activity against 10 EID50 influenza A/Vietnam/1203/04 H5N1 virus inoculated ferrets assessed as weight loss at 5 mg/kg after 4 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID1073036 | Induction of fluorescence at 100 uM relative to 4-methylumbelliferone | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | Computer-guided approach to access the anti-influenza activity of licorice constituents. |
| AID542949 | Inhibition of Influenza A virus (A/Yamagata/3/2002(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1460731 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction in viral HA titer by measuring reduction in chicken RBC lysis after 24 hrs by hemagglutination test | 2017 | Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7 | Boronic Acid Modifications Enhance the Anti-Influenza A Virus Activities of Novel Quindoline Derivatives. |
| AID542981 | Inhibition of Influenza B virus (B/Aichi/3/2006(Victoria)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1365375 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity treated 1 hr before virus infection and measured after 48 hrs by SRB assay | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. |
| AID515138 | Fold resistance, ratio of Ki for Influenza B virus (B/Perth/211/2001) wild type recombinant neuraminidase preincubated for 30 mins to Ki for Influenza B virus (B/Perth/211/2001) neuraminidase E197 mutant preincubated for 30 mins | 2010 | Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17 | Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. |
| AID1183511 | Antiviral activity against Influenza A virus A/Viet Nam/1203/2004(H5N1) infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay | 2014 | Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15 | Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. |
| AID1401150 | Inhibition of Influenza A virus A/California/04/2009(H1N1) neuraminidase H274Y mutant using MUNANA as substrate preincubated for 5 to 15 mins followed by substrate addition measured after 30 mins by fluorescence assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Synthesis and biological evaluation of NH |
| AID542973 | Inhibition of Influenza B virus (B/Malaysia/2506/2004(Victoria)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID558684 | Antiviral activity against influenza virus (A/Sidney/5/97 (H3N2)) R292 infected in MDCK cells expressing human ST6Gal 1 gene in hollow fiber model system assessed as decrease in hemagglutinination units at 1 ng/ml administered as 1 hr infusion every 8 hrs | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. |
| AID1266214 | Ratio of IC50 for Influenza A virus H1N1 wild type neuraminidase to IC50 for Influenza A virus H1N1 neuraminidase H275Y mutant | 2015 | Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24 | 1,2,3-Triazolyl-4-oxoquinolines: A feasible beginning for promising chemical structures to inhibit oseltamivir-resistant influenza A and B viruses. |
| AID1654871 | Cytotoxicity in MDCK cells assessed as reduction in cell viability | 2020 | Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11 | 2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action. |
| AID392525 | Antiviral activity against influenza B virus | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2 | Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. |
| AID532107 | Inhibition of human NEU2 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. |
| AID581528 | Cmax in non-perfused Sprague-Dawley rat plasma at 30 mg/kg, iv | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID543188 | Ratio of IC50 for Influenza A virus (A/Kawasaki/MS31A-1030/2002(H3N2)) neuraminidase N294S mutant to IC50 for Influenza A virus (A/Kawasaki/MS31A-1030/2002(H3N2)) wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1460745 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in Kunming mouse assessed as viral titer reduction in lungs at 20 mg/kg/day, po qd for 4 days measured on day 4 post last dose by crystal violet staining based plaque assay | 2017 | Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7 | Boronic Acid Modifications Enhance the Anti-Influenza A Virus Activities of Novel Quindoline Derivatives. |
| AID634751 | Antiviral activity against Human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID1474166 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID1588932 | Potency index, ratio of IC50 for OSV to IC50 for test compound for inhibition of Influenza A virus (A/Anhui/1/2013 (H7N9) neuraminidase expressed by HEK293 cells incubated for 1 hr using 4-MU-NANA substrate by spectrofluorometric assay | 2019 | Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17 | Total synthesis of dryocrassin ABBA and its analogues with potential inhibitory activity against drug-resistant neuraminidases. |
| AID1235019 | Antiviral activity against Influenza A virus (A/FM/1/47(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect | 2015 | Journal of natural products, Jul-24, Volume: 78, Issue:7 | Bioactive Sesquiterpenes and Lignans from the Fruits of Xanthium sibiricum. |
| AID539957 | Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as cell viability after 2 days by MTS assay | 2010 | European journal of medicinal chemistry, Nov, Volume: 45, Issue:11 | Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones. |
| AID581734 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 100 uM | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1498140 | Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced visual cytopathicity | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12 | Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs. |
| AID1266216 | Antiviral activity against Influenza A virus infected in MDCK cells after 72 hrs by yield reduction assay | 2015 | Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24 | 1,2,3-Triazolyl-4-oxoquinolines: A feasible beginning for promising chemical structures to inhibit oseltamivir-resistant influenza A and B viruses. |
| AID560875 | Inhibition of Influenza A virus (A/duck/Laos/25/2006(H5N1)) neuraminidase by fluorometric assay | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID567719 | Ratio of IC50 for influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID542954 | Inhibition of Influenza A virus (A/Aichi/169/2005(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID523887 | Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by fluorescent NA inhibition assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. |
| AID542971 | Inhibition of Influenza A virus (A/Saitama/07/2006(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID350630 | Antiviral activity against Influenza A virus (A/Viet Nam/1203/2004(H5N1)) in MDCK cells assessed as inhibition of viral replication after 48 hrs by hemagglutinination assay | 2009 | Journal of medicinal chemistry, May-14, Volume: 52, Issue:9 | A novel small-molecule inhibitor of the avian influenza H5N1 virus determined through computational screening against the neuraminidase. |
| AID560895 | Antiviral activity against Influenza A virus (A/duck/Laos/25/2006(H5N1)) infected in BALB/c mouse assessed as virus-induced change body weight at 20 mg/kg, po BID for 5 days measured on day 6 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID286194 | Inhibition of 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus replication in ferrets spleen at 10 mg/kg after 24 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID1234205 | Cytotoxic activity against MDCK cells assessed as cytopathogenic effect incubated for 48 hrs | 2015 | Journal of natural products, Jul-24, Volume: 78, Issue:7 | Antiviral Matrine-Type Alkaloids from the Rhizomes of Sophora tonkinensis. |
| AID634754 | Antiviral activity against thymidine kinase-deficient Varicella Zoster virus 07/1 infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID558674 | Antiviral activity against influenza virus (A/Sidney/5/97 (H3N2)) R292 infected in MDCK cells expressing human ST6Gal 1 gene in hollow fiber model system assessed as decrease in hemagglutinination at 1 ng/ml administered as continuous infusion for 6 days | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. |
| AID1418309 | Inhibition of wild type Influenza A virus (A/chicken/Hubei/327/2004(H5N1)) M2 channel expressed in yeast after 46 to 48 hrs by yeast growth restoration assay | 2018 | European journal of medicinal chemistry, Nov-05, Volume: 159 | Synthesis and structure-activity relationship study of arylsulfonamides as novel potent H5N1 inhibitors. |
| AID561351 | Antiviral activity against Influenza A virus (A/Turkey/651242/2006(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in MCP1 production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID558682 | Antiviral activity against influenza virus (A/Sidney/5/97 (H3N2)) R292 infected in MDCK cells expressing human ST6Gal 1 gene in hollow fiber model system assessed as decrease in hemagglutinination units at 1 ng/ml administered as 1 hr infusion every 24 hr | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. |
| AID1360192 | Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in BALB/c mouse assessed as protection against virus-induced infection at 48 umol/kg/day administered via oral gavage for 5 days | 2018 | European journal of medicinal chemistry, Jun-25, Volume: 154 | Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses. |
| AID582083 | Prodrug conversion in commercial liver S9 fractions assessed as conversion of oseltamivir to oseltamivir carboxylate | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID625290 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID625280 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID611628 | Antiviral activity against HIV 2 ROD infected in CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopy | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID1365374 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity treated 2 hrs before virus infection and measured after 48 hrs by SRB assay | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. |
| AID1365373 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity treated 6 hrs before virus infection and measured after 48 hrs by SRB assay | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. |
| AID565247 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 50 nM of zanamivir after 4 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID542581 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) infected in BALB/c mouse assessed as mortality rate at 1 mg/kg, po administered 4 hrs before infection for 5 days measured on day 5 (Rvb = 100 %) | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID561145 | Inhibition of Influenza A virus (A/duck/Laos/25/2006(H5N1)) neuraminidase isolated from virus-infected BALB/c mouse by fluorometric assay | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID763859 | Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/Perth/16/2009(H3N2)) | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones. |
| AID1498123 | Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity by MTS assay | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12 | Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs. |
| AID634748 | Antiviral activity against thymidine kinase-deficient acv-resistant Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID542968 | Inhibition of Influenza A virus (A/Saitama/80/2003(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID561150 | Antiviral activity against Influenza A virus (A/duck/Laos/25/2006(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in TNFalpha production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID565253 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G mutant infected in MDCK cells selected at 781 uM of zanamivir after 10 passage after 48 hrs by hemagglutininin ti | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID523884 | Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by fluorescent NA inhibition assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. |
| AID1222296 | Drug uptake in CHOK1 cells at 100 uM at 4 degC after 10 mins by HPLC coupled with radiodetection analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1660631 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 48 hrs by crystal violet staining based assay | 2020 | Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13 | Chemoreactive-Inspired Discovery of Influenza A Virus Dual Inhibitor to Block Hemagglutinin-Mediated Adsorption and Membrane Fusion. |
| AID581676 | Terminal half life in non-perfused Sprague-Dawley rat cerebrospinal fluid at 30 mg/kg, iv | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID582080 | Prodrug conversion in 77 years old male human brain S9 fractions assessed as conversion of oseltamivir to oseltamivir carboxylate | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1204727 | Tmax in CD1 mouse at 30 mg/kg, po | 2015 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12 | Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay. |
| AID561349 | Antiviral activity against Influenza A virus (A/duck/Laos/25/2006(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in IFNalpha production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID542550 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) infected in BALB/c mouse assessed as mortality rate at 10 mg/kg, po administered 48 hrs postinfection for 5 days measured on day 5 (Rvb = 100 %) | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID581713 | Ratio of AUC (0 to infinity) after iv dose to AUC (0 to 8 hrs) after po dose in perfused Sprague-Dawley rat brain at 1000 mg/kg | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1498142 | Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced visual cytopathicity | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12 | Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs. |
| AID1365386 | Inhibition of neuraminidase in influenza A virus (A/Puerto Rico/8/1934(H1N1)) assessed as remaining enzyme activity at 10 ug/ml pre-incubated for 30 mins before NA-Star substrate addition for 30 mins by luminescence based assay | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. |
| AID560883 | Antiviral activity against Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) infected in BALB/c mouse assessed as survival rate at 20 mg/kg, po BID for 5 days measured post last dose | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID565457 | Ratio of IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase E119G mutant to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1470963 | Inhibition of Influenza A virus (A/Puerto Rico/8/1934(H1N1)) neuraminidase H259Y mutant using 4-MU-NANA as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence assay | 2017 | Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10 | Discovery of acylguanidine oseltamivir carboxylate derivatives as potent neuraminidase inhibitors. |
| AID542979 | Inhibition of Influenza B virus (B/Yamagata/145/2003(Victoria)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1372136 | Antiviral activity against Influenza A virus (A/WSN/33(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect | 2017 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24 | Design, synthesis and biological evaluation of novel oseltamivir derivatives as potent neuraminidase inhibitors. |
| AID542978 | Inhibition of Influenza B virus (B/Tokushima/1/2003(Victoria)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID634838 | Antiviral activity against Human immunodeficiency virus 1 infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID527165 | Cytotoxicity against MDCK cells after 48 hrs by neutral red dye assay | 2010 | Journal of natural products, Oct-22, Volume: 73, Issue:10 | C-Methylated Flavonoids from Cleistocalyx operculatus and Their Inhibitory Effects on Novel Influenza A (H1N1) Neuraminidase. |
| AID542991 | Inhibition of Influenza B virus (B/Sapporo/29/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | |||
| AID286197 | Inhibition of 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus replication in ferrets spleen at 25 mg/kg after 24 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID543189 | Inhibition of Influenza B virus (B/Yokohama/UT2203/2005)) neuraminidase N294S mutant after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID582044 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 in presence of P-gp inhibitor elacridar | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1222268 | AUC(0 to 5 hrs) in juvenile fasted Sprague-Dawley rat at 30 mg/kg, po administered as solution in bovine milk by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1470966 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) harboring neuraminidase H259Y mutant infected in MDCK cells assessed as inhibition of viral replication preincubated for 36 hrs followed by reinfection in new monolayer of MDCK cell | 2017 | Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10 | Discovery of acylguanidine oseltamivir carboxylate derivatives as potent neuraminidase inhibitors. |
| AID753435 | Inhibition of Influenza A virus H1N1 A/duck/China/QJ/01 neuraminidase N1 using 4-MU-NANA as substrate after 5 mins by fluorescence assay | 2013 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12 | Caffeic acid derivatives: a new type of influenza neuraminidase inhibitors. |
| AID634756 | Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID582056 | Prodrug conversion in commercial brain S9 fractions assessed as paranitrophenol generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID581516 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 914 uM | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID565275 | Ratio of IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase D198G mutant to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID565476 | Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID458820 | Inhibition of Spanish flu (A/Bervig_Mission/1/18) neuraminidase | 2010 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3 | Inhibition of neuraminidase activity by polyphenol compounds isolated from the roots of Glycyrrhiza uralensis. |
| AID1160744 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity after 48 hrs by CellTiter-Glo assay | 2014 | ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8 | Identification and synthesis of quinolizidines with anti-influenza a virus activity. |
| AID567715 | Ratio of IC50 for influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID561125 | Antiviral activity against Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) infected in BALB/c mouse assessed as decrease in viral load in lung at 20 mg/kg, po BID for 5 days measured on day 6 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1073035 | Induction of fluorescence quenching at 100 uM relative to 4-methylumbelliferone | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | Computer-guided approach to access the anti-influenza activity of licorice constituents. |
| AID1222286 | Drug uptake in CHOK1 cells expressing human PEPT1 incubated for 30s to 15 mins by HPLC coupled with radiodetection analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID473065 | Inhibition of human neuraminidase 2 | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7 | Complexity in influenza virus targeted drug design: interaction with human sialidases. |
| AID1200484 | Cytotoxicity against MDCK cells assessed as cell growth after 40 hrs by CellTiter-Glo assay | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin. |
| AID1409724 | Antiviral activity against Influenza A virus A/WSN/33 H1N1 harboring N31S mutant infected in MDCK cells assessed as reduction in virus-induced cytopathic effect by crystal violet staining based light-microscopic analysis | 2018 | ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3 | Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants. |
| AID625288 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID658747 | Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | 2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies. |
| AID634761 | Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID542556 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) H274Y mutant infected in BALB/c mouse assessed as reduction in body weight at 1 mg/kg, po administered 48 hrs postinfection for 5 days measured on day 5 (Rvb = 22.2 %) | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID567705 | Ratio of IC50 for influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID674870 | Cytotoxicity against MDCK cells incubated for 48 hrs by CPE method | 2012 | European journal of medicinal chemistry, Sep, Volume: 55 | Synthesis and antiviral activity of substituted bisaryl amide compounds as novel influenza virus inhibitors. |
| AID581733 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 9918 uM | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID582054 | Prodrug conversion in 77 years old male human brain S9 fractions assessed as paranitrophenol generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID558673 | Antiviral activity against influenza virus (A/Sidney/5/97 (H3N2)) R292 infected in MDCK cells expressing human ST6Gal 1 gene in hollow fiber model system assessed as decrease in viral replication after 48 to 72 hrs by plaque assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. |
| AID1473450 | Synergistic antiviral activity against Influenza A virus (A/WSN/33(H1N1)) infected in MDCK cells expressing ST6Gal-1 assessed as reduction in virus-induced cytopathic effect after 44 to 48 hrs in presence of 1:5 3-{[(5-Cyclopropyl-1,2-oxazol-3-yl)methyl]a | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses. |
| AID1064130 | Antiviral activity against Influenza A virus A/Hong Kong/8/1968 (H3N2) infected in MDCK cells assessed as reduction in virus plaque formation after 5 days | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | Bifunctional thiosialosides inhibit influenza virus. |
| AID561132 | Antiviral activity against Influenza A virus (A/whooper swan/Mongolia/1/2009(H5N1)) infected in BALB/c mouse assessed as decrease in viral load in brain at 20 mg/kg, po BID for 5 days measured on day 9 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID611757 | Antiviral activity against VSV infected in HeLa cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID1365383 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity at 1 ug/ml treated before virus infection and measured after 48 hrs by SRB assay relative to untreate | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. |
| AID712807 | Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis | 2012 | ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12 | Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds. |
| AID561146 | Antiviral activity against Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in TNFalpha production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID565274 | Ratio of IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID542958 | Inhibition of Influenza A virus (A/Kitakyushu/159/1993(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567615 | Antiviral activity against influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID581740 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 3500 uM | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID581739 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 1750 uM | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | |||
| AID565242 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M and H274Y mutant infected in MDCK cells selected at 390 uM of oseltamivir after 9 passage after 48 hrs by hemag | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID581736 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 350 uM | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID582032 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 9918 uM in presence of P-gp inhibitor elacridar | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1064128 | Inhibition of Influenza A virus A/Hong Kong/8/1968 (H3N2) neuraminidase using MUNANA as substrate preincubated for 30 mins measured after 2 hrs | 2014 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2 | Bifunctional thiosialosides inhibit influenza virus. |
| AID1505283 | Antiviral activity against Influenza A virus (A/HK/68(H3N2)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 48 hrs by microscopic analysis | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12 | Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses. |
| AID560894 | Antiviral activity against Influenza A virus (A/whooper swan/Mongolia/1/2009(H5N1)) infected in BALB/c mouse assessed as virus-induced change body weight at 20 mg/kg, po BID for 5 days measured on day 6 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID542965 | Inhibition of Influenza A virus (A/Shiga/5/2002(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID416780 | Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method | 2009 | Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7 | Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus. |
| AID567703 | Ratio of IC50 for influenza A (A/New York/18/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1617145 | Therapeutic index, ratio of CC50 for human A549 cells to IC50 for Influenza A virus (A/Puerto Rico/8/34(H1N1)) | 2019 | Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21 | Design, Synthesis, and Biological Evaluation of Novel Indoles Targeting the Influenza PB2 Cap Binding Region. |
| AID567727 | Ratio of IC50 for influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID548444 | Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | 4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation. |
| AID768188 | Antiviral activity against influenza A virus H3N3 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies. |
| AID565055 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 125 nM of oseltamivir after 4 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID582034 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 350 uM in presence of P-gp inhibitor elacridar | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID582068 | Prodrug conversion in human liver S9 fractions assessed as oseltamivir carboxylate generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID625281 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1470961 | Inhibition of Influenza A virus (A/Puerto Rico/8/1934(H1N1)) neuraminidase using 4-MU-NANA as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence assay | 2017 | Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10 | Discovery of acylguanidine oseltamivir carboxylate derivatives as potent neuraminidase inhibitors. |
| AID561121 | Antiviral activity against Influenza A virus (A/whooper swan/Mongolia/1/2009(H5N1)) infected in BALB/c mouse assessed as virus-induced change body weight at 20 mg/kg, po BID for 5 days measured on day 15 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1415636 | Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/Puerto Rico/8/34(H1N1)) | 2017 | MedChemComm, May-01, Volume: 8, Issue:5 | Synthesis and |
| AID523880 | Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by NA inhibition assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. |
| AID565259 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 3,125 nM of zanamivir after 6 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID543186 | Inhibition of Influenza A virus (A/Kawasaki/MS31A-1030/2002(H3N2)) wild type neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID581529 | Cmax in non-perfused Sprague-Dawley rat cerebrospinal fluid at 30 mg/kg, iv | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1473439 | Synergistic antiviral activity against Influenza A virus (A/WSN/33(H1N1)) infected in MDCK cells expressing ST6Gal-1 assessed as reduction in virus-induced cytopathic effect after 44 to 48 hrs in presence of 1:1 3-{[(5-Cyclopropyl-1,2-oxazol-3-yl)methyl]a | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses. |
| AID548440 | Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | 4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation. |
| AID1266209 | Inhibition of Influenza A virus H1N1 wild type neuraminidase | 2015 | Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24 | 1,2,3-Triazolyl-4-oxoquinolines: A feasible beginning for promising chemical structures to inhibit oseltamivir-resistant influenza A and B viruses. |
| AID1713958 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/34 (H1N1) infected in MDCK cells assessed as decrease in viral titer preincubated for 1 hr followed by viral infection and cultivated for 48 hrs followed by supernatant transferred to chicken e | 2016 | Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22 | Biological evaluation of tetracationic compounds based on two 1,4-diazabicyclo[2.2.2]octane moieties connected by different linkers. |
| AID1731310 | Antiviral activity against Influenza A virus A/Hebei Xinhua/SWL1106/2017 (H1N1) pdm09 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect preincubated for 1 hr followed by viral infection and measured after 48 hrs by crystal vi | 2021 | European journal of medicinal chemistry, Mar-05, Volume: 213 | Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors. |
| AID1588930 | Inhibition of Influenza A virus (A/Anhui/1/2013 (H7N9) neuraminidase expressed by HEK293 cells incubated for 1 hr using 4-MU-NANA substrate by spectrofluorometric assay | 2019 | Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17 | Total synthesis of dryocrassin ABBA and its analogues with potential inhibitory activity against drug-resistant neuraminidases. |
| AID582078 | Prodrug conversion in 42 days old female rat liver S9 fractions assessed as conversion of oseltamivir to oseltamivir carboxylate | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID542953 | Inhibition of Influenza A virus (A/Okinawa/42/2004(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID581716 | AUC ratio in cerebrospinal fluid to plasma in Sprague-Dawley rat at 30 mg/kg, iv | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1186764 | Inhibition of influenza A virus (A/Perth/16/2009(H3N2)) neuraminidase using MUNANA substrate pre-incubated for 30 mins before substrate addition by fluorometric assay | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | Inhibitory potency of flavonoid derivatives on influenza virus neuraminidase. |
| AID582036 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 1750 uM in presence of P-gp inhibitor elacridar | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID515126 | Fold resistance, ratio of IC50 for Influenza B virus (B/Perth/211/2001) wild type recombinant neuraminidase preincubated for 30 mins to IC50 for Influenza B virus (B/Perth/211/2001) neuraminidase E197 mutant preincubated for 30 mins | 2010 | Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17 | Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. |
| AID1405018 | Inhibition of MBP-fused recombinant human neuraminidase 3 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured every 1 min for 30 mins by fluorescence analysis | 2018 | Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19 | Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity. |
| AID283467 | Toxicity in BALB/c mouse assessed as survival at 20 mg/kg/day, po twice daily for 5 days | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. |
| AID567716 | Ratio of IC50 for influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID612398 | Octanol-water distribution coefficient, log D of the compound at pH 7.4 at 100 ug/mL | 2011 | Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16 | Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir. |
| AID634834 | Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID1432503 | Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 40 hrs | 2017 | Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6 | Structure-activity relationship studies of 1-(1'-hydroxyalkyl)rupestonic acid methyl esters against influenza viruses. |
| AID1588931 | Inhibition of Influenza A virus (A/Shanghai/1/2013 (H7N9)) neuraminidase R294K mutant expressed by HEK293 cells incubated for 1 hr using 4-MU-NANA substrate by spectrofluorometric assay1 | 2019 | Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17 | Total synthesis of dryocrassin ABBA and its analogues with potential inhibitory activity against drug-resistant neuraminidases. |
| AID1226077 | Inhibition of oseltamivir/amantadine-resistant Influenza A virus (A/Puerto Rico/8/1934(H1N1)) hemagglutinin-mediated hemolysis of chicken RBC at 10 uM preincubated with virus for 30 mins followed by RBC addition measured after 30 mins by microplate reader | 2015 | ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3 | Phenolic diterpenoid derivatives as anti-influenza a virus agents. |
| AID523883 | Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by NA inhibition assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. |
| AID565245 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 5 nM of zanamivir after 2 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID611767 | Antiviral activity against Influenza A H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID753436 | Inhibition of Influenza A virus (A/chicken/Sandong/Li/2008(H9N2)) neuraminidase N2 using 4-MU-NANA as substrate after 5 mins by fluorescence assay | 2013 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12 | Caffeic acid derivatives: a new type of influenza neuraminidase inhibitors. |
| AID766685 | Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity | 2013 | European journal of medicinal chemistry, Sep, Volume: 67 | Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity. |
| AID634750 | Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID311524 | Oral bioavailability in human | 2007 | Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24 | Hologram QSAR model for the prediction of human oral bioavailability. |
| AID567616 | Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1222249 | AUC(0 to infinity) in adult fed Sprague-Dawley rat at 30 mg/kg, po administered as water solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID565243 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring hemagglutininin K234Q mutant gene and neuraminidase I222M and H274Y mutant infected in MDCK cells selected at 1950 uM of oseltamivir after 10 passage after 48 hrs by hem | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | |||
| AID766694 | Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity | 2013 | European journal of medicinal chemistry, Sep, Volume: 67 | Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity. |
| AID715108 | Octanol-water partition coefficient, log D of the compound at pH 7.4 at 1 mg after 24 hrs by HPLC analysis | 2012 | Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20 | Development of oseltamivir phosphonate congeners as anti-influenza agents. |
| AID565268 | Ratio of IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant to IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | |||
| AID1401148 | Inhibition of Influenza A virus A/California/04/2009(H1N1) neuraminidase using MUNANA as substrate preincubated for 5 to 15 mins followed by substrate addition measured after 30 mins by fluorescence assay | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Synthesis and biological evaluation of NH |
| AID1266217 | Cytotoxicity against MDCK cells after 72 hrs by XTT assay | 2015 | Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24 | 1,2,3-Triazolyl-4-oxoquinolines: A feasible beginning for promising chemical structures to inhibit oseltamivir-resistant influenza A and B viruses. |
| AID565052 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) infected in MDCK cells selected at 1 nM of oseltamivir after 1 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID542952 | Inhibition of Influenza A virus (A/Aichi/193/2004(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID558675 | Antiviral activity against influenza virus (A/Sidney/5/97 (H3N2)) R292 infected in MDCK cells expressing human ST6Gal 1 gene in hollow fiber model system assessed as decrease in viral replication at 100 ng/ml administered as continuous infusion for 6 days | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. |
| AID542975 | Inhibition of Influenza B virus (B/Shiga/17/2002(Victoria)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1365378 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity treated 2 hrs after virus infection and measured after 48 hrs by SRB assay | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. |
| AID1200485 | Antiviral activity against influenza A virus A/WSN/33 (H1N1) infected in MDCK cells assessed as inhibition of plaque formation after 3 days at 37 degC | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin. |
| AID625287 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1073045 | Inhibition of Influenza A virus J/8178/09 neuraminidase by chemiluminescence based assay | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | Computer-guided approach to access the anti-influenza activity of licorice constituents. |
| AID549518 | Inhibition of Influenza A H9N2 virus neuraminidase activity after 2 hrs by spectrofluorometry | 2011 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1 | Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata. |
| AID565252 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring hemagglutininin K234N mutant gene and neuraminidase D198G and E119G mutant infected in MDCK cells selected at 31 uM of zanamivir after 9 passage after 48 hrs by hemaggluti | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1222252 | AUC(0 to 6 hrs) in adult fed Sprague-Dawley rat at 30 mg/kg, po administered as solution in bovine milk by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1470967 | Cytotoxicity against MDCK cells after 72 hrs by Alamar-Blue assay | 2017 | Bioorganic & medicinal chemistry, 05-15, Volume: 25, Issue:10 | Discovery of acylguanidine oseltamivir carboxylate derivatives as potent neuraminidase inhibitors. |
| AID582038 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 10000 uM in presence of P-gp inhibitor elacridar | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID560871 | Inhibition of Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) neuraminidase by fluorometric assay | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID539958 | Antiviral activity against influenza B virus infected in MDCK cells assessed as cell viability after 2 days by MTS assay | 2010 | European journal of medicinal chemistry, Nov, Volume: 45, Issue:11 | Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones. |
| AID567723 | Ratio of IC50 for influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID567607 | Antiviral activity against influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID582067 | Prodrug conversion in 77 years old male human brain S9 fractions assessed as oseltamivir carboxylate generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID560890 | Antiviral activity against Influenza A virus (A/duck/Laos/25/2006(H5N1)) infected in BALB/c mouse assessed as mean day to death at 20 mg/kg, po BID for 5 days measured post last dose | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1473438 | Synergistic antiviral activity against Influenza A virus (A/WSN/33(H1N1)) infected in MDCK cells expressing ST6Gal-1 assessed as reduction in virus-induced cytopathic effect after 44 to 48 hrs in presence of 5:1 3-{[(5-Cyclopropyl-1,2-oxazol-3-yl)methyl]a | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses. |
| AID1222269 | Cmax in juvenile fasted Sprague-Dawley rat at 30 mg/kg, po administered as 125 mM aqueous Gly-Sar solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1280361 | Antiviral activity against oseltamivir-resistant influenza A virus LN/1109 (H1N1) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus. |
| AID611769 | Cytotoxicity against african green monkey Vero cells assessed as alteration of cell morphology after 3 days by microscopy | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID443299 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) in MDCK cells assessed as reduction in plaque number by plaque reduction assay | 2010 | Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2 | Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. |
| AID443296 | Inhibition of Influenza Virus A/Brest/IDT7490/08 (H1N1) neuraminidase | 2010 | Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2 | Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. |
| AID611759 | Antiviral activity against Coxsackievirus B4 infected in HeLa cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID542990 | Inhibition of Influenza B virus (B/Saitama/01/2005(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1385612 | Antiviral activity against Influenza A virus A/95-359 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect | 2018 | Journal of natural products, 08-24, Volume: 81, Issue:8 | Minor Nortriterpenoids from the Twigs and Leaves of Rhododendron latoucheae. |
| AID1222281 | Drug uptake in CHOK1 cells at pH 5 by HPLC coupled with radiodetection analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1160753 | Binding affinity to recombinant Influenza A virus (A/Puerto Rico/8/1934(H1N1)) nucleoprotein in culture medium assessed as protection from Influenza A virus H3N2 VR1679-induced MDCK cytocidal activity after 2 days by CellTiter-Glo assay | 2014 | ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8 | Identification and synthesis of quinolizidines with anti-influenza a virus activity. |
| AID567588 | Antiviral activity against influenza A (A/New York/18/2009 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID561348 | Antiviral activity against Influenza A virus (A/whooper swan/Mongolia/1/2009(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in IFNalpha production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID581741 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 7000 uM | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID561138 | Antiviral activity against Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in IL1alpha production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1280345 | Cytotoxicity against MDCK cells after 40 hrs by Celltiter-Glo assay | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus. |
| AID634749 | Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID1384745 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in C57BL/6J mouse assessed as recovery of weight loss at 8 mg/mouse/day, ip qd treated for 1 day starting at 5 to 10 mins post infection measured up to day 12 | 2018 | Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16 | From Naproxen Repurposing to Naproxen Analogues and Their Antiviral Activity against Influenza A Virus. |
| AID1460728 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction in virus titer at 10 uM preincubated with virus for 1 hr followed by viral infection measured after 24 hrs by crystal violet staining base | 2017 | Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7 | Boronic Acid Modifications Enhance the Anti-Influenza A Virus Activities of Novel Quindoline Derivatives. |
| AID283447 | Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. |
| AID581677 | Terminal half life in non-perfused Sprague-Dawley rat brain at 30 mg/kg, iv | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID558672 | Antiviral activity against influenza virus (A/Sidney/5/97 (H3N2)) R292 infected in MDCK cells expressing human ST6Gal 1 gene in hollow fiber model system assessed as decrease in viral replication at 1 ng/ml administered as continuous infusion for 6 days m | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. |
| AID1588927 | Inhibition of Influenza A virus (A/California/04/2009 (H1N1) neuraminidase expressed by HEK293 cells incubated for 1 hr using 4-MU-NANA substrate by spectrofluorometric assay | 2019 | Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17 | Total synthesis of dryocrassin ABBA and its analogues with potential inhibitory activity against drug-resistant neuraminidases. |
| AID763863 | Antiviral activity against Influenza B virus (B/Florida/4/2006) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones. |
| AID625282 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1222239 | Cmax in healthy human at 150 mg, po administered as single dose by HPLC-tandem mass spectrometry under fed conditions | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID416785 | Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method | 2009 | Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7 | Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus. |
| AID582081 | Prodrug conversion in human liver S9 fractions assessed as conversion of oseltamivir to oseltamivir carboxylate | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1222247 | Tmax in adult fed Sprague-Dawley rat at 30 mg/kg, po administered as water solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID286201 | Antiviral activity against 10^6 EID50 influenza A/turkey/15/06 H5N1 virus inoculated ferrets assessed as increase in temperature at 10 mg/kg twice daily after 24 hrs inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID561136 | Antiviral activity against Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in IL1alpha production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID582051 | Prodrug conversion assessed as oseltamivir carboxylate level in presence of Sf9 cell culture supernatant expressing human recombinant HCE1 after 30 mins | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1071443 | Oral bioavailability in Sprague-Dawley rat at 10 mg/kg by LC-MS/MS analysis | 2014 | Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3 | Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A. |
| AID567597 | Antiviral activity against influenza A (A/Washington/10/2008 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID286190 | Antiviral activity against 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus inoculated ferrets assessed as increase in temperature at 25 mg/kg after 24 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID515127 | Selectivity ratio of IC50 for Influenza B virus (B/Perth/211/2001) wild type recombinant neuraminidase to IC50 for Influenza B virus (B/Perth/211/2001) wild type recombinant neuraminidase preincubated for 30 mins | 2010 | Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17 | Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. |
| AID283459 | Inhibition of increase in lung weight of BALB/c mouse infected with influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) at 20 mg/kg/day, po twice daily for 5 days administered 1 hr after infection measured on day 6 relative to carboxymethyl cellulose | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. |
| AID611771 | Cytotoxicity against human HeLa cells assessed as growth inhibition after 3 days by coulter counting analysis | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID539954 | Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days | 2010 | European journal of medicinal chemistry, Nov, Volume: 45, Issue:11 | Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones. |
| AID1386755 | Antiviral activity against oseltamivir-resistant Influenza A virus (H1N1) LN/1109 | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. |
| AID565246 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 25 nM of zanamivir after 3 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID567714 | Ratio of IC50 for influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID674872 | Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus (A/Guangdong-Luohu/219/2006(H1N1)) | 2012 | European journal of medicinal chemistry, Sep, Volume: 55 | Synthesis and antiviral activity of substituted bisaryl amide compounds as novel influenza virus inhibitors. |
| AID565042 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 1 nM of oseltamivir after 1 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID392529 | Antiviral activity against influenza H3N2 virus | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2 | Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. |
| AID542565 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) H274Y mutant infected in BALB/c mouse assessed as lung viral titer at 1 mg/kg, po administered 48 hrs postinfection for 5 days measured on day 4 (Rvb = 1 x 10'6 +/- 0.3 x 10'6 PFU | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID1222314 | Drug uptake in CHOK1 cells at 100 uM at pH 4 to 8 after 10 mins by HPLC coupled with radiodetection analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1713959 | Cytotoxicity against MDCK cells assessed as cell death incubated for 48 hrs by MTT assay | 2016 | Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22 | Biological evaluation of tetracationic compounds based on two 1,4-diazabicyclo[2.2.2]octane moieties connected by different linkers. |
| AID1222257 | AUC(0 to 6 hrs) in adult fed Sprague-Dawley rat at 30 mg/kg, po administered as 125 mM aqueous Gly-Sar solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID581517 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 618 uM | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID561141 | Inhibition of Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) neuraminidase isolated from virus-infected BALB/c mouse by fluorometric assay | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID286170 | Survival of 10 EID50 influenza A/Vietnam/1203/04 H5N1 virus inoculated ferrets at 5 mg/kg after 4 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID1773432 | Selectivity index, ratio of CC50 for cytotoxicity against dog MDCK cells to EC50 for antiviral activity against Influenza A virus H1N1 (A/PR/8/34) infected in MDCK cells assessed as reduction in virus titer treated 1 hr post viral infection followed by re | 2021 | European journal of medicinal chemistry, Dec-05, Volume: 225 | Novel betulin dicarboxylic acid ester derivatives as potent antiviral agents: Design, synthesis, biological evaluation, structure-activity relationship and in-silico study. |
| AID548442 | Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | 4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation. |
| AID1771094 | Selectivity index, ratio of CC50 for cytotoxicity against dog MDCK cells to EC50 for antiviral activity against Influenza A virus (A/chicken/Hubei/327/2004(H5N1)) infected in dog MDCK cells | |||
| AID392527 | Antiviral activity against influenza H1N1 virus | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2 | Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. |
| AID1432507 | Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza B virus infected in MDCK cells | 2017 | Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6 | Structure-activity relationship studies of 1-(1'-hydroxyalkyl)rupestonic acid methyl esters against influenza viruses. |
| AID565461 | Ratio of IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V mutant to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID286188 | Antiviral activity against 10^2 EID50 influenza A/Vietnam/1203/04 H5N1 virus inoculated ferrets assessed as weight loss at 25 mg/kg after 24 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID1077004 | Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus (A/FM/1/1947(H1N1)) | 2014 | European journal of medicinal chemistry, Apr-09, Volume: 76 | 1,2,3-Triazole-containing derivatives of rupestonic acid: click-chemical synthesis and antiviral activities against influenza viruses. |
| AID561347 | Antiviral activity against Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in IFNalpha production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1498139 | Cytotoxicity against MDCK cells assessed as alteration of cell morphology by microscopic analysis | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12 | Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs. |
| AID582058 | Prodrug conversion in 7 days old male rat brain S9 fractions assessed as oseltamivir carboxylate generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1160749 | Antiviral activity against Influenza A virus H3N2 VR1679 infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity compound treated 4 hrs post infection by time of addition assay | 2014 | ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8 | Identification and synthesis of quinolizidines with anti-influenza a virus activity. |
| AID1167296 | Inhibition of Influenza A virus H5N1 neuraminidase using 4-methylumbelliferyl-alpha-D-Nacetylneuraminic acid sodium salt hydrate as substrate by fluorometry | 2014 | Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21 | Neuraminidase inhibitory activities of quaternary isoquinoline alkaloids from Corydalis turtschaninovii rhizome. |
| AID542962 | Inhibition of Influenza A virus (A/New York/55/2004(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID283446 | Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. |
| AID542561 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) H274Y mutant infected in BALB/c mouse assessed as time to death at 1 mg/kg, po administered 48 hrs postinfection for 5 days (Rvb = 5.1 days) | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID1222262 | AUC(0 to 5 hrs) in juvenile breast-fed Sprague-Dawley rat at 30 mg/kg, po administered as water solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID565264 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID581706 | Cmax in perfused Sprague-Dawley rat plasma at 1000 mg/kg, po | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID763858 | Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza B virus (B/Florida/4/2006) | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones. |
| AID1432505 | Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus H3N2 infected in MDCK cells | 2017 | Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6 | Structure-activity relationship studies of 1-(1'-hydroxyalkyl)rupestonic acid methyl esters against influenza viruses. |
| AID515130 | Inhibition of Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant expressed in Sf21 insect cells after 60 mins by MUNANA based assay | 2010 | Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17 | Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. |
| AID1858132 | Selectivity index, ratio of CC50 for human A549 cells to EC50 for group 2 influenza A virus H3N2 (A/Hong Kong-11/1968) infected in human A549 cells | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Synthesis, Optimization, and Structure-Activity Relationships of Imidazo[1,2- |
| AID582033 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 100 uM in presence of P-gp inhibitor elacridar | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID565266 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID560891 | Antiviral activity against Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) infected in BALB/c mouse assessed as virus-induced change body weight at 20 mg/kg, po BID for 5 days measured on day 6 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1222274 | Terminal half life in healthy human at 150 mg, po administered as single dose by HPLC-tandem mass spectrometry under fasting conditions | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID1289284 | Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining-based microplate reader analysis | 2016 | Journal of natural products, Jan-22, Volume: 79, Issue:1 | Antiviral Merosesquiterpenoids Produced by the Antarctic Fungus Aspergillus ochraceopetaliformis SCSIO 05702. |
| AID567709 | Ratio of IC50 for influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID543001 | Inhibition of Influenza A virus (A/duck/Ukraine/1/1963(H3N8)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1183506 | Antiviral activity against Influenza A virus A/Texas/48/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay | 2014 | Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15 | Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. |
| AID581742 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 10000 uM | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID455709 | Antiviral activity against influenza A virus H1N1 A/PR/8/34 infected in MDCK cells assessed as reduction in fluorescence positive cells at 50 uM immunofluorescence assay | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. |
| AID565458 | Ratio of IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M mutant to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1460723 | Selectivity index, ratio of CC50 for MDCK cells to IC50 for Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect | 2017 | Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7 | Boronic Acid Modifications Enhance the Anti-Influenza A Virus Activities of Novel Quindoline Derivatives. |
| AID1280363 | Antiviral activity against amantadine-resistant influenza A virus HN/1222 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus. |
| AID712810 | Antiviral activity against amantadine-sensitive Influenza A virus (A/Ned/378/05 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis | 2012 | ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12 | Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds. |
| AID1432504 | Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 40 hrs | 2017 | Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6 | Structure-activity relationship studies of 1-(1'-hydroxyalkyl)rupestonic acid methyl esters against influenza viruses. |
| AID581678 | Terminal half life in perfused Sprague-Dawley rat plasma at 30 mg/kg, iv | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1222307 | Cmax in adult fasted Sprague-Dawley rat at 30 mg/kg, po administered as 125 mM aqueous Gly-Sar solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID634832 | Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID712814 | Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis | 2012 | ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12 | Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds. |
| AID1222303 | Cmax in adult fasted Sprague-Dawley rat at 30 mg/kg, po administered as solution in bovine milk by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID582065 | Prodrug conversion in 42 days old female rat liver S9 fractions assessed as oseltamivir carboxylate generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID558671 | Antiviral activity against influenza virus (A/Sidney/5/97 (H3N2)) R292 infected in MDCK cells expressing human ST6Gal 1 gene after 48 to 72 hrs by plaque assay | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. |
| AID561343 | Antiviral activity against Influenza A virus (A/whooper swan/Mongolia/1/2009(H5N1)) infected in BALB/c mouse assessed as decrease in virus-induced increase in IL6 production at 20 mg/kg, po BID for 5 days measured on day 3 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID634753 | Antiviral activity against thymidine kinase-positive Varicella Zoster virus Oka infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID350635 | Antiviral activity against influenza A virus H1N1 A/HK/54/98 in MDCK cells assessed as inhibition of viral replication at 100 uM after 18 hrs by transmission electron microscopy | 2009 | Journal of medicinal chemistry, May-14, Volume: 52, Issue:9 | A novel small-molecule inhibitor of the avian influenza H5N1 virus determined through computational screening against the neuraminidase. |
| AID567596 | Antiviral activity against influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID542967 | Inhibition of Influenza A virus (A/Yamagata/2/2002(H3N2)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID561135 | Antiviral activity against Influenza A virus (A/Turkey/651242/2006(H5N1)) infected in BALB/c mouse assessed as decrease in viral load in brain at 20 mg/kg, po BID for 5 days measured on day 9 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID473066 | Inhibition of human neuraminidase 2 at 5 mM | 2010 | Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7 | Complexity in influenza virus targeted drug design: interaction with human sialidases. |
| AID581683 | Ratio of AUC (0 to infinity) after iv dose to AUC (0 to 8 hrs) after po dose in non-perfused Sprague-Dawley rat brain at 30 mg/kg | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID286202 | Antiviral activity against 10^6 EID50 influenza A/turkey/15/06 H5N1 virus inoculated ferrets assessed as viral titer in lungs at 10 mg/kg after 24 hrs of inoculum for 5 days | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. |
| AID523879 | Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD2 additional passages in MDCK cells by NA inhibition assay | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. |
| AID1415634 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction in viral titer preincubated with cells for 1 hr followed by viral inoculation and measured after 48 hrs by hemagglutination test | 2017 | MedChemComm, May-01, Volume: 8, Issue:5 | Synthesis and |
| AID542999 | Inhibition of Influenza A virus (A/duck/England/1/1956(H11N6)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID567728 | Ratio of IC50 for influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID543184 | Inhibition of Influenza A virus (A/Yokohama/IMS9A-2029/2003(H3N2)) neuraminidase E119V mutant after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID558687 | Half life in MDCK cells expressing human ST6Gal 1 gene in hollow fiber model system at 1 ng/ml administered as 1 hr infusion every 24 hrs by LC-MS-MS | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system. |
| AID542972 | Inhibition of Influenza B virus (B/Brisbane/32/2002(Victoria) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID582082 | Prodrug conversion in commercial brain S9 fractions assessed as conversion of oseltamivir to oseltamivir carboxylate | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1660682 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in Kunming mouse assessed as decrease in lung IL6 level at 10 mg/kg/day, po starting 4 hrs after viral challenge and continued for 4 days by ELISA | 2020 | Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13 | Chemoreactive-Inspired Discovery of Influenza A Virus Dual Inhibitor to Block Hemagglutinin-Mediated Adsorption and Membrane Fusion. |
| AID1201118 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay | 2015 | European journal of medicinal chemistry, Apr-13, Volume: 94 | A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives. |
| AID560896 | Antiviral activity against Influenza A virus (A/Thailand/1(KAN-1)/2004(H5N1)) infected in BALB/c mouse assessed as virus-induced change body weight at 20 mg/kg, po BID for 5 days measured on day 9 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID763924 | Antiviral activity against Influenza A virus (A/duck/Minnesota/1525/1981(H5N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay | 2013 | European journal of medicinal chemistry, Aug, Volume: 66 | Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones. |
| AID1432506 | Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus H1N1 infected in MDCK cells | 2017 | Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6 | Structure-activity relationship studies of 1-(1'-hydroxyalkyl)rupestonic acid methyl esters against influenza viruses. |
| AID1365368 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 48 hrs by SRB assay | 2017 | Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20 | Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase. |
| AID625279 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1409723 | Antiviral activity against Influenza A virus A/Udorn/72 H3N2 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect by crystal violet staining based light-microscopic analysis | 2018 | ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3 | Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants. |
| AID581737 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 700 uM | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID733270 | Cytotoxicity against MDCK cells after 3 days by fluorescein diacetate-based fluorimetric analysis | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition. |
| AID478325 | Antiviral activity against influenza B virus assessed as cell viability by cell based MTS assay | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9 | Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity. |
| AID542558 | Antiviral activity against recombinant Influenza A virus (A/WSN/1933(H1N1)) H274Y mutant infected in BALB/c mouse assessed as mortality rate at 1 mg/kg, po administered 4 hrs before infection for 5 days measured on day 5 (Rvb = 100 %) | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. |
| AID548439 | Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | 4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation. |
| AID1201122 | Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay | 2015 | European journal of medicinal chemistry, Apr-13, Volume: 94 | A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives. |
| AID581710 | AUC (0 to 8 hrs) ratio in cerebrospinal fluid to brain in perfused Sprague-Dawley rat at 1000 mg/kg, po | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID560888 | Antiviral activity against Influenza A virus (A/chicken/Yogjakarta/BBVet-IX/2004(H5N1)) infected in BALB/c mouse assessed as mean day to death at 20 mg/kg, po BID for 5 days measured post last dose | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1498125 | Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathicity by MTS assay | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12 | Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs. |
| AID542948 | Inhibition of Influenza A virus (A/Shiga/1/2002(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1473448 | Synergistic antiviral activity against Influenza A virus (A/WSN/33(H1N1)) infected in MDCK cells expressing ST6Gal-1 assessed as reduction in virus-induced cytopathic effect after 44 to 48 hrs in presence of 5:1 3-{[(5-Cyclopropyl-1,2-oxazol-3-yl)methyl]a | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses. |
| AID478324 | Antiviral activity against influenza B virus assessed as inhibition of viral induced cytopathic effect | 2010 | Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9 | Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity. |
| AID733266 | Antiviral activity against Influenza B virus (B/Taiwan/2/62) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis | 2013 | European journal of medicinal chemistry, Apr, Volume: 62 | Efficient synthesis of 3H,3'H-spiro[benzofuran-2,1'-isobenzofuran]-3,3'-dione as novel skeletons specifically for influenza virus type B inhibition. |
| AID1222271 | AUC(0 to 5 hrs) in juvenile fasted Sprague-Dawley rat at 30 mg/kg, po administered as 125 mM aqueous Gly-Sar solution by HPLC-tandem mass spectrometry | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID528273 | Inhibition of influenza A virus H9N2 Neuraminidase using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid sodium salt hydrate substrate | 2010 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22 | New stilbenoid with inhibitory activity on viral neuraminidases from Erythrina addisoniae. |
| AID1473451 | Synergistic antiviral activity against Influenza A virus (A/WSN/33(H1N1)) infected in MDCK cells expressing ST6Gal-1 assessed as reduction in virus-induced cytopathic effect after 44 to 48 hrs in presence of 1:10 3-{[(5-Cyclopropyl-1,2-oxazol-3-yl)methyl] | 2018 | Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3 | In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses. |
| AID1403781 | Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in BALB/c mouse assessed as mouse survival at 0.96 umol/day, po for 5 consecutive days measured on day 14 post dose | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145 | Peramivir conjugates as orally available agents against influenza H275Y mutant. |
| AID1073034 | Inhibition of Clostridium perfringens neuraminidase by fluorescence based assay | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | Computer-guided approach to access the anti-influenza activity of licorice constituents. |
| AID1200495 | Antiviral activity against OSV-resistant influenza A virus A/LiaoNing-ZhenXing/1109/2010 (H1N1) strain | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin. |
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | |||
| AID443294 | Inhibition of Influenza Virus A/Belzig/2/01 (H1N1) neuraminidase | 2010 | Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2 | Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. |
| AID1405015 | Inhibition of MBP-fused recombinant human neuraminidase 4 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence analysis | 2018 | Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19 | Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity. |
| AID567594 | Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID1460754 | Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in Kunming mouse assessed as survival rate at 20 mg/kg/day, po qd for 7 days measured on day 14 post infection (Rvb = 30%) | 2017 | Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7 | Boronic Acid Modifications Enhance the Anti-Influenza A Virus Activities of Novel Quindoline Derivatives. |
| AID542946 | Inhibition of Influenza A virus (A/Yamagata/32/1989(H1N1)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID634835 | Antiviral activity against Felid herpesvirus 1 infected in CrFK cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID542985 | Inhibition of Influenza B virus (B/Shiga/31/2002(Yamagata)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID1183508 | Antiviral activity against Influenza A virus A/California/07/2009 infected in MDCK cells assessed as cell protection after 3 days by cytopathic effect assay | 2014 | Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15 | Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. |
| AID443829 | Antiviral activity against Influenza A virus (A/Hong Kong/7/87(H3N2)) assessed as inhibition of virus-induced cytopathic effect by cell-based assay | 2009 | Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19 | Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study. |
| AID634836 | Antiviral activity against Feline coronavirus infected in CrFK cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID565273 | Ratio of IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant to IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID658748 | Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | 2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies. |
| AID1222279 | Drug uptake in CHOK1 cells at 5 to 100 uM after 10 mins by HPLC coupled with radiodetection analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID561122 | Antiviral activity against Influenza A virus (A/duck/Laos/25/2006(H5N1)) infected in BALB/c mouse assessed as virus-induced change body weight at 20 mg/kg, po BID for 5 days measured on day 15 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID582049 | Inhibition of human MDR1-mediated digoxin permeability expressed in pig LLC-PK1 cells | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID542980 | Inhibition of Influenza B virus (B/Yamagata/398/2003(Victoria)) neuraminidase after 30 mins by fluorescence analysis | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. |
| AID565459 | Ratio of IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase H274Y mutant to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID416778 | Cytotoxicity against MDCK cells assessed as drug level causing microscopically detectable alteration of normal cell morphology | 2009 | Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7 | Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus. |
| AID443293 | Inhibition of Influenza Virus A/Potsdam/15/81 (H1N1) neuraminidase | 2010 | Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2 | Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. |
| AID625292 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1401147 | Inhibition of Influenza A virus A/Anhui/1/2005(H5N1) neuraminidase at 100 uM using MUNANA as substrate preincubated for 5 to 15 mins followed by substrate addition measured after 30 mins by fluorescence assay relative to control | 2017 | European journal of medicinal chemistry, Dec-01, Volume: 141 | Synthesis and biological evaluation of NH |
| AID565474 | Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID481717 | Inhibition of Influenza A PR/8/34 H1N1 virus neuraminidase activity by MUN-ANA substrate based fluorimetric assay | 2010 | European journal of medicinal chemistry, May, Volume: 45, Issue:5 | QSAR study of flavonoids and biflavonoids as influenza H1N1 virus neuraminidase inhibitors. |
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | |||
| AID581709 | AUC (0 to 8 hrs) ratio in brain to plasma in perfused Sprague-Dawley rat at 1000 mg/kg, po | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1505284 | Antiviral activity against Influenza A virus (A/Aichi/2/68 (H3N2)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 48 hrs by microscopic analysis | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12 | Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses. |
| AID283471 | Effect on weight change in BALB/c mouse at 20 mg/kg/day, po measured after 18 hrs of final treatment | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. |
| AID634752 | Antiviral activity against Human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID1858131 | Antiviral activity against group 2 influenza A virus LPAI H7N7 (A/Netherlands/219/2003) infected in human A549 cells assessed as inhibition of viral entry preincubated with compound for 30 mins followed by viral infection for 1 hour further incubated for | 2022 | Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20 | Synthesis, Optimization, and Structure-Activity Relationships of Imidazo[1,2- |
| AID1612769 | Antiviral activity against Influenza A virus A/WSN/33/H1N1 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 40 hrs by CellTiter-Glo assay | 2019 | European journal of medicinal chemistry, Feb-01, Volume: 163 | Synthesis, structure activity relationship and in vitro anti-influenza virus activity of novel polyphenol-pentacyclic triterpene conjugates. |
| AID611629 | Antiviral activity against VSV infected in HEL cells assessed as protection against virus-induced cytopathicity | 2011 | Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11 | New prodrugs of Adefovir and Cidofovir. |
| AID567711 | Ratio of IC50 for influenza A (A/North Carolina/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. |
| AID581530 | Cmax in non-perfused Sprague-Dawley rat brain at 30 mg/kg, iv | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID634746 | Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM | 2012 | European journal of medicinal chemistry, Jan, Volume: 47, Issue:1 | Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker. |
| AID1167295 | Inhibition of recombinant Influenza A virus H1N1 neuraminidase using 4-methylumbelliferyl-alpha-D-Nacetylneuraminic acid sodium salt hydrate as substrate by fluorometry | 2014 | Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21 | Neuraminidase inhibitory activities of quaternary isoquinoline alkaloids from Corydalis turtschaninovii rhizome. |
| AID1222235 | AUC(0 to 24 hrs) in healthy human at 150 mg, po administered as single dose by HPLC-tandem mass spectrometry under fasting conditions | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID416782 | Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method | 2009 | Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7 | Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus. |
| AID560889 | Antiviral activity against Influenza A virus (A/whooper swan/Mongolia/1/2009(H5N1)) infected in BALB/c mouse assessed as mean day to death at 20 mg/kg, po BID for 5 days measured post last dose | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID561126 | Antiviral activity against Influenza A virus (A/Turkey/651242/2006(H5N1)) infected in BALB/c mouse assessed as decrease in viral load in lung at 20 mg/kg, po BID for 5 days measured on day 9 postinfection | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1222280 | Drug uptake in CHOK1 cells expressing human PEPT1 at 5 to 100 uM after 10 mins by HPLC coupled with radiodetection analysis | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8 | Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies. |
| AID560880 | Inhibition of Influenza A virus (A/duck/Laos/25/2006(H5N1)) neuraminidase by Michaelis-Menten equation analysis | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1405017 | Inhibition of MBP-fused recombinant human neuraminidase 2 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured every 1 min for 30 mins by fluorescence analysis | 2018 | Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19 | Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity. |
| AID581527 | Prodrug conversion in 7 days old male rat brain S9 fractions assessed as paranitrophenol generation rate assessed per mg of protein per min | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID532109 | Inhibition of human NEU4 expressed in HEK293 cells by fluorometric high-performance liquid chromatography using 4MU-NeuAc substrate | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. |
| AID565045 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 50 nM of oseltamivir after 4 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1427858 | Cytotoxicity against MDCK cells assessed as growth inhibition after 48 hrs | |||
| AID1372137 | Cytotoxicity against MDCK cells infected with Influenza A virus (A/WSN/33(H1N1)) after 72 hrs by CellTiter-Glo assay | 2017 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24 | Design, synthesis and biological evaluation of novel oseltamivir derivatives as potent neuraminidase inhibitors. |
| AID560887 | Antiviral activity against Influenza A virus (A/Turkey/651242/2006(H5N1)) infected in BALB/c mouse assessed as mean day to death at 20 mg/kg, po BID for 5 days measured post last dose | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. |
| AID1386761 | Antiviral activity against influenza A virus assessed as inhibition of viral replicon activity up to 100 uM incubated for 30 hrs by firefly luciferase reporter gene assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19 | De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. |
| AID1636356 | Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA | 2016 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16 | Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. |
| AID1617174 | Invivo antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in BALB/c mouse assessed as survival rate at 10 mg/kg, po administered bid for 10 days after 48 hrs post infection and observed for 21 days relative to control | 2019 | Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21 | Design, Synthesis, and Biological Evaluation of Novel Indoles Targeting the Influenza PB2 Cap Binding Region. |
| AID581732 | Permeability from apical to basolateral side of pig LLC-PK1 cells over expressing human MDR1 at 6918 uM | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. |
| AID1156849 | Inhibition of Influenza A H1N1 virus neuraminidase at 0.8 nM after 1 hr by spectrofluorimetry using 2-(4-meythylumbelliferyl)-alpha-D-acetylneuramic acid as substrate | 2014 | European journal of medicinal chemistry, Aug-18, Volume: 83 | Design and synthesis of 6-oxo-1,4,5,6-tetrahydropyrimidine-5-carboxylate derivatives as neuraminidase inhibitors. |
| AID1505285 | Antiviral activity against Influenza A virus (A/duck/Guangdong/1/1996 (H7N3)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 48 hrs by microscopic analysis | 2018 | Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12 | Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses. |
| AID565043 | Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) infected in MDCK cells selected at 5 nM of oseltamivir after 2 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID565260 | Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells selected at 16 uM of zanamivir after 7 passage after 48 hrs by hemagglutininin titer assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| AID1803041 | Neuraminidase Activity Assay from Article 10.3109/14756366.2011.568415: \\A screening assay for neuraminidase inhibitors using neuraminidases N1 and N3 from a baculovirus expression system.\\ | 2012 | Journal of enzyme inhibition and medicinal chemistry, Feb, Volume: 27, Issue:1 | A screening assay for neuraminidase inhibitors using neuraminidases N1 and N3 from a baculovirus expression system. |
| AID1795726 | Neuraminidase Inhibition Assay from Article 10.1021/jm010277p: \\Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity.\\ | 2001 | Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25 | Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity. |
| AID1803040 | Neuraminidase Inhibition Assay from Article 10.3109/14756366.2011.568415: \\A screening assay for neuraminidase inhibitors using neuraminidases N1 and N3 from a baculovirus expression system.\\ | 2012 | Journal of enzyme inhibition and medicinal chemistry, Feb, Volume: 27, Issue:1 | A screening assay for neuraminidase inhibitors using neuraminidases N1 and N3 from a baculovirus expression system. |
| AID1745855 | NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay | 2023 | Disease models & mechanisms, 03-01, Volume: 16, Issue:3 | In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. |
| AID1745854 | NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS | 2023 | Disease models & mechanisms, 03-01, Volume: 16, Issue:3 | In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 34 (1.05) | 18.2507 |
| 2000's | 850 (26.15) | 29.6817 |
| 2010's | 1966 (60.49) | 24.3611 |
| 2020's | 400 (12.31) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (115.88) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 186 (5.52%) | 5.53% |
| Reviews | 346 (10.27%) | 6.00% |
| Case Studies | 367 (10.90%) | 4.05% |
| Observational | 43 (1.28%) | 0.25% |
| Other | 2,426 (72.03%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised Controlled Trial on the Effect of Post-exposure Oseltamivir Prophylaxis on Influenza Transmission in Nursing Homes [NCT01053377] | Phase 4 | 900 participants (Anticipated) | Interventional | 2009-12-31 | Enrolling by invitation | ||
| An Observational Study on the Pharmacokinetics of Oseltamivir in the Treatment of Influenza During Lactation, Phase IV Trial [NCT01130636] | Phase 4 | 6 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| A Randomized, Open-label, Single-Dose, Two-Period, Crossover Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers [NCT01258530] | Phase 1 | 28 participants (Actual) | Interventional | 2010-12-20 | Completed | ||
| Oseltamivir Versus Paracetamol for Influenza-like Illness During the Influenza Season: a Randomized Controlled Trial [NCT03754686] | Phase 4 | 436 participants (Anticipated) | Interventional | 2019-02-10 | Not yet recruiting | ||
| A Multicenter, Randomized, Double-Blind, Active (Oseltamivir)-Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Otherwise Healthy Pediatric Patients 1 to <12 Years of Age With Influenza-Like Symptoms [NCT03629184] | Phase 3 | 173 participants (Actual) | Interventional | 2018-11-20 | Completed | ||
| A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza [NCT02954354] | Phase 3 | 1,436 participants (Actual) | Interventional | 2016-12-08 | Completed | ||
| Duration of Prophylactic Treatment With Oseltamivir: A Randomized Clinical Trial [NCT03899571] | 222 participants (Actual) | Interventional | 2019-01-22 | Completed | |||
| A Double-blind Randomised Controlled Trial on Flufenamic Acid for Hospitalised Influenza Infection [NCT03238612] | Phase 2 | 200 participants (Anticipated) | Interventional | 2018-01-08 | Recruiting | ||
| A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Patients With Influenza at High Risk of Influenza Complications [NCT02949011] | Phase 3 | 2,184 participants (Actual) | Interventional | 2017-01-11 | Completed | ||
| Phase 2b, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of IV VIS410 in Addition to Oseltamivir Compared With Oseltamivir Alone in Hospitalized Adults With Influenza A Infection Requiring Oxygen Support [NCT03040141] | Phase 2 | 89 participants (Actual) | Interventional | 2018-01-03 | Completed | ||
| Convalescent Plasma Treatment in Patients With Severe 2009 H1N1 Infection: a Prospective Cohort Study [NCT01306773] | 80 participants (Actual) | Interventional | 2009-12-31 | Completed | |||
| A Randomized Controlled Trial on the Treatment of Severe Influenza A Infection [NCT02108366] | Phase 3 | 107 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| A Phase II, Global, Randomized Study to Evaluate the Efficacy and Safety of Danirixin (GSK1325756) Co-administered With a Standard-of-care Antiviral (Oseltamivir), in the Treatment of Adults Hospitalized With Influenza [NCT02927431] | Phase 2 | 10 participants (Actual) | Interventional | 2017-01-19 | Terminated(stopped due to The study was stopped early due to lack of enrollment.) | ||
| A Phase 1/2a Clinical Study to Evaluate the Efficacy of MEDI8852 in the Treatment of Influenza in Adults Challenged With a Wild-Type Influenza Strain [NCT03903718] | Phase 2 | 0 participants (Actual) | Interventional | 2020-04-03 | Withdrawn(stopped due to Terminated due to delay in site enrollment timelines) | ||
| Phase I, Open-Label Study to Evaluate Potential Pharmacokinetic of Orally Administered Oseltamivir in Healthy Obese Thai Adult Subjects [NCT01049763] | Phase 1 | 24 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Oseltamivir From Oseltamivir 75 mg Caps (Pharmacare PLC, Palestine) and Tamiflu® 75 mg Caps (Hoffmann-La Roche, Switzerland) [NCT02507648] | Phase 1 | 24 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled，Clinical Study. [NCT02232945] | Phase 4 | 177 participants (Anticipated) | Interventional | 2012-04-30 | Recruiting | ||
| A Randomized Open Label Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Amantadine and Ribavirin With Oseltamivir Versus Oseltamivir to Influenza A Virus Infected Immunocompromised Subjects [NCT00979251] | Phase 2 | 2 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| An Adaptive Study of the Pharmacokinetics of Favipiravir in Patients With Severe [NCT03394209] | Phase 2 | 34 participants (Actual) | Interventional | 2018-02-06 | Completed | ||
| A Randomized Controlled Trial of Oseltamivir in Outpatients With Chronic Pulmonary Disease: a Pilot Study [NCT02282384] | Phase 4 | 0 participants (Actual) | Interventional | 2014-10-31 | Withdrawn(stopped due to Sites were unable to recruit participants) | ||
| A Randomized Controlled Trial of Oseltamivir in High-Risk Patients Presenting to the Emergency Department With Influenza [NCT02561169] | Phase 4 | 1 participants (Actual) | Interventional | 2015-12-31 | Terminated | ||
| Indian Herbal Medicine for Influenza - Randomized Controlled Study [NCT03365336] | 100 participants (Anticipated) | Interventional | 2018-02-01 | Recruiting | |||
| A Randomized, Multicenter Trial of Oseltamivir [Tamiflu] Doses of 75 mg for 5 or 10 Days Versus 150 mg for 5 or 10 Days to Evaluate the Effect on the Duration of Viral Shedding in Influenza Patients With Pandemic (H1N1) 2009 [NCT01032837] | Phase 4 | 102 participants (Actual) | Interventional | 2009-11-30 | Terminated(stopped due to Study closed prematurely due to the end of the influenza (H1N1) 2009 pandemic) | ||
| Pilot Study of Interferon Alpha Lozenges Plus Oseltamivir in the Treatment of Influenza A Infection [NCT01146535] | Phase 2 | 40 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| A Multicenter, Randomized, Open Label, Add-on Study to Assess Efficacy and Safety of Xiyanping Injection in Pediatric Participants With Severe Influenza-Like Symptoms [NCT03947411] | 72 participants (Anticipated) | Interventional | 2019-03-04 | Recruiting | |||
| Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination With Oseltamivir, in Adults With COVID-19 [NCT04516915] | Phase 2 | 38 participants (Actual) | Interventional | 2020-06-15 | Completed | ||
| An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics of HIP1403 in Healthy Male Subjects [NCT02473900] | Phase 1 | 32 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Validation of the Efficiency of Molecules Reproposed on the Basis of Their Cellular Transcriptomic Signature, Antagonist of the Signature Determined in Infection Due to Virus Influenza A. [NCT03212716] | Phase 2 | 85 participants (Actual) | Interventional | 2017-12-23 | Terminated(stopped due to rate of inclusion and study affected by covid-19 epidemic) | ||
| A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults [NCT01314911] | 716 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| Efficacy of Different Regimens in Influenza Postexposure Chemoprophylaxis With Oral Neuraminidase Inhibitor in Children [NCT04297462] | 50 participants (Anticipated) | Interventional | 2016-11-17 | Recruiting | |||
| Reduning Injection for the Treatment of Influenza in Children:a Randomized, Double-blinded, Parallel-controlled Clinical Study [NCT04183725] | Phase 4 | 240 participants (Anticipated) | Interventional | 2019-12-01 | Not yet recruiting | ||
| Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A Infection [NCT00830323] | Phase 2 | 60 participants (Anticipated) | Interventional | 2009-01-31 | Terminated | ||
| A Clinical Trial to Investigate the Influence of CES1 Polymorphism on Pharmacokinetic Characteristics of Oseltamivir in Healthy Korean Volunteers [NCT01902342] | Phase 1 | 20 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| A Phase 1, Randomized, 3-way Crossover, Open-label Study to Assess the Drug-drug Interaction Between VX-787 and Tamiflu®, Followed by a Double-blind, Randomized, Placebo-controlled Study to Collect Safety, Tolerability and Pharmacokinetics of VX-787, in H [NCT02262715] | Phase 1 | 38 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide Plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza [NCT01610245] | Phase 3 | 1,941 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| A Randomized Double-blind Controlled Study of CS-8958 Versus Oseltamivir Phosphate in Patients With Influenza Virus Infection [NCT00803595] | Phase 3 | 1,002 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Clinical Effect of Oral Danirixin (GSK1325756) in the Treatment of Healthy Adults With Acute, Uncomplicated Influenza (201682) [NCT02469298] | Phase 2 | 45 participants (Actual) | Interventional | 2015-06-01 | Completed | ||
| A Four-part, Single-center, Open-label, Phase I Clinical Study to Evaluate the Drug-drug Interactions (DDIs) Between GP681 and Rosuvastatin/Digoxin/Itraconazole/Oseltamivir in Chinese Healthy Volunteers [NCT05789342] | Phase 1 | 54 participants (Actual) | Interventional | 2023-02-15 | Completed | ||
| Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With Coronavirus Disease 2019 (COVID-19) [NCT04973462] | Phase 4 | 80 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | ||
| Randomized Double-blind, Placebo-controlled Single Center Pilot Study to Evaluate the Efficacy and Safety of Baloxavir in Combination With Oseltamivir in Adult Allogeneic Bone Marrow Transplant Recipients With Influenza [NCT05170009] | Phase 2/Phase 3 | 30 participants (Anticipated) | Interventional | 2022-04-22 | Recruiting | ||
| [NCT02572583] | Phase 1/Phase 2 | 300 participants (Anticipated) | Interventional | 2014-11-30 | Recruiting | ||
| A Double-Blind, Randomized, Stratified Multi-Center Trial Evaluating Conventional and Double Dose Oseltamivir in the Treatment of Immunocompromised Patients With Influenza [NCT00545532] | Phase 3 | 228 participants (Actual) | Interventional | 2008-02-04 | Completed | ||
| A Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir (Tamiflu®) for the Treatment of Children Less Than 24 Months of Age With Confirmed Influenza Infection (CASG 114) [NCT00391768] | Phase 1/Phase 2 | 87 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Phase II, Multicenter, Randomized, Double-Mask, Double-Dummy Study Comparing Efficacy and Safety of Intravenous Peramivir Once Daily Versus Oral Oseltamivir Twice Daily in Adults With Acute Serious or Potentially Life-Threatening Influenza [NCT00453999] | Phase 2 | 137 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia [NCT02735707] | Phase 3 | 10,000 participants (Anticipated) | Interventional | 2016-04-11 | Recruiting | ||
| Antiviral and Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) Virus Pneumonia: Multi-centre, Prospective, Randomized Controlled Study [NCT00936013] | Phase 4 | 400 participants (Anticipated) | Interventional | 2009-08-31 | Recruiting | ||
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs [NCT04278404] | 5,000 participants (Anticipated) | Observational | 2020-03-05 | Recruiting | |||
| A Double-blind, Randomized, Placebo Controlled, Multi-center Trial of Oseltamivir for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients [NCT00412737] | Phase 4 | 477 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Multicentre, Randomized, Controlled Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As The First Line Treatment For Human Swine Influenza (H1N1) Infection In Designated Flu Clinics During The Pandemic Influenza in Hong Kong [NCT00979667] | Phase 3 | 4 participants (Actual) | Interventional | 2009-10-31 | Terminated(stopped due to Decreased Influenza activity; thus decrease/no eligible patient to recruit) | ||
| Initiating Oseltamivir in Adults Hospitalized With Influenza -- a Study on the Impact of Virological Clearance and Clinical Recovery for Higher-dose Treatment Started Within 96 Hours [NCT01052961] | Phase 4 | 157 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years [NCT01050257] | Phase 3 | 118 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Influenza Resistance Information Study (IRIS) [NCT00884117] | 4,561 participants (Actual) | Observational | 2009-01-31 | Completed | |||
| Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination Therapy vs. Oseltamivir Alone for Hospitalised Paediatric Influenza Patients [NCT04315194] | 54 participants (Actual) | Observational [Patient Registry] | 2017-12-18 | Completed | |||
| A Single-Center, Randomized, Double-Blind, Single and Multiple Doses, Placebo-Controlled Study,To Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Food Effects of HEC116094HCl•3H2O and the Interaction With Oseltamivir Phosphate Capsules [NCT04982913] | Phase 1 | 118 participants (Actual) | Interventional | 2021-08-24 | Completed | ||
| A Randomized Controlled Trial of Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza [NCT03901001] | Phase 3 | 160 participants (Anticipated) | Interventional | 2023-05-08 | Recruiting | ||
| A Study of the Pharmacology of Oseltamivir (Tamiflu) in Pregnancy [NCT00873886] | Phase 1 | 0 participants (Actual) | Interventional | 2009-04-30 | Withdrawn(stopped due to We will focus on other Tamiflu research studies. No subjects were enrolled.) | ||
| A Phase IIIb, Open-label, Comparative, Randomized Study on Resistance of Influenza A/H1N1 2009 Virus to Treatment With Oseltamivir at Standard Dose Versus Double Dose [NCT00949533] | Phase 3 | 37 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Antiviral and Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) Virus Infection: Multi-centre, Prospective, Randomized Controlled Study [NCT00935194] | Phase 4 | 102 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| An Open Label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Oseltamivir (Tamiflu) in the Treatment of Children 1 to 12 Years of Age With Influenza Infection [NCT01033734] | Phase 1 | 8 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic Interactions Between Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects [NCT00921726] | Phase 1 | 17 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| A Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir (Tamiflu®) in Patients in the Intensive Care Unit [NCT00844155] | 0 participants (Actual) | Interventional | 2009-03-31 | Withdrawn(stopped due to Study has been withdrawn as the H1N1 epidemic made this study redundant) | |||
| An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia. [NCT04255017] | Phase 4 | 400 participants (Anticipated) | Interventional | 2020-02-01 | Recruiting | ||
| Randomized, Double-Blinded, Oseltamivir-and-Placebo-Controlled Clinical Study About Lingdancao Granules in the Treatment of Seasonal Influenza [NCT02662426] | Phase 3 | 318 participants (Anticipated) | Interventional | 2016-04-30 | Not yet recruiting | ||
| Pharmacokinetics of Oseltamivir in Newborns and Infants [NCT01388439] | 19 participants (Actual) | Observational | 2011-01-31 | Completed | |||
| Study on the Human Bioequivalence of Oseltamivir Phosphate For Oral Suspension [NCT05297968] | Phase 1 | 72 participants (Actual) | Interventional | 2021-05-13 | Completed | ||
| A Phase IV, Multi-center, Randomized, Partially Double Blinded, Placebo Controlled Study, to Evaluate the Safety of Daily Inhaled Zanamivir 10 mg Versus Placebo and Daily Oral Oseltamivir 75 mg Versus Placebo for Influenza Prophylaxis in Healthy Volunteer [NCT00980109] | Phase 4 | 390 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Evaluation of Combination Therapy With Oseltamivir and Zanamivir Versus Monotherapy in the Treatment of Virologically Confirmed Influenza in Primary Care a Randomises Double Blind Controlled Trial Study [NCT00799760] | Phase 3 | 541 participants (Actual) | Interventional | 2008-12-31 | Terminated(stopped due to Just Terminated for the end of the pandemia) | ||
| Oseltamivir Treatment in Children Under One Year of Age With Moderate or Severe Influenza Lower Respiratory Tract Infection - a Clinical and Pharmacokinetic Study [NCT01037634] | Phase 2 | 0 participants (Actual) | Interventional | 2010-03-31 | Withdrawn | ||
| "A Randomized, Double-Blinded Controlled Trial Comparing High vs Standard Dose Oseltamivir in Severe, Influenza Infection in ICU. ROSII Study" [NCT01010087] | Phase 2 | 59 participants (Actual) | Interventional | 2009-11-30 | Terminated(stopped due to Patient population no longer available.) | ||
| Efficacy of Combination Baloxovir and Oseltamivir Therapy in Influenza Infected Immunocompromised Hosts [NCT04712539] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-10-11 | Recruiting | ||
| A Multicenter Randomized Open-label Study of Oseltamivir Combined With High-dose Dexamethasone Versus High-dose Dexamethasone in the Management of Immune Thrombocytopenia [NCT01965626] | Phase 2 | 96 participants (Actual) | Interventional | 2016-02-01 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study in Healthy Volunteers to Evaluate the Efficacy and Safety of MHAA4549A in an Influenza Challenge Model [NCT01980966] | Phase 2 | 101 participants (Actual) | Interventional | 2013-11-25 | Completed | ||
| An Open-label, Multiple Dose, Randomized, Three-period Crossover Study in Healthy Subjects to Evaluate the Effect of Co-administration of Oseltamivir (Ro 64-0796) 75 mg Twice Daily and Rimantadine 100 mg Twice Daily on the Pharmacokinetic Properties of Os [NCT01172847] | Phase 1 | 24 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults [NCT01231620] | Phase 3 | 626 participants (Actual) | Interventional | 2011-01-15 | Completed | ||
| The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19: An Open Label Trial [NCT04558463] | Phase 3 | 100 participants (Anticipated) | Interventional | 2020-04-16 | Recruiting | ||
| Oseltamivir and Oseltamivir Carboxylate Pharmacokinetics in Obese Adults [NCT01179919] | Phase 1/Phase 2 | 21 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment [NCT04530422] | Phase 3 | 250 participants (Actual) | Interventional | 2020-04-15 | Completed | ||
| A Double-Blind, Randomized, Placebo-Controlled Study of Early Oseltamivir Treatment of Influenza in Children 1-3 Years of Age [NCT00593502] | Phase 4 | 409 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia [NCT04261270] | Phase 3 | 60 participants (Anticipated) | Interventional | 2020-02-01 | Recruiting | ||
| Efficacy of Oseltamivir in Reducing the Duration of Clinical Illness, Viral Shedding, and Transmissibility Reduction Within Households Among Participants in an Influenza Disease Burden Surveillance Cohort in Urban Dhaka, Bangladesh [NCT00707941] | Phase 3 | 1,190 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| A Phase-1, Open-label, Four Group, Fixed-Sequence Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir, JNJ-63623872, and Probes for P-glycoprotein, CYP3A and OATP1B1 in Healthy Volunteers [NCT02888327] | Phase 1 | 68 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| An Open-label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Oseltamivir in the Treatment of Infants Less Than One Year of Age With Influenza Infection [NCT01053663] | Phase 1 | 9 participants (Actual) | Interventional | 2011-01-31 | Terminated(stopped due to The study was terminated prematurely after three influenza seasons.) | ||
| Evaluation of Alternative Oseltamivir (Tamiflu[R]) Dosing Strategies for Use During Influenza Prophylaxis [NCT00334529] | Phase 2 | 48 participants | Interventional | 2006-06-05 | Completed | ||
| An Open-label Study to Evaluate the Efficacy of Neuraminidase Inhibitor Treatment in ST-Elevation Myocardial Infarction (STEMI) Patients [NCT04684498] | Phase 4 | 382 participants (Anticipated) | Interventional | 2020-03-01 | Recruiting | ||
| Oseltamivir Pharmacokinetics in Morbid Obesity [NCT01002729] | 20 participants (Actual) | Interventional | 2009-11-30 | Completed | |||
| ADaptive ASsessment of TReatments for influenzA: A Phase 2 Multi-centre Adaptive Randomised Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic Influenza Infection (AD ASTRA) [NCT05648448] | Phase 2 | 250 participants (Anticipated) | Interventional | 2023-02-22 | Recruiting | ||
| A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study of 2 Dose Levels of VX 787 Administered as Monotherapy and One Dose Level of VX-787 Administered in Combination With Oseltamivir for the Treatment of Acute Uncompl [NCT02342249] | Phase 2 | 292 participants (Actual) | Interventional | 2014-12-11 | Completed | ||
| Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic Interactions Between Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects [NCT00540501] | Phase 1 | 0 participants (Actual) | Interventional | 2007-10-31 | Withdrawn(stopped due to Contract agreement not reached) | ||
| An Open-label, Randomized 2-period Crossover Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Warfarin in Combination With Oseltamivir in Volunteers Stabilized on Warfarin Therapy [NCT02780622] | Phase 4 | 20 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Pharmacologic Study of Oseltamivir in Healthy Volunteers [NCT00439530] | Phase 1 | 21 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Randomised, Open-label, Multi-Centre, Phase IV Study Assessing the Effect of Oseltamivir Treatment on Cognitive Function in Subjects With Confirmed Influenza Virus Infection [NCT01249833] | Phase 4 | 122 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications [NCT01227967] | Phase 2 | 881 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| An Open-Label, Multiple Dose, Randomized, Three-Period Crossover Study in Healthy Volunteers to Evaluate the Effect of co-Administration of Amantadine 100 mg BID and Oseltamivir 75 mg BID on the Pharmacokinetic Properties of Amantadine and Oseltamivir. [NCT00416962] | Phase 1 | 18 participants | Interventional | 2006-08-31 | Completed | ||
| Title: Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia During the Influenza Season (U18) [NCT01248715] | Phase 4 | 1,107 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| A Randomized, Open Label Study to Evaluate the Effect of Tamiflu on Viral Shedding and on Serum and Cytoplasmic Inflammatory Cytokine Concentrations in Patients With Laboratory-confirmed Influenza [NCT00436124] | Phase 4 | 0 participants | Interventional | 2007-01-31 | Terminated(stopped due to poor recruitment, no patients were enrolled) | ||
| An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics of HIP1403 in Healthy Male Subjects [NCT02941731] | Phase 1 | 32 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| SEA022 Oseltamivir Treatment in Children Under One Year of Age With Moderate or Severe Influenza Lower Respiratory Tract Infection - a Clinical and Pharmacokinetic Study. [NCT01546935] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2012-12-31 | Withdrawn(stopped due to Study drugs (Oseltamivir suspension from Roche) were unavailable) | ||
| Comparative Effectiveness of Baloxavir Versus Oseltamivir for Influenza Outbreak Management in U.S. Nursing Homes [NCT05012189] | Phase 4 | 1,000 participants (Anticipated) | Interventional | 2021-08-06 | Active, not recruiting | ||
| An Open-label Multi-center Trial of Oseltamivir for the Seasonal Prophylaxis of Influenza in Children. [NCT00412555] | Phase 4 | 52 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment [NCT04338698] | Phase 3 | 550 participants (Actual) | Interventional | 2020-04-22 | Completed | ||
| A Phase 1, Open-label, Randomized, Crossover Study in Two Panels of Healthy Adult Subjects to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-63623872/Oseltamivir Fixed-dose Combination Tablet and Single Agent Concept Formulations of JNJ- [NCT03023852] | Phase 1 | 45 participants (Actual) | Interventional | 2017-02-14 | Completed | ||
| Monitoring Influenza Severity on Tamiflu (MIST) [NCT00555893] | 194 participants (Actual) | Interventional | 2008-01-31 | Completed | |||
| A Pilot, Randomized Study Comparing the Safety, Tolerability and Pharmacokinetics of Combination Therapy (Amantadine, Ribavirin, Oseltamivir) Versus Neuraminidase Inhibitor Monotherapy to Influenza Virus Infected Immunocompromised Patients [NCT00867139] | Phase 1/Phase 2 | 7 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Oseltamivir Phosphate 75 mg Capsule of Yangtze River Pharmaceutical (Group) Co., Ltd., China and TAMIFLU® (Oseltamivir Phosphate) Ca [NCT04536415] | Phase 4 | 96 participants (Actual) | Interventional | 2020-08-25 | Completed | ||
| Oseltamivir (Tamiflu) Dosing Strategies for Use During Influenza Prophylaxis (VA01) [NCT00304434] | Phase 4 | 48 participants (Anticipated) | Interventional | 2005-02-28 | Completed | ||
| Efficacy of Early Oseltamivir Phosphate Treatment at Hospital Admission to Reduce Severity of Illness Among Children Aged Less Than 10 Years Hospitalized With Influenza in El Salvador and Panama [NCT01690637] | Phase 4 | 721 participants (Actual) | Interventional | 2012-09-30 | Terminated(stopped due to Slower than anticipated participant accrual) | ||
| Inhibition of Carboxylesterase Metabolism by Ethanol [NCT01708369] | Phase 1 | 19 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| An Open-Label, Randomized, Adaptive, Two-Arm, Multicenter Trial to Evaluate Pharmacokinetics And Pharmacodynamics of Two Doses of Oseltamivir (Tamiflu®) in The Treatment Of Influenza in Immunocompromised Children Less Than 13 Years Of Age, With Confirmed [NCT01715909] | Phase 1 | 20 participants (Anticipated) | Interventional | 2014-01-22 | Completed | ||
| Multicentre Open Label Comparative Parallel-group Randomized Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza [NCT01804946] | Phase 4 | 161 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| A Phase 1, Open-Label, Three-Period, Single-center Study to Assess the Pharmacokinetic Interactions Between ZSP1273 and Oseltamivir in Healthy Subjects [NCT05108051] | Phase 1 | 36 participants (Actual) | Interventional | 2020-11-19 | Completed | ||
| Characterisation of the Human Carboxylesterase 1 (CES1) Mutation(s) Which May be Responsible for Markedly Reduced Conversion of Oseltamivir Phosphate to Oseltamivir Carboxylate [NCT01443806] | Phase 4 | 1 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving CVVHD and/or ECMO [NCT01048879] | Phase 4 | 15 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| An Open Label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir (Tamiflu®) in the Treatment of Infants 0 to <12 Months of Age With Confirmed Influenza Infection [NCT00988325] | Phase 1 | 65 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| A Phase 2a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-4482 in Healthy Participants Inoculated With Experimental Influenza Virus [NCT05818124] | Phase 1 | 160 participants (Anticipated) | Interventional | 2023-08-21 | Recruiting | ||
| A Phase 2a, Randomized, Partial Double-blind, Single Dose, Active-controlled, Dose Ranging Study to Evaluate the Safety of MEDI8852 in Adults With Acute, Uncomplicated Influenza [NCT02603952] | Phase 1/Phase 2 | 126 participants (Actual) | Interventional | 2015-12-07 | Completed | ||
| A Phase 2b, Randomized, Double-blind, Single-dose, Active-controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Influenza Caused by Type A Strains [NCT03028909] | Phase 2 | 0 participants (Actual) | Interventional | 2017-07-24 | Withdrawn(stopped due to Study is withdrawn due to company decision.) | ||
| Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019 [NCT04371601] | Early Phase 1 | 60 participants (Actual) | Interventional | 2020-03-01 | Active, not recruiting | ||
| Comparative Parallel-group Randomized Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza [NCT01850446] | Phase 4 | 184 participants (Actual) | Interventional | 2015-02-20 | Completed | ||
| A Phase 3, Randomized, Open Label, Active-controlled Study to Evaluate the Safety, Pharmacokinetics and Effectiveness of IV Peramivir Compared to Oral Oseltamivir in Pediatric Subjects With Acute Uncomplicated Influenza [NCT02369159] | Phase 3 | 137 participants (Actual) | Interventional | 2015-03-11 | Completed | ||
| A Randomized, Double-blind Phase III Clinical Study of ZSP1273 Tablets Compared With Placebo or Oseltamivir Patients With Acute Uncomplicated Influenza A [NCT04683406] | Phase 3 | 750 participants (Actual) | Interventional | 2020-12-28 | Completed | ||
| A Single Center, Open Label, Multiple-Dose Oral Oseltamivir Suspension Study in End-Stage-Renal Disease (ESRD) Patients on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD) [NCT02617784] | Phase 1 | 24 participants (Actual) | Interventional | 2001-10-31 | Completed | ||
| High-Dose Versus Standard-Dose Oseltamivir for the Treatment of Severe Influenza and Avian Influenza: A Phase II Double-Blind, Randomized Clinical Trial [NCT00298233] | Phase 2 | 326 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| Bioavailability of a Formulation of Oseltamivir Phosphate 75 mg Capsules With Regards to the Reference Product [NCT05083325] | Phase 1 | 36 participants (Actual) | Interventional | 2021-10-08 | Completed | ||
| The Effects of Neuraminidase Inhibitor Oseltamivir in Patients With Chronic Heart Failure: an Open Label, Randomized, Blank-controlled Study. [NCT05008679] | 388 participants (Anticipated) | Interventional | 2021-02-25 | Recruiting | |||
| An Open Label, Prospective, Single Oral Dose Study Evaluating the Pharmacokinetics, Safety, and Tolerability of Oseltamivir in Adult Subjects on Peritoneal Dialysis (PD) Using a Rapid Cycle Regimen to Simulate APD and in Adult Subjects With Creatinine Cle [NCT01556633] | Phase 1 | 16 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult and Elderly Hospitalized Patients With Influenza A Infection [NCT02532283] | Phase 2 | 102 participants (Actual) | Interventional | 2015-12-11 | Completed | ||
| Comparison of Time From Symptom Onset to Oseltamivir Access When Oseltamivir is Prescribed by Pharmacists vs. Physicians and the Impact on Symptoms, Oseltamivir Resistance, and Patient Safety [NCT01456234] | Phase 4 | 48 participants (Actual) | Interventional | 2011-11-30 | Terminated(stopped due to Insufficient recruitment) | ||
| A Study to Evaluate Drug-drug Interaction of ZX-7101A Tablets and Oseltamivir Phosphate Capsules in Healthy Adult Subjects -a Single-center, Open-labelled, Six-sequence, Three-cycle Crossover Design [NCT06057103] | Phase 1 | 18 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| Influenza Therapeutic Trial: A Pilot Randomized Controlled Trial for Feasibility of Enrolling Subjects for Influenza Therapeutic Trials and Administering Influenza Antivirals in the Emergency Department to High Risk Subjects [NCT02609399] | Phase 4 | 180 participants (Actual) | Interventional | 2015-11-01 | Completed | ||
| [NCT02989012] | Phase 2 | 96 participants (Anticipated) | Interventional | Not yet recruiting | |||
| A Multiple-Center, Randomized, Double-blind, Multiple-Dose, Placebo-Controlled, Parallel-Group Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO0640796 (Oseltamivir) and Its Carboxylate Metabolite, RO0640802, Following Intravenous [NCT02717754] | Phase 1 | 99 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Proof of Concept; A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia [NCT03520049] | Phase 3 | 30 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | ||
| Application of Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy for Critically-Ill COVID-19 Patients [NCT04457609] | Phase 1 | 40 participants (Anticipated) | Interventional | 2020-07-31 | Recruiting | ||
| [NCT02293863] | Phase 2 | 168 participants (Actual) | Interventional | 2015-01-14 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||